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In Western countries the health of the pregnant woman and the unborn child are 
monitored in routine prenatal care. Prevention and early detection of birth defects are 
part of prenatal care. To prevent birth defects, pregnant women are taught to avoid 
known teratogens, for example alcohol. Furthermore, they are screened through 
blood tests for infections and a potential maternal immune response against fetal 
blood cells. Many birth defects become apparent during gestation because of reduced 
fetal growth or abnormalities, visible on ultrasound scan. Therefore, pregnant women 
are offered regular ultrasound examinations and a fetal anomaly ultrasound scan at 
18 to 20 weeks of gestation. Additionally, prenatal screening and diagnostic tests for 
prenatally detectable genetic disorders are offered. In this thesis, I focus on the latter 
group of tests. 
1.1  Prenatal screening and diagnosis: definitions  
Before describing the research upon which this doctoral dissertation is based, it is 
necessary to clarify exactly what is meant by the different terms referring to prenatal 
screening and diagnosis in this thesis. 
First and foremost, the terms screening and diagnostic will be used to describe the 
character of the test itself. The term prenatal diagnostic test will be used for any test 
providing a definite answer to a clinical question, not requiring a follow-up test to 
confirm the result. The term prenatal screening test will be applied for any test that 
offers a risk-assessment and requires a follow-up diagnostic test to clarify abnormal 
screening results. 
Secondly, the concepts of prenatal screening and prenatal diagnosis are described. The 
term prenatal diagnosis will be used solely when referring to pregnant women with 
increased risk undergoing a prenatal diagnostic test to investigate the presence of any 
genetic disorder in the fetus. Women can have an a priori increased risk for a fetus 
with a genetic disorder, e.g. because they have the genetic disorder themselves, or 
can have an increased risk after a prenatal screening test, e.g. an ultrasound 
examination. In other words, women have a medical indication to undergo the 
diagnostic test.  
In this thesis, the term prenatal screening will be used in its broadest sense to refer to 
pregnant women undergoing a prenatal screening test. Prenatal screening can be 
followed by prenatal diagnosis in the case of abnormal screening results. In other areas 
of medicine, the term screening tends to be used to refer to tests offered to people 
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without symptoms nor another reason to seek medical help. However, it would not be 
correct to simply extrapolate this definition and therefore assume that prenatal 
screening is only offered to women without a medical indication. Women undergoing 
prenatal screening can also have an increased risk for the tested genetic disorder, but 
this is not obligatory. 
Prenatal testing is a term frequently used in the literature, and is used in general as a 
synonym for prenatal screening. 
Finally, the term prenatal screening program will be used to describe an organized 
program comprising prenatal screening tests usually followed by a prenatal diagnostic 
test to confirm any abnormal result of the first risk-assessment. A prenatal screening 
program can be offered to all pregnant women or only to high-risk pregnant women.  
1.2 An a priori increased risk for a genetic disorder in the 
fetus 
Future mothers and fathers can have an a priori increased risk for a chromosome 
disorder or for a single-gene disorder in their unborn child.  
In chromosome disorders the birth defect is due to an excess or deficiency of the 
genes in a part of a chromosome, or a whole chromosome.1 Future mothers and 
fathers have an a priori increased risk for a chromosome disorder in the fetus if they 
had a previous child with a chromosome abnormality or if they have a structural 
chromosome abnormality themselves. Mothers over the age of 35 (advanced maternal 
age) also have an increased risk of fetal chromosome disorders. The effect of 
progressing maternal age on the risk of chromosome disorders is well known by 
prenatal care providers and pregnant women.2 During the last decades, advanced 
maternal age was used as a sole criterion for further prenatal diagnosis of fetal 
chromosome disorders, but this is no longer recommended by the International 
Society for Prenatal Diagnosis.3 Recently, in 2015, advanced maternal age was also 
abandoned as a sole criterion to undergo a prenatal diagnostic test in the 
Netherlands.4 
Single-gene disorders are caused by a critical error in the genetic information carried 
by a single gene.1 Such error, called a mutation, may be present in only one 
chromosome of a pair (i.e. in one allele, matched with a normal gene without the error 
on the homologous allele), or in both chromosomes of a pair (i.e. in both alleles). 
Single-gene disorders have recessive, dominant and X-linked Mendelian inheritance 
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patterns. Couples with single-gene disorders themselves or in their family are offered 
genetic counseling to discuss the risk of transmitting this disorder to their unborn child. 
A new gene error (also called “de novo mutation”) may be suspected when ultrasound 
malformations clearly point towards a specific disorder or a group of disorders, e.g. 
skeletal dysplasia. Furthermore, advanced paternal age (> 40 years) is associated with 
an increased risk of de novo mutations in the unborn child, that were not inherited 
from the mother or father.5,6 The increased risk of advance paternal age is far less well-
known among prospective parents than the increased risk of chromosome disorders 
in the case of advanced maternal age in pregnancy. It is also not yet included in 
prenatal counseling guidelines. 
1.3 Traditional prenatal screening for chromosome disorders 
Since the 1980s, multiple biochemical prenatal screening tests have been developed 
for the identification of three chromosome disorders: Down syndrome (trisomy 21), 
Edwards syndrome (trisomy 18) and Patau syndrome (trisomy 13). In Europe, the 
prevalences of trisomy 13, 18 and 21 in pregnancy are 2, 5 and 22 per 10 000 births, 
respectively.7 All other nonmosaic autosomal trisomies are incompatible with 
postnatal survival. Each of these autosomal trisomies is associated with growth 
retardation, mental retardation, and multiple congenital abnormalities.1 Double, triple 
and quad marker prenatal testing was proposed for women in the second trimester of 
pregnancy, based on various combinations of serum markers.8 In the Netherlands, the 
second trimester triple test was introduced in 1990.9,10 This test measured the serum 
levels of alpha-fetoprotein (AFP), unconjugated estriol (uE3) and free beta human 
chorionic gonadotropin (free-βhCG), and interpreted these levels combined with the 
maternal age to calculate the woman’s individual risk of fetal trisomies 13, 18 and 21.  
Later, in 1992, it was shown that the fetal ultrasound marker nuchal translucency was 
a very good indicator of the risk of Down syndrome in the first trimester of pregnancy.8 
This led to the implementation of the first trimester combined test (FCT). The FCT 
includes a nuchal translucency measurement by ultrasound at 12 weeks of gestation 
and a blood test between 11 and 14 weeks of gestation. In this blood test two serum 
hormones are quantified, namely pregnancy-associated plasma protein-A (PAPP-A) 
and free-βhCG. The results of these tests are combined with the maternal age and the 
gestational age to calculate the woman’s individual risk for fetal trisomies 13, 18 and 
21. A few years after the introduction of the triple test in the Netherlands, the Health 
Council, an advisory board of the Dutch Ministry of Health, advised the use of the FCT 
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instead of the triple test.10 In 1999, the integrated test was developed, combining first 
and second trimester markers.8 
In Europe, an early prenatal risk assessment with the FCT has classically been 
preferred.8 In 2007, in the Netherlands a national prenatal screening program was 
introduced aiming to provide all pregnant women the option of prenatal screening 
with the FCT.11 Nowadays, the FCT is still offered to all pregnant women. Traditionally, 
women with a risk of fetal trisomies 13, 18 or 21 of 1 in 200 or higher after the FCT are 
offered prenatal diagnosis to further investigate these fetal chromosome disorders. 
1.4 Invasive prenatal diagnosis 
Women may undergo prenatal diagnosis in the case of an a priori increased risk for a 
genetic disorder, an increased risk of a chromosome disorder following a screening 
test, or in the case of fetal abnormalities detected on ultrasound. Conventional 
prenatal diagnosis requires invasive procedures to provide fetal cells, either chorionic 
villus sampling between 11 and 14 weeks gestation or amniocentesis after 15 weeks 
of gestation. The procedures are called invasive because they involve a catheter or 
needle being inserted into the amniotic fluid-filled cavity or into the placenta. The 
additional risk of miscarriage in women undergoing amniocentesis and chorionic villus 
sampling is estimated between 0.11-1% and 0.22-2%, respectively.12-14  
The invasive procedures provide fetal cells for chromosome analysis as well as for DNA 
analysis. Karyotyping detects all microscopically visible chromosome aberrations, 
while submicroscopic chromosomal aberrations below the resolution of a standard 
karyotype analysis are nowadays routinely investigated by microarray analysis.15 
Additionally, an imbalance of the chromosomes 13, 18, 21 or the sex chromosomes 
can be diagnosed within 1-3 days, with one of the so called rapid aneuploidy detection 
techniques.16 These include interphase fluorescence in situ hybridization (FISH), 
quantitative fluorescent polymerase chain reaction (QF-PCR) and/or multiplex 
ligation-dependent probe amplification (MLPA). DNA analysis can be performed either 
by using direct mutation detection by PCR-based methods, or by closely linked 
microsatellite markers, or by using a combination of these methods.1  
The invasive approaches to obtain fetal material for genetic chromosome and DNA 
analysis currently provide the gold standard for prenatal diagnosis. The pregnant 
couple receives a definite answer to the question whether the genetic disorder is 
present in the fetus. 
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1.5 Noninvasive prenatal screening and diagnosis 
To avert the risk of miscarriage of the invasive procedures, there has been a long-
lasting search for a reliable and safe noninvasive prenatal diagnostic test. In 1997, 
Dennis Lo first showed the presence of fetal cell-free DNA (cfDNA) in the maternal 
blood circulation by amplifying DYS14, a multicopy marker sequence on the Y 
chromosome.17 Since then, the boundaries of what could be detected in the fetal 
cfDNA have been enthusiastically expanded, with save noninvasive prenatal tests for 
the mother and the future child in mind. These tests are referred to as noninvasive, as 
they only require maternal venous blood sampling. In this thesis, prenatal detection 
of genetic disorders through analysis of cfDNA in maternal blood is reported, as well 
as the responsible application of cfDNA-based tests in prenatal screening. 
1.5.1 The origin of cell-free DNA and RNA 
The placenta and umbilical cord form a transport system for substances (nutrients, 
oxygen, waste materials and carbon dioxide) between the mother and fetus. The 
placenta is a fetomaternal organ that has two components: a fetal part, derived from 
the dividing fertilized egg, and a maternal part, derived from the endometrium of the 
uterus.18 Fetal cfDNA originates from degenerating trophoblast cells from the fetal part 
of the placenta.19,20 Trophoblast degeneration occurs in all normal pregnancies, as part 
of physiological villous remodeling, and may be exaggerated in case of placenta 
pathology.19 In this process the DNA from the degenerating cells is released into the 
maternal blood circulation passing through the placenta next to the trophoblast cells.  
CfDNA of maternal origin, derived from degeneration of hematopoietic cells, is also 
present in the blood circulation of the mother, and in much higher amounts than fetal 
cfDNA.21 The fetal cfDNA represents on average a fraction of 6-10% of the total cfDNA 
in the plasma in first and second trimester pregnancies. This fetal fraction may rise up 
to 10-20% in third trimester pregnancies.21,22  
Maternal as well as fetal cfDNA exist of short, fractionated, DNA sequences. Most 
cfDNA sequences have a size between 50 and 200 bp.23 The most significant difference 
in the size distribution between the fetal and the maternal cfDNA is that maternal 
cfDNA is predominantly 166 bp in size, while most fetal cfDNA sequences have size 
between 122 and 166 bp.23 A small portion of the cfDNA, mostly of maternal origin, is 
larger than 300 bp.24 Fetal cfDNA is detectable in maternal serum as well as maternal 
plasma, but the lysis of maternal nucleated blood cells during the clotting process 
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leads to an increased proportion of maternal cfDNA in the serum sample in 
comparison with plasma.25 Fetal cfDNA has also been detected in maternal urine.26,27 
However, this cfDNA is even more fragmented than in serum and plasma, and is 
present in low concentrations.27 Serum and urine of the pregnant women are 
therefore less suitable for prenatal tests than plasma. Also cell-free trophoblast RNA 
(cfRNA) and circulating placental microRNAs (miRNAs) have been detected in the 
maternal circulation.28-30 The cfRNA is mRNA from genes expressed in trophoblast 
cells.28,29 Placental miRNAs regulate placental development and trophoblast cell 
activities.30 
Fetal cfDNA can already be detected in the maternal circulation at the fourth week of 
gestation.31 The concentration is very low. Often cited is an expected concentration of 
1000 genome equivalents/mL in a human blood sample for the total (maternal and 
fetal) cfDNA.32,33 However, both the concentrations of the total and fetal cfDNA vary 
between individuals.34-36 The amount of maternally derived cfDNA can vary depending 
on maternal health factors, such as obesity or diabetes.34 The amount of fetal cfDNA, 
i.e. the fetal fraction, is affected by gestational age, maternal weight, and the health 
of the placenta.34-36 Additionally, quantification of cfDNA and of the fetal fraction is 
influenced by pre-analytical and analytical factors, including storage conditions, delay 
before plasma separation, blood-processing protocols, DNA extraction method, 
amplicon size, target gene choice, and the used quantification method.33,34 
Concentrations in maternal plasma as low as 220 genome equivalents/mL and 20 
genome equivalents/mL have been described for total cfDNA and fetal cfDNA, 
respectively.21,34  
Fetal cfDNA and cfRNA are rapidly cleared from the maternal plasma after 
pregnancy.28,37 Consequently, the fetal cfDNA in the plasma of a pregnant woman has 
the same genetic profile as the child she is bearing, and does not resemble the genetic 
profile from a previous child. This makes fetal cfDNA very useful for prenatal screening 
and diagnosis. 
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1.5.2 Early developed clinical applications 
Noninvasive prenatal tests using fetal cfDNA are technically very challenging to 
develop, due to the predominance of maternal cfDNA sequences in the blood sample. 
Initially, clinical applications of fetal cfDNA mostly focused on fetus-specific sequences 
that could be distinguished from the maternal sequences.  
A. Noninvasive fetal sex determination  
The Y chromosome is unique to the male fetus, and is not present in the genetic 
blueprint of the mother or a female fetus. This made the development of noninvasive 
fetal sex determination, where the presence of Y chromosome in the maternal plasma 
is verified, relatively easy. Sex determination was one of the first clinical applications 
of fetal cfDNA testing and is routinely used in European countries.38 In the Netherlands, 
it has been offered as a prenatal diagnostic test for clinical purpose since the beginning 
of 2003.39 
Early prenatal diagnosis of fetal sex is indicated in case of a fetus at risk of one of the 
more than 100 known X-linked inherited disorders.40 X-linked disorders are caused by 
a mutation on the X chromosome, and affect mostly boys, and not or to a lesser degree 
girls. Their prenatal diagnosis is often performed early in pregnancy by mutation 
analysis of chorionic villi. Since prenatal diagnosis is only desired in boys for the 
majority of X-linked disorders, early fetal sex determination by a noninvasive 
procedure prevents unnecessary chorionic villus sampling in girls. A second indication 
for fetal sex determination is a fetus at risk of congenital adrenal hyperplasia (CAH) 
due to 21-hydroxylase deficiency (CYP21 CAH).41,42 If female fetuses affected with CAH 
are exposed to androgens at the critical time of sexual differentiation (between 9 and 
15 weeks of gestation) this will result in masculinization of the external genitalia. 
Starting treatment of the pregnant woman carrying an affected female fetus with 
dexamethasone before 9 weeks of gestation counters the virilisation.43 Prenatal 
diagnosis of CYP21 CAH requires a chorionic villus sampling or amniocentesis. Early sex 
determination by a noninvasive procedure prevents an unnecessary invasive 
procedure and start of dexamethasone treatment in women that are pregnant of a 
boy. Following the noninvasive identification of a female fetus, dexamethasone is 
given to the pregnant woman. If the fetus is later determined to be an unaffected 
female upon DNA analysis, most often after chorionic villus sampling, treatment with 
dexamethasone can be discontinued. Third, if a fetus presents with ambiguous 
genitalia on ultrasound examination, noninvasive prenatal determination of the 
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genetic sex can be helpful to determine the sex of the fetus and the defect that 
resulted in genital ambiguity.42,44 
In the case of amplification of Y chromosome-derived cfDNA sequences in the 
maternal plasma, the fetus is presumed to be male. However, to conclude whether a 
negative result is a true-negative result, indicating female gender of the fetus, or a 
false-negative result, due to a low amount of fetal cfDNA, a marker to confirm the 
presence of fetal nucleic acids is crucial (a so-called “fetal marker”). The confirmation 
of the presence of fetal nucleic acids in the maternal plasma requires extra time and 
expenses by the laboratory. Sometimes the fetal marker fails to confirm the presence 
of fetal material, and as a result, the assays cannot provide a fetal gender.39,45 In 
Chapter 2 we address these problems and describe the development of a novel single-
tube noninvasive fetal sex determination assay, in which a gender-independent 
fetoplacental marker is incorporated in the test, requiring no extra time or expenses 
by the laboratory.  
B. Noninvasive genotyping of fetal blood group antigens  
Another early developed application was the noninvasive determination of the 
presence of the Rh blood group, D antigen gene (RHD) in the plasma of alloimunised 
rhesus D (RhD)-negative pregnant women.46,47 The presence of RHD in the plasma 
suggests that the fetus is RhD positive and at risk of hemolytic disease of the fetus and 
newborn. The maternal immune response against the fetal blood cells can be 
prevented by prophylactic antenatal and postnatal anti-D immunoglobulin. Next to 
RhD incompatibility between the pregnant woman and the fetus, also incompatibility 
of other red blood cell antigens can cause hemolytic disease of the fetus and the 
newborn and should therefore be discovered as soon as possible.48 Nowadays, 
noninvasive fetal blood group genotyping has replaced the invasive procedures to 
prenatally determine the fetal antigen status. In the Netherlands, blood group 
genotyping for rhesus D is offered since 2003, followed by rhesus K in 2006 and rhesus 
c and E in 2007 in alloimunised women.49 
1.5.3 Noninvasive prenatal tests and next-generation sequencing: parallel 
developments 
While research on fetal cfDNA clinical applications was flourishing, the technical 
possibilities to investigate the human DNA were also developing fast. Next-generation 
sequencing (NGS), also called massively parallel sequencing, now allows us to analyze 
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and quantify millions of DNA fragments in one single experiment.50 All maternal and 
fetal cfDNA sequences of a plasma sample are sequenced in one experiment with this 
approach. NGS is increasingly being used in noninvasive prenatal detection of single-
gene disorders and chromosome disorders. 
A. Developments in noninvasive prenatal diagnosis of single-gene disorders 
A few years after the discovery of fetal cfDNA in the plasma of pregnant women, the 
first studies aiming at diagnosing single-gene disorders in cfDNA were published. 
Early developed tests for fetal single-gene disorders  
The development of cfDNA-based tests to diagnose single-gene disorders is 
challenging from several perspectives: most cfDNA fragments in the maternal blood 
circulation are of maternal origin, the cfDNA exist of short sequences and the levels of 
total and fetal cfDNA in the maternal circulation are low.21-23,32 Consequently, 
noninvasive prenatal determination of single-gene disorders depends on subtle 
changes in the relative proportions of normal and mutated cfDNA in the plasma 
sample. Moreover, direct mutation detection is not applicable for disorders caused by 
a mutation longer than the size of the cfDNA fragments, such as repeat expansions 
and large deletions. Furthermore, the disorders are individually rare.1 Collecting a 
large cohort of pregnant women requesting prenatal diagnosis for an individual single-
gene disorder is problematic. As a result, large-scale clinical validation studies are not 
possible. 
Early studies aimed at diagnosing disorders where the mutation is not present in the 
maternal cfDNA. These are disorders in which the mutation is carried on the paternal 
allele, disorders caused by a de novo mutation, and autosomal recessive disorders 
where the parents carry different mutations and diagnosis is based on the detection 
or exclusion of the paternal mutation. The basic principle of the early studies was the 
amplification of the mutated allele by PCR, mostly real-time quantitative PCR (qPCR). 
Early onset primary dystonia and Crouzon syndrome are examples of dominant 
disorders in which the mutation, carried on the paternal allele, was detected or 
excluded in fetal cfDNA.51,52 Examples of diagnosed autosomal dominant disorders 
caused by a de novo mutation, suspected following abnormal ultrasound findings, are 
achondroplasia, thanatophoric dysplasia and Apert syndrome.53-58 Repeat expansion 
disorders that were tested in fetal cfDNA for the detection or exclusion of the paternal 
inherited allele from an affected father are Huntington disease and myotonic 
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dystrophy type 1.59-62 Cystic fibrosis, Leber congenital amaurosis, congenital adrenal 
hyperplasia, and alpha and beta-thalassemia are all autosomal recessive disorders in 
which the presence of a paternal mutation, different from the maternal mutation, was 
excluded or confirmed in cfDNA.63-78 Later, digital PCR and digital relative mutation 
dosage were used in the X-linked disorders hemophilia A and B, to measure the 
concentration difference between the total amount (maternal- plus fetal-derived) of 
mutant and wild-type alleles in the plasma of heterozygous pregnant women carrying 
male fetuses.79 In sickle cell anemia, digital qPCR was used to analyze the dosage of 
the variant encoding hemoglobin S relative to that encoding wild-type hemoglobin A.80 
Also one case at risk of methylmalonic acidemia was tested in cfDNA using digital PCR 
to quantify allelic counts.81 In these early studies, only a single affected case or a few 
affected and non-affected cases were tested, due to the low prevalence of single-gene 
disorders. Only in the case of the inherited autosomal recessive blood disorders, more 
plasma samples were available to test. 
The introduction of NGS for fetal single-gene disorders 
In 2010, genome-wide deep sequencing (up to 65-fold haploid genome coverage) of a 
plasma sample revealed that both the entire fetal and maternal genome is 
represented in the fetal and maternal cfDNA, at a constant relative proportion.23 In 
2012, another group used genome-wide deep sequencing of a maternal plasma 
sample to a deeper extent (78-fold haploid genome coverage), in combination with 
haplotype-resolved genome sequencing of the mother and shotgun genome 
sequencing of the father, to detect both inherited variations and de novo mutations in 
the fetal cfDNA.82 These two studies led to a promising start for a reliable noninvasive 
detection of all types of single-gene disorders. Using NGS, it is possible to assess the 
under-representation or over-representation of fetal alleles (by relative mutation 
dosage). As a result, also cfDNA testing of maternally inherited mutations and 
recessive disorders is possible. 
Noninvasive prenatal diagnosis of fetal single-gene disorders 
NGS has been used to detect single-gene disorders in maternal plasma since 2012 
(Table 1.1).83-94 Noninvasive assays for single-gene disorders by NGS provide a definite 
answer to the question whether the disorder is present in the fetus, without the need 
for a follow-up test to confirm the result. Therefore, these tests are referred to as 
“noninvasive prenatal diagnosis” (NIPD).  
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Both direct and indirect methods have been developed. The direct NIPD methods aim 
to detect or exclude the mutation in the cfDNA. In the case of paternal inheritance or 
de novo mutations, deep targeted sequencing is used to detect the mutation in a 
background of wild-type maternal reads.90-92 In the case of maternal inheritance, the 
over-representation of the mutated allele in the plasma sample (i.e. the fetus has 
inherited the mutation) is determined by relative mutation dosage. The relative 
mutation dosage relies on the reliable quantification of the fetal fraction. The second 
method, the indirect NIPD method, uses single nucleotide polymorphisms (SNPs) for 
genotyping of the parents. Based on SNP genotyping, informative SNPs from the 
parents are selected to determine the parental haplotypes. After targeted sequencing 
of the informative SNPs in the cfDNA, the percentages of NGS reads containing the 
variant or wild-type nucleotide allows to determine whether or not the mutated allele 
from an affected parent of from both affected parents is present in the maternal 
plasma.83-86 The indirect NIPD method can be used to detect single-gene disorders 
caused by mutations that are larger than the short cfDNA fragment, such as triple 
repeat expansions or deletions.  
In Chapter 3 we report on the development of a novel NIPD assay to detect the 
inherited fetal alleles in the cfDNA, using an indirect haplotype-based approach. In our 
assay, we use single molecule molecular inversions probes (smMIPs) for targeted 
multiplex NGS of common SNPs. The method enables precise quantification of the 
variation in the cfDNA. Furthermore, the method has proven to be robust to relatively 
small amounts and poor quality of source DNA.95 As a proof of concept, we applied our 
smMIP-based NIPD assay to the cfDNA isolated from the plasma of a woman carrying 
a fetus affected with myotonic dystrophy type 1 (DM1), also known as Steinert's 
disease. DM1 is an autosomal dominant genetic disorder that affects skeletal and 
smooth muscle, the eye, heart, endocrine and central nervous systems.96,97 It is caused 
by expansion of a CTG trinucleotide repeat in the dystrophia myotonica protein kinase 
gene (DMPK).98,99 The disorder is characterized by anticipation: in successive 
generations, affected family members are at risk for further expansion of the CTG 
repeat, resulting in decreasing age of onset and increasing severity.96 
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Further development and implementation of NIPD of single-gene disorders 
A translation into clinical practice of a targeted NGS-based method for some single-
gene disorders has already been seen.100 At the Great Ormond Street Hospital in 
London, NIPD for FGFR3-related skeletal dysplasias, FGFR2-related craniosynostosis, 
Apert syndrome, Crouzon syndrome with acanthosis nigricans and cystic fibrosis is 
possible and offered to pregnant women.101 It is currently not possible for this 
laboratory to offer NIPD for conditions where the mother is a carrier of the genetic 
condition in question, or to detect the inheritance of a nucleotide repeat expansion. 
At the moment, more NIPD assays are being developed. In the near future, it is 
expected that a noninvasive prenatal diagnostic test for more single-gene disorders 
will be offered to pregnant women, also in the Netherlands. 
B. Developments in noninvasive prenatal detection of chromosome disorders 
The search for a noninvasive prenatal test that could reliably detect fetal trisomies 13, 
18 and 21 started very soon after the discovery of fetal cfDNA in maternal plasma. The 
search for this test was compared in the literature to with the search for the Holy 
Grail.102 The origin of the drive to find this test lays in the fact that these chromosome 
imbalances have always been important indications for invasive prenatal diagnosis.  
Early developed tests for fetal chromosome disorders  
It was for a long time (from the first attempts in 1999 until 2011) impossible to reliably 
detect fetal chromosome imbalances in the fetal cfDNA in maternal plasma. Several 
strategies were pursued by both researchers from academic hospitals and commercial 
companies. Early studies focused on the quantification of fetal and total cfDNA in 
maternal plasma.103-110 In trisomy 21, as well as in trisomies 13 and 18, an elevation of 
fetal cfDNA levels has been reported. However, a large overlap in cfDNA 
concentrations between non-trisomic and trisomic pregnancies was seen. Later, the 
amount of cfDNA or cfRNA of specific genes was examined.111-115 For instance, an 
upregulation of hemoglobin beta (HBB) cfDNA in trisomy 21 and a down regulation of 
chorionic gonadotropin, beta polypeptide (CGB) cfRNA in trisomy 18 pregnancies were 
observed, when compared with non-trisomic pregnancies. In addition, the comparison 
of maternally and paternally inherited fetal cfDNA and cfRNA sequences was explored. 
Trisomy 21 could be identified by the relative overrepresentation of maternal 
chromosome 21 fetal cfDNA or cfRNA sequences to the paternal chromosome 21 fetal 
cfDNA or cfRNA sequences.116-121 Next to these techniques, the dosage of a fetal 
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chromosome was determined based on the epigenetic differences between maternal 
and fetal cfDNA.122-130 None of these approaches led to a practical test that could be 
used routinely in prenatal care. 
The introduction of next-generation sequencing for fetal chromosome disorders 
In 2008 the use of NGS was suggested to allow one to detect fetal chromosome 
disorders through analysis of thousands of millions of cfDNA sequences.131 After 
identifying the chromosomal origin of each sequenced plasma cfDNA molecule, the 
over- or underrepresentation of any chromosome in maternal plasma could be 
determined.131,132 Different algorithms are now used to calculate the deviation of 
percentage sequence reads per chromosome reads in a trisomic fetus in comparison 
with a disomic fetus. Because of the enormous throughput of current NGS systems, an 
additional advantage of NGS is that the cfDNA sequences from the plasma from many 
pregnant women can be sequenced at the same time.  
Both NGS tests in which all, genome wide, cfDNA sequences in the maternal blood are 
sequenced (broad), as well as tests in which only specific chromosomes of clinical 
interest are sequenced (targeted), have been developed.132,133 In targeted NGS 
approaches, the pre-selection of chromosomes leads to less unutilized sequencing 
data and prevents unsolicited findings in other chromosomes. Furthermore, it was 
believed that because more rapid NGS devices could be used for targeted NGS, this 
would reduce the costs and turnaround time, and this would increase the number of 
pregnant women that could be tested per week. In recent years, these advantages 
have become less evident, because the broad NGS approaches can now also be 
performed rapidly and affordably. 
Noninvasive prenatal testing of fetal chromosome disorders using NGS 
In 2011 and 2012, the first diagnostic accuracy studies were published using NGS to 
detect fetal trisomies 13, 18 and 21 in maternal plasma, with or without pre-selection 
of chromosomes (Table 1.2).134-143 In these first studies NGS was mostly validated in 
women with an increased risk for fetal trisomies 13, 18 or 21. The diagnostic accuracy 
of the cfDNA-based test was established by comparing its results with karyotyping. In 
Chapter 4 we provide an overview of all studies evaluating of the diagnostic accuracy 
of molecular techniques for noninvasive detection of trisomy 21 between 1997 and 
the beginning of 2012. In this overview we compare these first studies using NGS with 
the older studies investigating other molecular techniques for trisomy 21 detection. 
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We evaluate the quality of the studies (potential bias and applicability) and the 
diagnostic parameters. 
Later studies included cohorts of low-risk pregnant women and mixed risk populations, 
and compared the performance of the cfDNA-based test with current prenatal 
screening tests (Table 1.2).144-164 It was shown that cfDNA-based tests using NGS can 
detect fetal trisomy in high-risk and in low-risk pregnant women from 10 weeks of 
gestation onwards with a sensitivity and specificity of more than 99%. The negative 
predictive value, the chance that in case of a negative NIPT result the fetus does not 
have a trisomy, is excellent (almost 100%). This means that a negative NIPT result 
reassures the pregnant couples. However, a variation in the likelihood that a pregnant 
woman with a positive cfDNA-based test result actually carries a fetus with a trisomy 
(positive predictive value) was observed. The positive predictive value drops especially 
when the a priori chance of carrying a fetus with a trisomy declines, and may even fall 
below 50% in young, low-risk women.134-165 Consequently, an invasive procedure, 
followed by a rapid aneuploidy detection technique or karyotyping, is recommended 
by the International Society for Prenatal Diagnosis to confirm suspicion of fetal trisomy 
following a positive cfDNA-based test result.3,166 
Soon after the first diagnostic accuracy studies, the term “noninvasive prenatal 
testing” (NIPT) was formulated and replaced the term “noninvasive prenatal 
diagnosis” (NIPD) that had been used until then to describe the cfDNA-based trisomy 
tests.167 NIPT refers to cfDNA-based tests that are used as a screening test and require 
a confirmation by a follow-up diagnostic test, to provide a definite answer on whether 
the genetic disorder is present in the fetus. Although NGS cfDNA-based tests maybe 
failed to provide the final answer on whether a trisomy is present in the fetus, they 
proved to be much better screening tests that the traditional biochemical screening 
tests used so far.152,159 For example, the FCT, combining nuchal translucency 
measurement and serum markers, is estimated to have a sensitivity of 89.0% and a 
specificity of 95.4% for fetal trisomy 21 detection, if considering women of all age 
categories and a risk threshold of 1 in 200.168 This is considerably lower than the 
sensitivity and specificity of the NIPT, that both exceed 99%. 
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Implementation of NIPT for fetal trisomies 13, 18 and 21 
Nowadays, commercial NIPT is already offered in over 60 countries throughout six 
continents.169 At present, several countries are organizing the implementation of NIPT 
in their prenatal trisomy screening program.170-172 In the Netherlands, a national 
implementation study has been organized (the TRIDENT study).173 In this study, the 
genetic laboratories of the country collaborate to investigate the accuracy of NIPT and 
compare it to the published accuracy. Since April 2014, prenatal screening for 
trisomies 13, 18 and 21 by NIPT is offered as a part of the TRIDENT-1 study to women 
with an increased risk based on the FCT (≥ 1:200), or on the basis of their personal 
history. As a part of the study, the attitudes and preferences of the Dutch women 
towards NIPT for the detection of fetal trisomy are investigated.171 Recently, the 
Health Council advised to offer pregnant women the choice for NIPT as the first 
screening test.174 The Minister of Health gave permission to start with the TRIDENT-2 
study in April 2017, in which all women in the Netherlands will be able to choose 
between NIPT and the FCT to screen for fetal aneuploidy from 10 weeks of gestation 
onward, after being advised about the advantages and disadvantages of both 
screening tests.173 
There are a number of ways to implement NIPT into a Down syndrome screening 
program. NIPT can for example be restricted to preselected high-risk women. 
Furthermore, its timing in pregnancy can differ. In Chapter 5 we describe a 
quantitative analysis of different NIPT implementation strategies in order to help 
health policy decision makers. Decision trees illustrate all plausible alternatives for 
pregnant women in five theoretical screening programs: classical screening by the FCT, 
pre-selection of high-risk women prior to NIPT by the FCT, NIPT as the first screening 
test at 10 weeks and at 13 weeks, and the simultaneous conductance of NIPT and the 
FCT. 
Expansion of disorders included in the NIPT panel  
The detection of other chromosome disorders requires only minor technical 
alterations to the original NIPT assays. Additionally, no biochemical prenatal screening 
tests have been available for pregnant women for other chromosome disorders than 
trisomies 13, 18 and 21. Therefore, broadening the scope of NIPT, by adding screening 
for other chromosome disorders to the assay, has been explored.  
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Since 2013, some NIPT assays can detect submicroscopic chromosomal 
abnormalities.175-179 Clinically significant microdeletion and microduplication 
syndromes can now be detected by cfDNA whole genome analysis, for instance 
DiGeorge syndrome (22q11.2 deletion). In the Netherlands, the detection of 
microdeletions and duplications is possible using the NIPT assay from the TRIDENT 
study.179 However, false negative results, and a remarkable high number of false 
positive results have been reported.178,180 For this group of disorders, confirmation of 
a positive result by an invasive procedure and microarray analysis is recommended.  
Since 2014, commercial laboratories have added detection of sex chromosome 
imbalances to their NIPT assay.181-184 Sometimes the ultrasound shows fetal anomalies 
that may point towards a sex chromosome imbalance, but more often the sex 
chromosome imbalances are prenatally diagnosed as an incidental finding of 
karyotyping aiming to rule out the autosomal chromosome disorders trisomies 13, 18 
and 21.185 These disorders include monosomy X and sex chromosome trisomies 
(47,XXX; 47,XXY and 47,XYY). The sex chromosome trisomies Klinefelter syndrome 
(47,XXY) and Triple X syndrome (47,XXX) are the most common sex chromosome 
imbalances, occurring in approximately 1 in 600 male births, and in approximately 1 in 
1 000 female births, respectively.186,187 The interpretation of NIPT results and the 
counseling of pregnant couples can be challenging, because of the mild and variable 
phenotype, the low positive predictive value (around 50%), and the possibility of 
maternal sex chromosome trisomy resulting in false positive results of the NIPT.188-190 
Similar to the autosomal trisomies, a sex chromosome imbalance suspicion by NIPT 
should always be confirmed by an invasive procedure and a rapid aneuploidy detection 
technique or karyotyping. The generally mild phenotype may not justify an invasive 
procedure for some parents. Little is known about the couples’ motives and 
considerations concerning screening for these conditions, as well as their wishes 
regarding information provision and support. In Chapter 6 we assess Dutch pregnant 
couples’ opinions about NIPT for sex chromosome trisomy within the broader context 
of the expansion of disorders included in the NIPT panel. 
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1.6 Outline of the thesis 
The general aim of this thesis is to increase our knowledge about the use of cfDNA-
based testing, from bench to clinic. This thesis can be subdivided into two themes:  
Part I: Design of noninvasive prenatal diagnostic tests 
In this part the use of cfDNA for prenatal genetic diagnostic testing is explored. The 
part comprises the design of in-house noninvasive diagnostic tests for fetal sex 
determination as well as single-gene mutation detection (Chapters 2 and 3). 
Part II: Noninvasive prenatal screening for fetal chromosome disorders 
This part investigates the responsible application of cfDNA-based tests in prenatal 
screening. It comprises the evaluation of the noninvasive prenatal screening for fetal 
trisomy 21 (Chapters 4 and 5), and an exploration of the opinion of pregnant women 
about the expansion of noninvasive prenatal screening to fetal sex trisomy (Chapter 
6). 
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2.1  Abstract 
Background: Noninvasive genetic tests that use cell-free fetal DNA (cffDNA) are used 
increasingly in prenatal care. A low amount of cffDNA can have detrimental effects on 
the reliability of these tests. A marker to confirm the presence of fetal nucleic acids is 
therefore required that is universally applicable and easy to incorporate. 
Methods: We developed a novel multiplex, single-tube, noninvasive fetal sex 
determination assay by combining amplification of AMELY cffDNA with one-step 
reverse transcription (RT)-PCR of trophoblast-derived cell-free RNA (cfRNA), which 
functions as a sex-independent fetoplacental marker. We tested plasma samples from 
75 pregnant women in duplicate in a blinded fashion. The fetus was considered to be 
male in the case of a positive result for AMELY and cfRNA amplification in both RT-
PCRs. The fetus was considered to be female in the case of negative AMELY and 
positive cfRNA result in both RT-PCRs. In other cases, the test was repeated. We 
compared the results with invasive prenatal testing and pregnancy outcomes. 
Results: The AMELY cffDNA amplification and cfRNA result was unambiguous and 
identical in duplicate in 71 of 75 plasma samples (95%). Four samples (5%) required an 
extra replicate because of an absent fetoplacental marker. Thereafter, fetal sex was 
correctly determined in all 75 plasma samples. 
Conclusions: Amplification of trophoblast-derived cfRNA is a reliable marker for the 
confirmation of the presence of fetoplacentally derived nucleic acids in noninvasive 
fetal sex determination. 
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2.2 Introduction 
Cell-free fetal DNA (cffDNA) in maternal plasma is analyzed for noninvasive prenatal 
diagnosis (NIPD), e.g., to determine the fetal sex. It is well known that the fetal 
fraction, i.e., the cffDNA subfraction from the total maternal and fetal cfDNA in the 
plasma, correlates with test success and interpretation reliability.1 The cffDNA 
represents on average 6-10% of the total cfDNA in first- and second-trimester 
pregnancies, and increases to 10-20% in third-trimester pregnancies.2,3 However, the 
fetal fraction can remain < 4% in the first trimester.4,5 To conclude whether a negative 
result of an NIPD assay is a true or false negative, a marker to confirm the presence of 
fetal nucleic acids (a fetal marker) is crucial. The ideal fetal marker can be used as an 
internal control in the same test to detect any technical failure of the assay. As such, 
the fetal marker should be (a) part of the NIPD assay, (b) specific for fetoplacentally 
derived nucleic acids, and (c) sex-independent. 
Trophoblastic cells from the fetal part of the placenta are the source of cffDNA.6 CfRNA 
derived from genes that are expressed only by the trophoblastic cells may be used as 
a sex-independent marker to prove the presence of fetoplacentally derived nucleic 
acids in the plasma sample. Trophoblast-derived messenger RNA (mRNA) of the 
pregnancy-specific hormones placental lactogen (PL) and human chorionic 
gonadotropin (hCG) is constantly released into maternal plasma during pregnancy.7,8 
The amount of cfRNA in maternal plasma corresponds with known expression patterns 
of the genes in the villous layer during placental development and with concentrations 
of released hormone in maternal serum.7,9,10 Therefore, the amount of hCG cfRNA is 
highest in the first trimester of pregnancy, whereas the amount of PL cfRNA is highest 
in the third trimester.7,8 This cfRNA is stable and rapidly cleared after delivery.7 cfRNA 
has been used as a marker to detect placental disease, fetal hypoxia, or ectopic 
pregnancy, but not as a fetal marker in noninvasive genetic tests.11-14 
This study examines the use of trophoblast-derived cfRNA as a fetoplacental marker 
in noninvasive fetal sex determination. Noninvasive fetal sex determination is often 
requested in case of a fetus at risk for 1 of the > 100 known X-linked inherited disorders 
or for autosomal recessive congenital adrenal hyperplasia.15,16 Furthermore, if a fetus 
presents with ambiguous genitalia on ultrasound examination, prenatal determination 
of the genetic sex can be part of the structured approach to detect the underlying 
condition. In the case of amplification of Y chromosome-derived cffDNA sequences in 
maternal plasma by real-time quantitative PCR (qPCR) or standard PCR, the fetus is 
presumed to be male. If no Y chromosome-derived cffDNA sequences are amplified, 
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the fetus is most likely female, but this could also be the result of an insufficient 
amount of cffDNA. To date, in general, 2 methods are used to confirm that cffDNA is 
present in the sample. The first is the detection of paternally inherited alleles17, and 
the second is the amplification of hypermethylated placental genes, such as RASSF1A 
[Ras association (RalGDS/AF-6) domain family member 1, isoform A], after removing 
maternal unmethylated gene sequences by a methylation-sensitive endonuclease.18 
Both approaches have drawbacks. They require extra time and expense by the 
laboratory, and they sometimes fail to confirm the presence of fetal nucleic acids.17,18 
In addition, the first method requires paternal DNA. As a consequence, the ideal fetal 
marker for noninvasive sex determination, which is incorporated in the test and 
requires no extra time or expense, is not yet available. In this study, we developed a 
novel single-tube NIPD assay for fetal sex determination by combining amplification of 
AMELY (amelogenin, Y-linked) cffDNA with one-step reverse transcription (RT)-PCR of 
trophoblast-derived cfRNA, which functions as a sex-independent fetoplacental 
marker. We present a proof-of-principle study in 75 pregnant women with known 
pregnancy outcomes. 
2.3 Materials and Methods 
2.3.1  Blood sample collection 
We collected EDTA-anticoagulated blood samples of 75 pregnant women at 9 + 4 to 
34 + 1 weeks (+ days) of gestation at the Department of Clinical Genetics of the 
Maastricht University Medical Center, the Netherlands. These pregnant women were 
scheduled to undergo invasive chorionic villous sampling or amniocentesis for prenatal 
microarray analysis because of structural abnormalities seen on prenatal ultrasound 
scan. Parental blood samples were collected for interpretation studies should an 
abnormality be detected in the prenatal sample upon array analysis. Additionally, we 
used EDTA-anticoagulated blood samples from 20 randomly selected male partners as 
positive Y chromosome control samples and from 20 nonpregnant women of 
reproductive age (nulli-, primi-, and multipara women) as negative nonpregnant non-
Y chromosome control samples.  
Blood was stored at 4 °C before processing. All participants agreed to the use of their 
coded body material for improvement of diagnostic tests, according to the Code of 
Conduct for Responsible Use of Human Tissue and Medical Research in the 
Netherlands. The sample characteristics are listed in Table 2.1. 
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Table 2.1 Sample characteristics 
 n  
Gestational age, weeks + days   
 9 + 4 to 11 + 6  9  
 12 + 0 to 14 + 6  12  
 15 + 0 to 17 + 6  12  
 18 + 0 to 20 + 6  27  
 21 + 0 to 23 + 6  12  
 24 + 0 to 34 + 1  3  
Venipuncture before/after any invasive procedure   
 Before 71  
 7-8 days after 3  
 2 months after 1  
Fetal sex   
 Boy 42  
 Girl 33  
Source fetal sex   
 Prenatal karyotyping/microarray analysis 72  
 Postnatal microarray analysis 2  
 Birth report only 1  
BMI at first prenatal visit, kg/m2   
 <20 12  
 20-25 40  
 25-30 12  
 >30 5  
 Unknown 6  
Parity in female-bearing pregnancies   
 Primipara 15  
 Multipara 17  
 Unknown 1  
Offspring in multipara female-bearing women   
 Male (n) 8 (1-2)  
 Female only 7  
 Unknown 1  
Storage    
 EDTA-anticoagulated blood samples (4°C), h   
 <24 62  
 24-48 11  
 48-72 1  
 Unknown 1  
 Plasma (-80°C), months   
 <1 6  
 1-6 65  
 7-12 0  
 12-13 3  
 Unknown 1  
 cfDNA/RNA (-80°C)   
 1-6 days 10  
 1-4 weeks 31  
 1-6 months 28  
 6-11 months 6  
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Further laboratory tests were conducted blinded to the clinical characteristics of the 
samples, except for the gestational age of the women at the time of blood sample 
collection. The blood samples of the controls were anonymized. Only the parity and 
number of male offspring were registered from the nonpregnant females. The women 
had 0-2 male pregnancies in the past. 
2.3.2 Sample processing and cfDNA/RNA extraction 
Figure 2.1 illustrates the test procedure and suggested time schedule. Blood samples 
were centrifuged at 1600 x g for 10 min at 4 °C. The plasma portion was transferred 
into plain polypropylene tubes and centrifuged at 7470 x g for 10 min at 4 °C. Cryogenic 
vials containing the supernatant were stored at -80 °C until cfDNA/RNA extraction. We 
performed simultaneous extraction of total cfDNA and cfRNA in duplicate from 2 x 2 
mL plasma from the pregnant women with the QIAamp Circulating Nucleic Acid Kit 
(Qiagen), following a slightly adjusted protocol (see Supplemental data). The 
cfDNA/RNA (elution volume 50 µL) was subsequently stored at -80 °C for optimal 
conservation of the cell-free nucleic acids. Additionally, we performed 1 cfDNA/RNA 
extraction with 1 mL plasma from the nonpregnant females and male controls (elution 
volume 25 µL). 
Figure 2.1 Test procedure and suggested time schedule. 
2.3.3 Primer design 
To investigate the presence of trophoblast-derived cfRNA in the maternal plasma, we 
designed oligonucleotide primer pairs for specific RT and amplification of trophoblast-
expressed genes encoding the hormones PL and hCG. For PL, these are the highly 
similar genes CSH1 and CSH2 [respectively, chorionic somatomammotropin hormone 
1 (placental lactogen) and chorionic somatomammotropin hormone 2], and for hCG, 
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4 highly homologous genes: CGB (chorionic gonadotropin, β polypeptide), CGB5, 
CGB7, and CGB8 [chorionic gonadotropin, β polypeptides 5, 7, and 8, respectively].10,19 
The primers were developed with the free web program Primer3 
(http://bioinfo.ut.ee/primer3-0.4.0/ primer3). Criteria for primer design were primer 
size (20-30 nucleotides), GC content (40-60%), melting temperature of the primers (65 
°C-70 °C, optimal 68 °C), primers preferably ending 3’ with a guanine or cytosine, and 
RNA PCR product lengths between 60 and 150 bp. The primers anneal to sequences in 
exons on both sides of an intron. As a result, a larger product amplified from cfDNA 
(both maternal and fetoplacental) and a smaller product amplified from the intronless 
cfRNA (fetoplacental) is predicted. The cfDNA product will provide an internal control 
in cases in which no amplification of cfRNA is expected, e.g., in plasma samples from 
males and nonpregnant females. All forward primers were fluorophore-labelled, 
allowing visualization of the PCR products after separation by a capillary sequencer. 
The sequences of the primers, their fluorescent labels, and the theoretic cfDNA and 
cfRNA product sizes are listed in Table 2.2. Because of the > 85-90% sequence identity 
among the genes in the human growth hormone/CSH gene cluster (17q22-24) and the 
LHB (luteinizing hormone β polypeptide)/CGB gene cluster (19q13.3), our primers will 
most likely also initiate RT and amplification of cfRNA from other trophoblast-
expressed genes. These are CSHL1 (chorionic somatomammotropin hormone-like 1), 
a paralog gene of CSH1 and CSH2, and CGB1 and CGB2 (chorionic gonadotropin, β 
polypeptides 1 and 2, respectively). The function of these genes is currently unclear, 
but their expression is trophoblast specific.9,10,20 We expect amplification products of 
the same size in all genes and transcript variants of the genes (see Supplemental Figure 
2.5). As such, the combined amplification of the cDNA of all genes can be used to 
investigate the presence of trophoblast-derived cfDNA. We refer to the amplified 
genes in the human growth hormone/CSH gene cluster as “CSH genes” and those in 
the LHB/CGB gene cluster as “CGB genes” throughout this article.  
To detect Y chromosome-specific cffDNA in the maternal plasma, we designed 
oligonucleotide primer pairs for the amplification of AMELY (Yp11.2). To facilitate 
combination of all primer pairs in a multiplex test, the primers were developed with 
Primer3 and the same criteria for primer design as for the cfRNA targets. The primers 
were designed to overlap with mismatches compared with the homologous gene on 
the X chromosome: AMELX (amelogenin, X-linked) (Xp22.31–p22.1). As a result, 
amplification of maternal cfDNA derived from the X chromosome was avoided (see 
Supplemental Figure 2.6). 
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Table 2.2 Primer sequences and product sizes 
 Chromosome and gene Sequence 5'- 3' with fluorescent dye* Product size, bp  
   cfDNA cfRNA  
 17, CSH genes     
   Forward VIC-CCAACATGGAGGAAACGCAACAG 163 70  
   Reverse GACTCGATGAGCAGCAGGGAGA    
 19, CGB genes     
   Forward VIC-TGTGCATCACCGTCAACACCAC 364 129  
   Reverse GGATGGACTCGAAGCGCACA    
 Y, AMELY     
   Forward NED-AGCCACCTCTGCCTCCAATGTTC 81   
   Reverse TTGCTGGCCAAGCTTCCAGATG    
Legend to Table 2.2: *VIC and NED emit fluorescent signals at 554 nm and 575 nm of 
wavelengths, respectively. 
2.3.4 One-step RT-PCR 
For each isolation, single-tube one-step RT-PCR was carried out with the Qiagen 
OneStep RT-PCR Kit (Qiagen), according to the manufacturer’s instructions. RT-PCRs 
were set up in a total volume of 25 µL, with 4 µL cfDNA/RNA, 1 µL OneStep RT-PCR 
Enzyme Mix (containing Omniscript and Sensiscript Reverse Transcriptases and 
HotStarTaq DNA polymerase), 5 µL 5 x OneStep RT-PCR Buffer, 1 µL dNTP mix 
(containing 10 mmol/L of each dNTP), and 2.5 or 2.1 µL PCR primer mix (containing 10 
pmol CGB forward and reverse primer, 7 pmol CSH forward and reverse primer, and 8 
or 4 pmol AMELY forward and reverse primer, for gestational ages < 15 weeks and > 
15 weeks, respectively). RT-PCR was performed on the GeneAmp® PCR System 9700 
(Applied Biosystems). The reaction was initiated at 50 °C for 30 min, allowing specific 
RT of CSH and CGB genes cfRNA. This was followed by 95 °C for 15 min for inactivation 
of the reverse transcriptases, denaturation of the cDNA and cffDNA template, and 
activation of the HotStarTaq DNA polymerase. Simultaneous amplification of AMELY 
cffDNA and CSH and CGB genes cDNA was conducted by 10 cycles of 94 °C for 10 s, 66 
°C for 1 min, and 72 °C for 1 min, followed by 35 cycles of 94 °C for 10 s, 66 °C for 30 s, 
and 72 °C for 30 s. The reaction was ended by a final incubation at 72 °C for 10 min. 
The RT-PCR products were either immediately separated and analyzed or stored at  
-20 °C. 
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2.3.5 Separation of RT-PCR products and data analysis 
The fluorescently labeled RT-PCR products were diluted 1:100 (1 part RT-PCR product 
and 99 parts H2O) before separation and separated by capillary electrophoresis on the 
ABI 3730 DNA Analyzer (Applied Biosystems by Life Technologies). The sizes, peak 
heights, and areas under the amplification peaks of the RT-PCR products were 
analyzed with data analysis software (GeneMarker v2.4.0, Soft Genetics). 
 
2.4 Results 
2.4.1 Analysis of the electropherograms 
The nonspecific background for each of the cfRNA and cfDNA amplification products 
was determined by use of the 40 plasma samples from the nonpregnant female and 
male controls. For all subsequent analyses, we used the criterion that if the area under 
the amplification peak was above the nonspecific background, a peak was considered 
present. 
Figure 2.2 shows the primer binding sites in the exons, the theoretic sizes of the cfDNA 
and cfRNA products, and examples of the amplified fluorescent RT-PCR products in 
different sample types. The electropherogram of all sample types (pregnant and 
nonpregnant controls) showed 2 amplified VIC fluorescent dye-labeled products of 
160 and 361 bp, representing CSH and CGB genes cfDNA, respectively. In case of a 
pregnancy, 2 smaller VIC-labeled products were seen (64 and 125 bp), representing 
CSH and CGB genes cfRNA, respectively. In case of the presence of a Y chromosome 
(male fetus or adult male), the electropherograms showed an amplified NED dye-
labeled product of 76 bp representing AMELY cffDNA or cfDNA. No trophoblast-
derived cfRNA peaks were found in the 40 control plasma samples in which no 
fetoplacental nucleic acids were expected (20 males and 20 nonpregnant females). 
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Figure 2.2 Multiplex one-step RT-PCR. (A), Primer binding sites in the exons. (B-E), GeneMapper 
electropherograms showing the amplified fluorescent products in a plasma sample of a woman 
carrying a male fetus (9 + 4 weeks of gestation) (B); a woman carrying a female fetus (19 + 4 
weeks of gestation) (C); an adult nonpregnant woman (D); and an adult male (E). In all samples, 
2 VIC-labeled products of 160 and 361 bp, representing CSH and CGB genes cfDNA, respectively, 
were detected (A-E). In case of a pregnancy, 2 smaller VIC-labeled products were seen (64 and 
125 bp), representing CSH and CGB genes cfRNA, respectively (A-C). In case of a male fetus or 
adult male, an amplified NED-labeled product of 76 bp representing AMELY cffDNA or cfDNA 
was detected (A, B, E). 
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2.4.2 Fetoplacental markers throughout pregnancy 
The fetoplacental marker was considered present if the trophoblast-derived cfRNA 
peaks were detected according to gestational age, i.e., according to the expression 
patterns during placental development. In the first trimester of pregnancy, we 
expected the area under the CGB genes cfRNA amplification peak to be higher than 
that of the CSH genes cfRNA amplification peak. In the second and third trimesters of 
pregnancy, we expected the area under the CGB genes cfRNA amplification peak to be 
below the area of the CSH genes cfRNA amplification peak. To confirm this, we 
evaluated the cfRNA peaks in the 75 plasma samples from the pregnant women. The 
ratio of both areas (CSH to CGB peak ratio) was calculated for each sample. The 
distribution of the CSH to CGB peak ratio throughout pregnancy is shown in Figure 2.3. 
Indeed, from this graph it can be seen that all first-trimester samples had a higher area 
under the CGB genes cfRNA amplification peak than under the CSH genes cfRNA 
amplification peak, and that with increasing gestational age the CSH to CGB peak ratio 
increases. Electropherograms early and later in the pregnancy illustrate this trend in 
Supplemental Figure 2.7. 
 
 
Figure 2.3 Fetoplacental markers throughout pregnancy. Box plots represent the distribution of 
CSH to CGB peak ratio in the first, second, and third trimesters in the sample set of 75 pregnant 
women. 
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2.4.3 Determination of fetal sex 
The sample was considered to be derived from a woman carrying a male fetus in the 
case of a positive result for AMELY cffDNA and trophoblast-derived cfRNA 
amplification in both RT-PCRs. The fetus was considered to be female in the case of a 
negative AMELY cffDNA amplification result and a positive trophoblast-derived cfRNA 
amplification result in both RT-PCRs. 
The AMELY and cfRNA amplification result was unambiguous and identical after 
conducting the duplicate one-step RT-PCR once in 71 of 75 plasma samples (Figure 
2.4). In 41, a distinct positive result for the AMELY cffDNA and cfRNA amplification was 
seen in both RT-PCRs, whereas the remaining 30 samples showed no AMELY cffDNA 
amplification in combination with a positive cfRNA result in both RT-PCRs. We 
classified the first 41 samples as male fetuses and the latter 30 samples as female 
fetuses. 
Three samples required a third replicate of RT-PCR (NY-19, 15 + 1 weeks; NY-41, 14 + 
1 weeks; NY-49, 21 + 1 weeks). They were classified as “probably female” fetuses after 
the second test, because the presence of fetoplacentally derived nucleic acids was 
evident in only 1 of the 2 RT-PCRs. We repeated the dubious RT-PCR run in all 3 
samples with the same starting materials and conditions. Thereafter, a 100% 
concordance rate between the clear RT-PCR and the repeated RT-PCR was reached for 
all samples. Samples NY-19, NY-41, and NY-49 were thus all classified as female-
bearing pregnancies. A last sample required a rerun of the duplicate RT-PCR. No sex 
could be determined for the sample (NY- 36, 19 + 6 weeks), because no AMELY cffDNA 
amplification and no positive cfRNA result was found in either RT-PCR. The same 
starting materials and conditions were used during the rerun. In both cfDNA/RNA 
isolations, the fetoplacental marker was present, as well as an AMELY cffDNA peak. 
Apparently, both RT-PCRs had initially failed, although they were performed at 
separate times. This sample was now classified as being derived from a woman 
carrying a male fetus.  
Comparison of the result of our noninvasive fetal sex determination test with the 
result of invasive prenatal testing and pregnancy outcomes revealed that the fetal sex 
was correctly determined in all of these 75 samples (100%). 
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Figure 2.4 Determination of fetal sex. The fetal sex could be determined unequivocally after 
conducting the RT-PCR once in 2 separate cfDNA/RNA isolations in 71 of 75 plasma samples. 
Three samples required a third repeat, and 1 sample required a rerun of the duplicate RT-PCR 
for a definitive conclusion, because of an absent fetoplacental marker. Thereafter, fetal sex was 
correctly determined in all 75 plasma samples. 
 
2.5 Discussion 
This study examined the use of cfRNA as a fetoplacental marker incorporated in a 
noninvasive fetal sex determination assay. In our proof-of-principle study, 75 blinded 
plasma samples from pregnant women were tested to find out whether the fetal sex 
could be determined and whether cfRNA was a reliable fetoplacental marker in this 
process. 
The fetal sex could be determined unequivocally after conducting RT-PCR once in 2 
separate cfDNA/RNA isolations in the majority of the plasma samples (95%). Absence 
of the fetoplacental marker in 1 of both RT-PCRs in 5% of the cases required a repeat 
RT-PCR to have an unambiguous result for fetal sex determination. After these 
replicates, the fetoplacental markers turned out to be present in all samples. More 
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importantly, the fetal sex was correctly determined in all cases (100%). 
Because of low template DNA, a noninvasive fetal sex determination assay sometimes 
requires multiple replicates to provide an unambiguous indication of fetal sex.17,18 In 
clinical practice, it is advisable to test each cfDNA/RNA extraction at least twice. If the 
fetoplacental marker is not detected after repeated testing in AMELY-negative 
samples, it is recommended to redraw blood from the pregnant women. 
Our proof-of-principle study results indicate that the presence of the fetoplacental 
cfRNA marker in this single-tube assay is tightly correlated with an adequate amount 
of cffDNA in the plasma for noninvasive sex determination. We conclude this on the 
basis that in all pregnancies with male fetuses, both AMELY cffDNA and trophoblast-
specific cfRNA were reliably detected, and in none was AMELY cffDNA detected 
without the trophoblast-specific cfRNA peaks. Also, in none of these samples were the 
trophoblast-specific cfRNA peaks present while the AMELY cffDNA peak was absent. 
Moreover, we would have determined 1 sample from a male fetus as being derived 
from a female-bearing pregnancy without the use of the fetoplacental marker. In 
addition, no AMELY cffDNA was detected above background in any of the nullipara or 
multipara nonpregnant women or women carrying a female fetus. In case of a negative 
result of the cfRNA marker, however, it was also clear there was an insufficient amount 
of fetal nucleic acids present (if not due to a technical failure) and the test needed to 
be repeated, on the same or a new blood sample. 
Clearly, this proof-of-principle study needs further replication before entering the 
diagnostic arena. One of the limitations of our study is that we did not test samples 
from pregnant women at 7-8 weeks of gestation and only 1 at 9 weeks of gestation 
(male fetus). However, our data do not show a decreased detection rate for 8 
pregnancies at 11 weeks of gestation. After conducting the duplicate one-step RT-PCR 
once, the fetal sex was unambiguous and correct in all 8 samples (2 male fetuses, 6 
female fetuses). Although these numbers are small, they suggest that the assay can be 
reliably applied early in pregnancy. A follow-up study, including samples from women 
between 7 and 10 weeks of pregnancy, is now recommended. 
RT of cfRNA to cDNA could be added to other noninvasive prenatal tests investigating 
fetal alleles, e.g., for monogenic traits. cfDNA and cfRNA are extracted simultaneously 
from the plasma sample in most extraction kits, and therefore no additional procedure 
is necessary to obtain cfRNA. The cfRNA peaks did not appear to be strongly influenced 
by high BMI or longer storage of blood, plasma, or cfDNA/RNA. As an example, the 
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cfDNA/RNA of NY-92 was stored for 11 months at -80 °C before analysis. This was a 
plasma sample collected at 13 + 2 weeks of gestation from a woman with a BMI of 
30.9. The cfRNA peak areas obtained for this sample are in the expected range for 
gestational age. This was also found in the other samples stored for a long time and in 
all women with high BMI. 
Our test is based on AMELY only for fetal sex determination. Sex determination on the 
basis of AMELY is widely accepted in genetic diagnosis for sex determination, e.g., in 
the forensic field, prenatal diagnosis, and preimplantation genetic diagnosis. However, 
a few cases with AMELY deletion resulting in allelic dropout have been reported in 
different populations.21 The frequency of AMELY negatives is low, and ethnic 
differences seem to exist (0.018% in Europe, 0.02% in Australia, 1.85-2.36% in 
India).21,22 In a pilot study, we have attempted to incorporate other Y chromosome 
genes, SRY (sex-determining region Y) and UTY (ubiquitously transcribed 
tetratricopeptide repeat containing, Y-linked), but found too many primer interactions 
in the multiplex RT-PCR (data not shown). 
Finally, massively parallel sequencing approaches also can be used to determine the 
sex of the fetus, but at the moment this is still rather expensive.23,24 Our noninvasive 
fetal sex determination assay is a useful addition to the next-generation sequencing 
flow, as it is cheap, fast, and easy to use and provides a result within 1 or 2 days. 
Furthermore, it can be conducted in laboratories that do not have access to next-
generation sequencing facilities. 
In conclusion, in this proof-of-principle study, we have shown that amplification of 
placenta-expressed genes is an elegant way to confirm the presence of fetal nucleic 
acids in the maternal plasma and can be combined in a single tube with a sex-
determination assay. 
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Isolation of cell-free DNA and cell-free RNA using the QIAamp® Circulating 
Nucleic Acid Kit and a slightly adjusted protocol 
Procedure 
1. Pipet 200 µL QIAGEN Proteinase K into a 15 mL centrifuge tube.  
2. Add 2 mL of plasma to the 15 mL tube. Add PBS if less than 2 mL plasma. 
3. Add 1.6 mL Buffer ACL. Close the cap and mix thoroughly by pulse vortexing for 30 s.  
4. Incubate at 60°C for 30 min in water bath.  
5. Place the tube back on the lab bench and unscrew the cap. 
6. Add 3.6 mL Buffer ACB to the lysate in the tube. Close the cap and mix thoroughly by pulse-
vortexing for 15-30 s. 
7. Incubate the lysate-Buffer ACB mixture in the tube for 5 min on ice. 
8. Carefully apply 750 µL of the lysate from step 7 onto the QIAamp Mini column, without 
wetting the rim. Close the cap and centrifuge at 6000 x g (8000 rpm) for 1 min. Place the 
QIAamp Mini column in a clean 2 mL collection tube, and discard the collection tube 
containing the filtrate. Repeat this step 9 times. 
9. Carefully open the QIAamp Mini column, and add 600 µL Buffer ACW1 without wetting 
the rim. Close the cap and centrifuge at 6000 x g (8000 rpm) for 1 min. Place the QIAamp 
Mini column in a clean 2 mL collection tube, and discard the collection tube containing the 
filtrate.  
10. Carefully open the QIAamp Mini column, and add 750 µL Buffer ACW2 without wetting 
the rim. Close the cap and centrifuge at 6000 x g (8000 rpm) for 1 min. Place the QIAamp 
Mini column in a clean 2 mL collection tube, and discard the collection tube containing the 
filtrate. 
11. Carefully open the QIAamp Mini column, and add 750 µL ethanol (96-100%) without 
wetting the rim. Close the cap and centrifuge at 6000 x g (8000 rpm) for 1 min. Discard 
the collection tube containing the filtrate. 
12. Close the lid of the QIAamp Mini column. Place the QIAamp Mini column in a clean 2 mL 
collection tube. Close the cap and centrifuge at full speed (20 000 x g; 14 000 rpm) for 3 
min. 
13. Place the QIAamp Mini column into a new 2 mL collection tube. Open the lid, and incubate 
the assembly at 56°C for 10 min to dry the membrane completely.  
14. Place the QIAamp Mini column in a clean 1.5 mL elution tube and discard the 2 mL 
collection tube from step 13. Carefully apply 55 µL of Buffer AVE to the center of the 
QIAamp Mini membrane. Close the lid and incubate at room temperature for 30 min 
before proceeding to the next step (improves yield). 
15. Centrifuge in a microcentrifuge at full speed (20 000 x g; 14 000 rpm) for 1 min to elute 
the nucleic acids.  
16. Storage of the vials: use immediately or store at -80 °C. 
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Supplemental Figure 2.6 Primer sequences and locations of the primers for AMELY cffDNA 
amplification. The primers were designed to overlap with mismatches compared with the 
homologous gene on the X-chromosome: AMELX. The forward and reverse primer are 
underlined. 
 
 
Supplemental Figure 2.7 Electropherograms showing the fetoplacental marker throughout 
pregnancy. GeneMapper electropherograms showing the amplified fluorescent-labelled (NED 
or VIC) products of the multiplex one-step RT-PCR in plasma samples of a pregnant woman 
carrying A) a male fetus at 9 + 4 weeks of gestation; B) a female fetus at 11 + 0 weeks of 
gestation; C) a male fetus at 15 + 2 weeks of gestation; D) a female fetus at 16 + 3 weeks of 
gestation; E) a male fetus at 20 + 5 weeks of gestation; F) a female fetus at 21 + 0 weeks of 
gestation. 
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3.1 Abstract 
Background: Myotonic dystrophy 1 (DM1) is an autosomal dominant disorder, caused 
by an unstable CTG trinucleotide repeat, ranging from 50 to > 1000 repeats. In patients 
with DM1 skeletal and smooth muscle are affected, as well as the eye, heart, endocrine 
and central nervous systems. DM1 is a frequent indication for prenatal diagnosis. 
Noninvasive prenatal diagnosis (NIPD) aims to detect the disorder in the fetal cell-free 
DNA (cfDNA) in maternal plasma, thereby avoiding the miscarriage risk associated with 
an invasive procedure. We present proof of concept of an haplotype-based NIPD assay 
to detect DM1 in the fetus. 
Methods: Single molecule molecular inversion probes (smMIPs) were designed and 
optimized for targeted next-generation sequencing of common SNP markers flanking 
the causative DMPK CTG repeat expansion. Plasma from a pregnant woman with a 
DM1 affected partner was collected. After sequencing the SNP markers from the 
parents and a previous child with DM1 (= reference), informative SNPs for the mutated 
allele of the father and reference were selected. Subsequently, the plasma cfDNA was 
sequenced to determine the fetal inheritance, calculated from the percentage of the 
informative SNPs in the cfDNA reads. 
Results: Twelve SNPs were informative. The paternal-specific allele was identified in 
on average 4% of the cfDNA reads (range 1.5-9.9%), corresponding to a fetal fraction 
of 8%. Ten SNPs unequivocally reported presence of the mutated paternal allele in het 
cfDNA. Furthermore there was no single marker reporting presence of the wild-type 
paternal allele. Fetal gDNA analysis from the invasive procedure (chorionic villus 
sampling) confirmed all findings.  
Conclusion: This assay has the potential to deliver a fast and reliable assay for NIPD of 
single-gene disorders caused by trinucleotide repeat expansion mutations through 
haplotyping of fetal alleles in fractionated, low input cfDNA. 
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3.2 Introduction 
Myotonic dystrophy 1 (DM1), also known as Steinert's disease, is an autosomal 
dominant genetic disorder that affects skeletal and smooth muscle, the eye, heart, 
endocrine and central nervous systems.1,2 It is caused by expansion of a CTG 
trinucleotide repeat in the non-coding intron 1 of the dystrophia myotonica protein 
kinase gene (DMPK).3,4 There is a broad spectrum of clinical severity, ranging from mild 
to severe. Five clinical phenotypes of DM1 were described that generally correlate 
with CTG repeat size, including premutation (38-49 CTG repeats), mild adult DM1 (50-
100 CTG repeats), classical adult DM1 (50-1000 CTG repeats), childhood-onset DM1 (> 
800 CTG repeats) and congenital DM1 (> 1000 CTG repeats).1 The classical adult DM1 
is characterized by progressive muscle weakness and wasting, myotonia, and cataract, 
and often cardiac conduction abnormalities.5 In congenital DM1 hypotonia and severe 
generalized weakness at birth is seen, often with respiratory insufficiency and early 
death.5 DM1 is characterized by anticipation: in successive generations, affected 
family members are at risk for further expansion of the CTG repeat, resulting in 
decreasing age of onset and increasing severity.1  
Prenatal diagnosis of DM1 is offered for pregnancies at increased risk, when the 
diagnosis of DM1 has been confirmed by molecular genetic testing in an affected 
family member.5 Traditionally, an invasive procedure is performed to provide fetal 
cells for genetic testing, either chorionic villus sampling (CVS) between 11 and 14 
weeks of gestation or amniocentesis after 15 weeks of gestation. The additional risk 
of miscarriage in women undergoing amniocentesis or CVS is estimated between 0.11-
1.00% and 0.22-2.00%, respectively.6-8 To avert the additional miscarriage risk of the 
invasive procedures, safe noninvasive prenatal tests using fetal cell-free DNA (cfDNA) 
in maternal plasma are now offered to pregnant women. Highly reliable and already 
implemented in clinical practice are noninvasive fetal sex determination, genotyping 
of fetal blood group antigens and fetal aneuploidy detection.9-12 Recently, the first 
efforts have been made to expand non-invasive prenatal cfDNA testing to single-gene 
disorders.13 
Noninvasive prenatal diagnosis (NIPD) of DM1 in fetal cfDNA is challenging from 
several perspectives. A first challenge is the CTG repeat size. The affected parent can 
easily have a CTG expansion of more than 500 bp, and the fetus can have an even 
higher repeat size due to the instability of the repeat. Cell-free DNA exists of short, 
fractionated, DNA sequences that vary in size, but are mostly shorter than 200 bp.14,15 
A second challenge is that most of cfDNA fragments in the maternal blood circulation 
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are of maternal origin. The fetal cfDNA represents on average a fraction of 6-10% of 
the total cfDNA in first and second trimester pregnancies.16,17 This so-called fetal 
fraction rises up to 10-20% in third trimester pregnancies.16,17 Evidently, the maternally 
inherited fetal DMPK allele, represented in the fetal cfDNA, is identical to half of the 
DMPK alleles in the abundantly present maternal cfDNA fragments. The paternally 
inherited fetal DMPK allele is only present in half of the fetal fraction of the cfDNA. A 
third challenge is the low level of cfDNA in maternal plasma. Often cited is an expected 
amount of total (maternal and fetal) cfDNA of 1000 genome equivalents/mL in a 
human blood sample.18,19 However, the level of the total cfDNA and the fraction of 
fetal cfDNA vary between individuals, depending on maternal health factors, such as 
obesity or diabetes, the condition of the placenta and the gestational age.20,21 
Additionally, quantification of the total cfDNA and of the fetal fraction is influenced by 
pre-analytical and analytical factors, including storage conditions, delay before plasma 
separation, blood-processing protocols, DNA extraction method, amplicon size, target 
gene choice, and used method.19,20 Concentrations in maternal plasma as low as 220 
genome equivalents/mL and 20 genome equivalents/mL have been described for total 
(maternal and fetal) cfDNA and fetal cfDNA, respectively.16,20 Due to an already known 
predisposition, prenatal diagnosis of DM1 is mostly requested early in pregnancy, 
when the fetal fraction is at its lowest.  
For NIPD of DM1, we have developed a method to detect the inherited DMPK alleles 
in the cfDNA, using an haplotype-based approach. Fetal haplotype inference using 
single nucleotide polymorphisms (SNPs) for NIPD of single-gene disorders has been 
suggested by others.22,23 In our assay, we use single molecule molecular inversions 
probes (smMIPs) for targeted multiplex next-generation sequencing of CTG repeat 
flanking common SNPs.24 MIPs can easily be adapted to target genomic regions of 
interest, and allow parallel capture across many targets. Adding single molecule 
tagging to the MIPs allows to mark sequence reads derived from a common progenitor 
molecule (that is, the same genomic equivalent in source DNA), resulting in counting 
of unique captured molecules, and tag-based consensus calling to minimize errors 
from PCR or sequencing. This enables precise quantification of the variation in the 
cfDNA. Furthermore, the method has proven to be robust to relatively small amounts 
and poor quality of source DNA.24 As a result, smMIPs are not only suitable to detect 
heterozygous and homozygous variation at the SNP loci in the gDNA from the parents, 
but are in theory also highly sensitive for the detection of low frequency variation in 
the fetal cfDNA. As a proof of concept, we applied our smMIP NIPD assay to the cfDNA 
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isolated from the plasma of a woman carrying a fetus affected with DM1. We 
demonstrate that we can detect the mutated DMPK allele, inherited from the father, 
in the fetal cfDNA.  
3.3 Materials and methods 
3.3.1 Patient recruitment 
The study was approved by the Ethics Committee of the Maastricht University Medical 
Center (MUMC+). A pregnant woman (I:2) undergoing CVS for prenatal diagnosis of 
DM1 was asked to participate, together with her partner. The pedigree of the family 
is illustrated in Figure 3.1. The father of the fetus (I:1) is affected and has a CTG repeat 
size between 77-86 repeats. The couple has an older son that was postnatally 
diagnosed with DM1 and has a CTG repeat size of approximately 350 repeats (II:1), and 
two healthy children (II:2 and II:3). The pregnant woman donated 6 x 6 mL EDTA blood 
at 10 weeks + 1 day of gestation, before the CVS, for cfDNA and gDNA isolation. Her 
partner donated 2 x 6 mL EDTA blood for gDNA isolation. Furthermore, gDNA was 
collected from the previous son with DM1 (II:1), to use as a reference during SNP 
genotyping. Analysis of the fetal cells from the chorionic villi revealed that the fetus 
(II:4) was affected and carried a CTG repeat that had an very high size. 
 
Figure 3.1 Pedigree of the included subjects. Plasma was collected at 10 weeks + 1 day of 
gestation of a pregnant woman (I:2) carrying a fetus affected with myotonic dystrophy type 1 
(DM1), as diagnosed by invasive prenatal testing (II:4). SNP genotyping was conducted in a trio 
of the pregnant woman, her partner with DM1 (I:1) and a previous affected son (II:1).  
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3.3.2 Sample processing and DNA extraction 
Processing of the blood samples for cfDNA isolation occurred within 1h after blood 
drawing. The blood samples were centrifuged at 1600 x g for 10 min at 4 °C. The plasma 
was transferred into plain polypropylene tubes, and re-centrifuged at 7470 x g for 10 
min at 4 °C. Cryo vials containing the supernatant were stored at -80 °C until cfDNA 
extraction.  
Extraction of cfDNA was performed out of 6 mL plasma from the pregnant woman, 
using the QIAamp Circulating Nucleic Acid Kit (Qiagen). Elution was performed in  
25 µL of AE buffer, included in the kit (consisting of 10 mM Tris-Cl and 0.5 mM EDTA). 
The cell-free nucleic acids were stored at -80 °C before use. Extraction of gDNA from 
the parents, the affected child and invasive prenatal procedure was performed from 
whole blood and chorionic villous sample cells, following standard procedures. 
3.3.3 Design of smMIPs and rebalancing 
SmMIPs are single stranded oligonucleotides consisting of a common linker sequence 
flanked by annealing arms which complement genomic sequences next to the target 
sequence. SmMIPs bind to one strand of the target DNA (sense or antisense strand).24 
Ninety-eight smMIPs were designed to contain common CTG repeat flanking SNPs 
markers (minor allele frequency 5-49%) in the targeted sequence. The principle is 
shown in Figure 3.2. All smMIPs were designed with the open-source software 
MIPGEN (Version 0.9.1), as previously described.25,26 In total, sixty SNPs were targeted, 
thirty up to 500 kbp upstream of the CTG repeat, and thirty up to 500 kbp downstream 
of the CTG repeat. For forty-eight SNP loci two independent smMIPs were designed, 
one for each DNA strand. One SNP was targeted by three smMIPs, one binding to the 
sense strand, and two binding to the antisense strand. The remaining eleven SNP loci 
were single tiled, either by a smMIP for the sense strand or a smMIP for the antisense 
strand. To be eligible for cfDNA, the predicted gap fill between the annealing arms was 
set to a fixed length of 80 nt, and the sum of the annealing arms was set to 40 nt. 
Theoretically, the smMIPs could bind to sequences of 120 nt and larger, and analysis 
of the majority of the cfDNA reads present in the maternal plasma was predicted. Two 
times five degenerate bases at either end of the common linker sequence were used 
as unique tag, marking sequence reads derived from a common smMIP capture. This 
enables duplicate removal and consensus calling. Two times five N allows for a 
maximum theoretical non-duplicate coverage of 410 (= 1 048 576).  
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In an initial experiment all individual smMIP probes were pooled at identical 
concentrations (1 x pool), phosphorylated and used to capture and sequence four 
control gDNAs.27 After coverage calculations of the control gDNAs, the following 
rebalancing of the probe ratios was performed: the lowest performing probes (n = 7) 
were rebalanced with a 10 x excess, other poor performing probes (n = 31) were 
rebalanced with a 5 x excess. The final MIP pool was phosphorylated. In addition over 
performing smMIPs (n = 3) were counter-acted by adding native, unphosphorylated 
probes. The rebalanced smMIP assay was applied to the included family. 
 
Figure 3.2 Single molecule molecular inversion probes (smMIPs) for multiplex targeted next-
generation sequencing of CTG repeat flanking SNPs. 
 
3.3.4 Multiplex capture and amplification of targeted sequences 
SmMIP-based target enrichment of the gDNA derived from the parents, the previous 
child with DM1 and the chorionic villi of the fetus, was performed as described 
previously.24,27-29 The probes were added to 100 ng of gDNA in a ratio of 800 copies of 
each smMIP to each haploid genome copy. Hybridization of smMIPs to gDNA or cfDNA, 
gap filling and ligation were performed in a 25 μL reaction, containing of 10x Ampligase 
buffer (Illumina), 0.25 mM dNTPs (Life technologies), 3 units of Hemo KlenTaq (NEB), 
1 unit of Ampligase DNA ligase (Westburg), and the calculated number of smMIPs. 
Reactions were incubated at 95 °C for 10 min, followed by capture at 60 °C for 24 h. 
Remaining linear gDNA, and unhybridized probes were removed by adding 2 μL of 
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exonuclease mix (containing 10 units of exonuclease I (NEB) and 50 units of 
exonuclease III (NEB) in 10 x Ampligase buffer), and incubation of the reaction at 37 °C 
for 45 min and then at 95 °C for 2 min. Amplification of the exonuclease-treated 
circularized probes was done by standard polymerase chain reaction (PCR) in a 25 μL 
reaction, containing 2 x iProof HF Master Mix (Bio-Rad), 100 μM of common forward 
primer (Illumina), 10 μM of barcode-containing reverse primer (Illumina) and 5 μL of 
exotreated product. The reaction was initiated at 98 °C for 30 s, followed by 22 cycles 
of 98 °C for 10 s, 60 °C for 30 s, and 72 °C for 30 s, and ended at 72 °C for 2 min. The 
optimal amount of PCR cycles was previously determined by real-time quantitative 
PCR (qPCR). PCR products were pooled and the desired products were purified from 
self-ligated smMIP probes and residual PCR primers or primer dimers with 0.7-1 x 
AMPure XP beads (Beckman Coulter) according to the manufacturer’s protocol. Pools 
were quantified using the Qubit dsDNA HS Assay. Illumina NextSeq sequencing was 
performed according to manufacturer’s instructions, with additional spike in of MIP 
custom primers (MIP_fwd, MIP_rev and MIP_index) into Illumina primer wells, as 
described previously.27-29 
Subsequently, the smMIPs were applied to the cfDNA from the plasma sample, with 
minor modifications to the protocol. The same amount of probes were added to the 
cfDNA sample; ensuring high capture rates of sparse cfDNA molecules. We used all 
cfDNA extracted from 6 mL of plasma. The concentration after cfDNA isolation (1.97 
ng/µL) was measured by Qubit dsDNA HS Assay (Life Technologies). However, 
measurements of cfDNA on Qubit are not always trustworthy. Additionally, no 
difference between maternal and fetal cfDNA can be made. We estimate that we 
extracted at least 160 fetal genome equivalents from 6 mL plasma.16,20 We divided the 
entire volume of the exonuclease-treated smMIP-captured product over two PCR 
tubes (2 x 25 µL reactions). PCR-amplification was done by qPCR in two separate 
reactions using two independent barcodes, in order to increase the amount of unique 
molecules to count after sequencing and to limit PCR-based artifacts. The same PCR 
program was used as for gDNA samples, but the qPCR was stopped in the linear phase 
of amplification (24 cycles). The cfDNA-derived NGS-library was prepared separately 
and sequenced in an independent sequencing run to avoid contamination or barcode 
bleed-through of high coverage gDNA samples.   
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3.3.5 smMIP sequencing analysis 
The SNP loci were analyzed using the MIP-based VARiant calling tool MIPVAR, a fully 
automated MIP Analysis Tool for large-scale MIP experiments.30 MIPVAR provides 
variant calling combined with detailed coverage information per MIP. It excludes reads 
of low quality. Additionally, when the adding of molecular barcodes to the MIPs 
(smMIPs) is specified in the pipeline configuration, reads for the same sample, aligning 
to the same position and with the same molecular barcode are removed. In this way 
all resulting reads will be guaranteed to originate from unique DNA fragments allowing 
for a more reliable identification of variants. All variants were called using the human 
reference genome hg19. The informative SNPs were selected according to the 
procedure explained in 3.3.6.  
All low frequency variant calling results in the cfDNA by MIPVAR were confirmed using 
the Integrative Genomics Viewer (IGV) software and the SeqNext software package 
(version 4.2.2; JSI medical systems GmbH), using the optional smMIP analysis 
module.31,32 In IGV, the same fastq-files are analyzed as in the MIPVAR tool. In SeqNext, 
reads with undefined nucleotides in their barcodes or of low quality are ignored. To 
generate consensus reads, all bases should be covered at least once in the consensus 
reads, at least two tagged reads are required to create a consensus read. 
Consequently, this is the most rigorous method. All informative SNP positions were 
manually inspected in these two software package, and the amount of unique 
molecules covering each key-SNP position were counted for each nucleotide. The error 
rate for every type of substitution at all SNP loci from the three gDNA samples was 
used as “noise” for the interpretation of the cfDNA substitutions. In case of informative 
SNPs, only the mother, who is homozygous for those loci, could be used for the error 
rate.  
3.3.6 Parental SNP genotyping and deducing of the fetal inheritance 
The procedure for SNP genotyping of the parents and the child with DM1, and 
subsequently the deduction of the fetal inheritance is illustrated in Figure 3.3. 
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First, the SNP loci that can be used for the calculation of the fetal fraction are selected. 
These are the SNP loci where one parent is homozygous for the wild-type allele, and 
the other parent is homozygous for the allele with the substitution. The fetal fraction 
is two times the percentage of substitution in the cfDNA sequencing reads if the 
mother is homozygous for the wild-type allele, and two times the percentage of the 
wild-type nucleotide if the mother is homozygous for the allele with the substitution. 
These SNPs are not informative for the disease status of the parents or the fetus, and 
can only be used to determine the fetal fraction. Furthermore, the SNP loci where the 
mother is homozygous for the wild-type allele or homozygous for the allele with the 
substitution, and where the father is heterozygous, can be used for the calculation of 
the fetal fraction, if the fetus inherited the other type of allele (wild-type or with 
substitution) from the father than the allele for which the mother is homozygous 
(Figure 3.4). Some of these SNPs may also be useful for the disease status of the fetus. 
Figure 3.4 Deduction of the fetal fraction 
 
Second, informative SNPs defining the mutated DMPK allele from the affected parent 
are identified. Only SNP loci where the father is heterozygous and where the mother 
is homozygous for the wild-type allele or for the allele with the substitution, are 
informative for the disease status of the affected father. The affected child can be 
heterozygous, homozygous for the wild-type allele or homozygous for the allele with 
the substitution. The deduction of the fetal inheritance is illustrated in Figures 3.3B 
and 3.5. For all informative SNPs, the genetic status of the fetus is determined by 
calculating the percentage of the substitution in the cfDNA sequencing reads. This 
percentage is than combined with the known genotype of the mother and the affected 
child to deduct the fetal inheritance. 
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Figure 3.5 Inferring of the fetal inheritance in case of a father affected with DM1, assuming 10% 
fetal fraction. 
 
3.4 Results 
We applied our smMIP NIPD assay to the cfDNA isolated from the plasma of a pregnant 
woman with a DM1 affected partner. After sequencing the SNP markers from the 
parents and a previous child with DM1 (= reference), informative SNPs for the mutated 
DMPK allele of the father and reference were selected. Subsequently, the plasma 
cfDNA was sequenced to determine the fetal inherited haplotypes, calculated from 
the percentages of the informative SNPs in the cfDNA sequencing reads. The 
determined haplotypes indicated that the fetus was affected with DM1. This result 
was confirmed with diagnostic DM1 testing of gDNA from the invasively obtained fetal 
cells (chorionic villi). Finally, the smMIP NIPD assay was also applied to the fetal DNA 
from the chorionic villi, to validate the SNP genotyping results from cfDNA. 
3.4.1 Coverage 
In the gDNA samples from the parents, the affected son , and the chorionic villi an 
adequate unique read coverage was obtained for 59 out of 60 SNP loci (98%). In one 
SNP locus, the sum of the unique reads of the sense-binding and antisense-binding 
smMIP was below 30 x. This SNP was excluded from SNP genotyping. In the cfDNA 
sample from the pregnant woman the coverage was on average 5-20 times higher for 
each smMIP locus in comparison to the gDNA samples (Table 3.1). This was because 
less samples were pooled, in order to obtain a maximum number of unique reads per 
SNP locus. 
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Table 3.1 Coverage of the SNPs in all samples 
 Affected child 
gDNA 
Father  
gDNA 
Pregnant woman 
gDNA 
Plasma 
cfDNA 
CVS  
gDNA 
Minimum 29 28 59 499 18 
Maximum 2723 2213 3290 20 994 2675 
Mean 458 382 625 5672 440 
Median 174 264 463 4782 250 
      
3.4.2 SNP genotyping of the parents and the affected previous child 
For the 59 adequately covered SNPs the percentages of variant was determined in the 
gDNA reads from the parents and the previous child with DM1 by the MIPVAR tool 
through counting of the number of unique reads for each individual tag. Noise variants 
in the raw reads from one tag, occurring from PCR mistakes or sequencing mistakes 
were filtered out, and only variants occurring in all raw reads from one tag were saved 
in the unique tag. The MIPVAR tool reported a homozygous or heterozygous 
substitution at 34 out of 59 SNP loci (58%) in at least one of the subjects. In 24 SNP loci 
out of the remaining 25 targeted loci (41%) both parents, and evidently their child, 
carried the wild-type nucleotide in both alleles. One SNP could not be evaluated 
because the genomic region containing the SNP was deleted in the three subjects. Out 
of the 34 SNPs present in the subjects, six SNP loci, all targeted by the one smMIP pair, 
were excluded from further analysis. High background noise of all four nucleotides in 
all patients suggested low quality of data at these loci. Consequently, 28 SNPs were 
available for SNP genotyping of the parents (Table 3.2). Five SNPs upstream of the CTG 
repeat and seven SNPs downstream of the repeat were informative for the disease 
status of the father, and the reference (affected child), i.e. SNP loci where the father 
is heterozygous and where the mother is homozygous for the wild-type allele or 
homozygous for the allele with the substitution. 
3.4.3 Targeted sequencing of the cfDNA 
For the twelve informative SNPs the percentage of substitution in cfDNA reads was 
determined by the MIPVAR tool. Figure 3.6 illustrates the detection of a paternally 
inherited SNP in four percent of the cfDNA reads. The remaining 96 percent of the 
reads represents the maternal wild-type allele. The percentage of substitution in the 
cfDNA reads, as determined by the MIPVAR tool, are illustrated and compared with 
the results from SeqNext in Table 3.3. 
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Figure 3.6 Plasma cfDNA smMIP reads for the informative SNP rs12104327 (g.46603075A>T). 
Two examples of raw reads for a consensus tag are illustrated. For all 234 consensus reads at 
this position the noise by PCR mistakes and sequencing mistakes was eliminated in the 
consensus read. For this SNP 224 (96%) of the consensus reads showed the wild-type nucleotide, 
while 10 (4%) of the consensus reads showed the variant. 
 
The fetal fraction was determined based on the average of the unique inherited 
paternal variants. In these loci, the mother was homozygous for the wild-type allele, 
and the father heterozygous (Table 3.3). The percentage of the substitution in the 
cfDNA in the background of the maternal wild-type reads was assumed to be half of 
the fetal fraction (the paternally inherited part of the fetal cfDNA). Depending of the 
analysis tool (Fastq in IGV or NextSeq), the variants were present in on average 4-4.7% 
of the cfDNA reads. The deducted fetal fraction was 8-9.4%. There were no SNP loci 
that could contribute to the determination of the fetal fraction where one parent was 
homozygous for the wild-type allele, and the other parent was homozygous for the 
allele with the substitution. The presence of the mutated paternal DMPK allele in the 
fetal cfDNA was predicted, based on the percentages of substitution or wild-type 
nucleotide in the twelve informative SNPs (Figure 3.7). Five of them unequivocally 
proved the presence of the paternal mutated allele in the plasma, while five showed 
that the paternal wild-type allele was excluded in the plasma. In the remaining two 
informative SNPs the percentage of paternal substitution was only seen in 1.5 % (both 
in IGV and SeqNext), and 1.7/1.2% (IGV/SeqNext), as illustrated in Table 3.2 and Figure 
3.7A), which is only slightly above the expected noise of 0-1% for that substitution at 
that SNP locus. Subsequently, the variants in the gDNA from chorionic villus sampling 
was used to confirm findings in the cfDNA reads. In the chorionic villi, the presence of 
the affected paternal DMPK allele was inferred in all informative SNP loci (Figure 3.7B). 
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Table 3.2 SNP genotyping and selection of the informative SNPs 
  Info targeted SNP  Genotype 
affected 
child 
 Genotype 
affected 
father  
 Genotype 
pregnant 
woman 
 Informative 
for disease 
status 
  SNP (hg19) rs MAF     
1 g.45769749G>A rs345421 A = 0.27  GA  GA  GG  informative 
2 g.45809208T>C rs8111989 C = 0.34  TC  TC  CC  informative 
3 g.45887622T>A rs375938885 Unknown  TA  TA  TA    
4 g.45887624C>A rs367683031  Unknown  CA  CA  CA    
5 g.45887653C>A rs73044586  C = 0.36  AA  AA  AA    
6 g.45938905G>T rs10408989 G = 0.44  GT  GT  GT    
7 g.45986890A>G rs7250901 A = 0.35  GG  GG  GG    
8 g.46059364T>G rs11673516  G = 0.32  GG  GT  GG  informative 
9 g.46076381C>A rs6509224 C = 0.32  CC  CA  CC  informative 
10 g.46105198A>G rs10411518 A = 0.25  GG  GG  GG    
11 g.46108455A>G rs35070164 G = 0.33  GG  AG  GG  informative 
12 g.46219145G>C rs35302007 C = 0.29  GG  GG  GC    
13 g.46267534C>T rs10775546 C = 0.10  CC  CC  CT    
14 g.46268902C>T rs2341097 T = 0.30  CC  CC  CT    
15 g.46269313G>C rs2014377  G = 0.10  GG  GG  GC    
CTG repeat region  
16 g.46282890A>T rs2070737 T = 0.29  AA  AA  AT    
17 g.46363689G>C rs113480080 C = 0.23  CC  CC  CG    
18 g.46363754G>C rs79839858 C = 0.14  GG  CG  GG  informative 
19 g.46363756G>T rs200360080 T = 0.14  GG  GT  GG  informative 
20 g.46459965T>C rs11083790 T = 0.29  CC  CC  CC    
21 g.46574845C>G rs10425314 C=0.32  GG  GG  GG    
22 g.46590131G>A rs4802288 G = 0.43  AA  AA  AA    
23 g.46603075A>T rs12104327 T = 0.22  AT  AT  AA  informative 
24 g.46603081T>G rs12104199 G = 0.22  TG  TG  TT  informative 
25 g.46603082G>C rs12104333 C = 0.22  GC  GC  GG  informative 
26 g.46614077A>T rs73046152 T = 0.21  AT  AT  AA  informative 
27 g.46628395G>C rs4803898 G = 0.27  CC  CC  CC    
28 g.46730614A>G rs1008591 G = 0.43  AG  AG  GG  informative 
Legend to Table 3.2: MAF, minor allele frequency. Twenty-eight SNPs were available for SNP 
genotyping of the parents. Twelve SNPs were informative for the disease status of the father, 
and the reference (affected child), i.e. where the father is heterozygous and where the mother 
is homozygous for the wild-type allele or homozygous for the allele with the substitution. 
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Figure 3.7 A. Pedigree with parental SNP genotypes and deduction of fetal inheritance. Purple 
bold SNP loci are proof of the presence of the mutated paternal allele in the plasma. Grey bold 
SNP loci showed the presence of the mutated paternal allele in only a low percentage of the 
cfDNA reads. The remaining five SNPs show that the paternal wild type allele is not present in 
the plasma. B. Confirmation of the fetal inheritance in the gDNA from chorionic villi. (Pregnant 
woman created by Petal Wijnen, fetus created by Anthony Bossard from Noun Project). 
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3.5 Discussion 
In this proof of concept study, we present a novel assay for NIPD of single-gene 
disorders, demonstrated in a pregnant woman carrying a fetus that inherited DM1 
from its affected father. Maternal plasma was obtained before chorionic villus 
sampling, at 10 weeks of gestation. Our assay is a haplotype-based approach, using 
smMIPs for targeted next-generation sequencing of common CTG repeat flanking 
SNPs. Following parental SNP genotyping, and identification of informative SNP loci, 
the fetal haplotypes are inferred based on the percentages of the substitution and 
wild-type nucleotide in the cfDNA reads. Our smMIP-based assay was successfully 
applied to identify the presence of the paternal mutated DMPK allele with the 
trinucleotide repeat expansion in twelve flanking SNPs in the maternal plasma. We are 
the first to use smMIPs for NIPD. Molecular inversion probes represent an attractive 
platform for targeted capture because of their very low per-sample cost, workflow 
simplicity, target-set modularity and low sample input requirement.24 Adding single 
molecule tagging to the MIPs allows for counting of unique captured molecules, and 
tag-based consensus calling to minimize error rates, thereby facilitating both highly 
sensitive variant calling and precise quantitation of mutation frequency. The smMIPs 
assay is also robust to relatively small amounts and poor quality of source DNA.24 As a 
result, smMIPs are not only suitable to detect heterozygous and homozygous variation 
at the SNP loci in the gDNA from the parents, but are also highly sensitive for SNPs that 
are present at a low relative abundance in a cfDNA sample. Furthermore, the assay is 
compatible with a desktop sequencing instrument for potential rapid return of results 
in a clinical setting.  
The assay was conducted with cfDNA obtained from 6 mL plasma at 10 weeks of 
gestation. We estimate that we extracted at least 160 fetal genome equivalents from 
6 mL plasma.16,20 A maximal amount of plasma for cfDNA extraction is 10 mL. Probably, 
the assay may benefit from increasing the amount of plasma for cfDNA extraction, 
which may lead to a higher cfDNA input for the assay. Because of the variable absolute 
concentration of fetal cfDNA and the fetal fraction in pregnant women, as a result of 
pre-analytic, analytic and biological factors, cfDNA extraction from 10 mL is 
recommended.18-20 In the cfDNA from this pregnant woman, the fetal fraction was 
approximately 8%, which is expected from a sample obtained at 10 weeks of gestation. 
We have to establish the minimal input cfDNA and minimal fetal fraction for a reliable 
assay. Targeting of 60 SNPs allowed for deduction of the fetal fraction based on seven 
SNPs and of the fetal inheritance based on twelve informative flanking SNPs. Of these 
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SNPs, three were targeted by the same smMIP pair. Reliability of variant calling 
depends highly on the coverage of unique molecules. After testing more samples with 
the assay, a minimal coverage of unique reads can be determined per SNP locus. Now, 
in this proof of principle study we have excluded one SNP locus, that was not 
adequately covered in the gDNA samples as well as in the cfDNA sample (< 30 unique 
reads). In the future, the assay can easily be adapted to obtain information from more 
SNP loci. SmMIPs offer the advantage to have a modular nature, i.e. additional SNP 
markers can be added to a subsequent design with relative ease. Also a more uniform 
performance of individual smMIPs can be reached by additional rebalancing. In two 
informative SNPs the percentage of paternal substitution from the mutated DMPK 
allele was only seen in 1.5% (both in IGV and SeqNext), and 1.7/1.2% (IGV/SeqNext). 
In one informative SNP the percentage of the paternal substitution from the wild-type 
DMPK allele, was present in 1.2/0.3% (IGV/SeqNext). The error rate for every type of 
substitution at all SNP loci from the parents and the previous child were used as 
“noise” for the interpretation of the cfDNA substitutions, because at the moment no 
other cfDNA samples were available for background noise analysis. In case of 
informative SNPs, only the mother, who is homozygous for those loci, could be used 
for the error rate. For further use of the assay, the error for every type of substitution 
at all SNP loci should be documented for a large sample of cfDNA samples, in order to 
reliably call a variant in het cfDNA. 
Also direct analysis of the mutations will benefit from additional haplotyping. It could 
be ideal to design smMIPs to target the coding regions as well as common SNPs outside 
these regions, in order to provide a reliable combined direct and indirect NIPD assay. 
As a result, this NIPD assay can be used for all autosomal dominant disorders, and 
paternal as well as maternal mutations may be detected. For the maternal mutations, 
replication of our assay is required to investigate if the quantification is accurate 
enough to determine the difference between a mutation that is only present in the 
maternal cfDNA, and a mutation that is present in the fetal cfDNA as well. In autosomal 
dominant disorders the reference can be an affected grandparent or previous child. 
The smMIP NIPD assay can also be used for autosomal recessive disorders, although a 
previous affected child should always be available to be used as a reference. In that 
case SNPs that are heterozygous in both parents and homozygous in the affected child, 
are informative for the deduction of the fetal inheritance, and as a result for the fetal 
disease status.  
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3.6 Conclusion 
In this proof of concept study, we presented a novel assay for NIPD of single-gene 
disorders, demonstrated in a pregnant woman carrying a fetus that inherited DM1 
from its affected father. Our haplotype-based assay uses smMIPs for targeted next-
generation re-sequencing of common repeat flanking SNPs. This assay can deliver a 
fast and reliable assay for noninvasive prenatal diagnosis of single-gene disorders 
caused by a trinucleotide repeat expansion mutation and by other mutation types. 
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4.1 Abstract 
Background: Research on noninvasive prenatal testing (NIPT) of fetal trisomy 21 is 
developing fast. Commercial tests have become available. To provide an up-to-date 
overview of NIPT of trisomy 21, an evaluation of the methodological quality and 
outcomes of diagnostic accuracy studies was made.  
Methods: We undertook a systematic review of the literature published between 1997 
and 2012 after searching PubMed, using MeSH terms ‘RNA’, ‘DNA’ and ‘Down 
Syndrome’ in combination with ‘cell-free fetal (cff) RNA’, ‘cffDNA’, ‘trisomy 21’ and 
‘noninvasive prenatal diagnosis’ and searching reference lists of reported literature. 
From 79 abstracts, 16 studies were included as they evaluated the diagnostic accuracy 
of a molecular technique for NIPT of trisomy 21, and the test sensitivity and specificity 
were reported. Meta-analysis could not be performed due to the use of six different 
molecular techniques and different cutoff points. Diagnostic parameters were derived 
or calculated, and possible bias and applicability were evaluated utilizing the revised 
tool for Quality Assessment of Diagnostic Accuracy (QUADAS-2). 
Results: Seven of the included studies were recently published in large cohort studies 
that examined massively parallel sequencing (MPS), with or without pre-selection of 
chromosomes, and reported sensitivities between 98.58% [95% confidence interval 
(CI) 95.9-99.5%] and 100% (95% CI 96-100%) and specificities between 97.95% (95% CI 
94.1-99.3%) and 100% (95% CI 99.1-100%). None of these seven large studies had an 
overall low risk of bias and low concerns regarding applicability. MPS with or without 
pre-selection of chromosomes exhibits an excellent negative predictive value (100%) 
in conditions with disease odds from 1:1500 to 1:200. However, positive predictive 
values were lower, even in high-risk pregnancies (19.7-100%). The other nine cohort 
studies were too small to give precise estimates (number of trisomy 21 cases: ≤ 25) 
and were not included in the discussion. 
Conclusions: NIPT of trisomy 21 by MPS with or without pre-selection of chromosomes 
is promising and likely to replace the prenatal serum screening test that is currently 
combined with nuchal translucency measurement in the first trimester of pregnancy. 
Before NIPT can be introduced as a screening test in a social insurance health-care 
system, more evidence is needed from large prospective diagnostic accuracy studies 
in first trimester pregnancies. Moreover, we believe further assessment, of whether 
NIPT can be provided in a cost effective, timely and equitable manner for every 
pregnant woman, is required. 
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4.2 Introduction 
In developed countries, the two-step prenatal care system includes a noninvasive risk 
assessment for the most common aneuploidies, before invasive prenatal procedures 
are offered. In this prenatal risk assessment, along with nuchal translucency 
measurement by ultrasound, different maternal serum biochemical screening tests 
are offered in the first or second trimester. At the moment, the most used noninvasive 
screening test for individual trisomy 21 (Down syndrome) risk calculation worldwide is 
the combined test. The combined test includes a serum screening test containing two 
blood markers, namely pregnancy-associated plasma protein-A and free beta human 
chorionic gonadotrophin, combined with nuchal translucency measurement (Figure 
4.1). In the case of an a priori high-risk or a positive individual risk assessment of 
trisomy 21 (Down syndrome), 18 (Edwards syndrome) or 13 (Patau syndrome), 
invasive prenatal diagnosis by fetal karyotyping or rapid aneuploidy detection is 
performed after preservation of fetal cells by amniocentesis or chorionic villus 
sampling.1,2 These invasive procedures carry a risk of miscarriage ranging from 0.6%, 
within 14 days of the procedure, to 2% for total pregnancy loss.3 To avert this risk of 
miscarriage, there is an increasing demand for a reliable and safe noninvasive prenatal 
test that is applicable as early in pregnancy as possible. Since the discovery of the 
presence of cell-free fetal (cff) DNA and cff placental-specific mRNA (cffRNA) in 
maternal plasma, the possibility of using this as the target for noninvasive prenatal 
testing (NIPT) of fetal genetic conditions is being explored widely.4-7 Maternal and fetal 
cell-free (cf) DNA consist of nuclease-fractionated histone-bound DNA sequences, with 
the most abundant sequence length (predominantly maternal) being between 133 and 
166 base pairs.8 The cffDNA represents a subfraction of 6-10% of the total cfDNA in 
first and second trimester pregnancies and rises up to 10-20% in third trimester 
pregnancies.8,9 
The small-sized fragments and the subfraction of cffDNA/RNA next to abundantly 
present maternal disomic genome are bottlenecks in developing NIPT techniques for 
aneuploidy detection. Nevertheless, several molecular techniques have been 
proposed for the detection of trisomy 21, 18 and 13. Early studies concerning NIPT of 
aneuploidy focused on the quantification of male cffDNA sequences in maternal 
plasma samples by real-time PCR (qPCR).10-17 Later, qPCR was used to examine a 
possible elevation of specific genes, e.g. ‘hemoglobin beta (HBB)’ and ‘chromosome 
21 open reading frame 105 (C21orf105)’.18-21 Another approach for noninvasive 
detection of trisomy 21 is determining the dosage of chromosome 21 cffRNA single 
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nucleotide polymorphism (SNP) alleles of genes that are not expressed in maternal 
blood cells, but only in placental tissue such as ‘placenta-specific 4 (PLAC4)’ or ‘serpin 
peptidase inhibitor, clade B (ovalbumin), member 2 (SERPINB2)’.22-25 The ratio of SNP 
alleles using cffDNA instead of cffRNA is also examined for NIPT of trisomy 21.26,27 A 
limitation of the SNP-dependent approaches is that they are only applicable for fetuses 
that are heterozygous for the studied SNP.28 Furthermore, additional conditions are 
sometimes required, e.g. a heterozygous or a homozygous mother. To overcome this, 
several researchers focus on single molecule counting techniques, including digital 
PCR, that has not been applied in real plasma samples yet.29-31 Recently, massively 
parallel sequencing (MPS) of maternal plasma DNA has been introduced.32-42 MPS can 
identify the chromosomal origin of each sequenced plasma DNA molecule and can 
detect the over- or underrepresentation of any chromosome in maternal plasma. 
Recently, two MPS techniques, in which only the chromosomes of clinical interest are 
sequenced, have been described. In these targeted MPS techniques, pre-selection of 
chromosomes leads to less unutilized sequencing data. Moreover, rapid next-
generation sequencing devices can be used, altering the costs, turnaround time and 
the number of patients who can be tested per week. One of these techniques is digital 
analysis of selected regions (DANSR), in which selected nonpolymorphic loci on 
chromosomes of clinical interest are simultaneously quantified.43-47 The other 
technique is parental support, in which the observed allele distribution after 
sequencing of polymorphic loci on the chromosomes of clinical interest is compared 
with the expected allele distribution based on parental genotypes.48 Next to these 
techniques, fetal chromosome dosage determination has been studied based on the 
well-known epigenetic differences between maternal and fetal DNA, an approach that 
also can be used for all fetuses.49-57  
At the moment, commercial NIPT of trisomy 21 by MPS has become available for high-
risk pregnant women and includes the MaterniT21TM PLUS test from Sequenom 
(http://www.sequenom.com), the Praena-Test® from their European partner 
LifeCodexx (http://www.lifecodexx.com), the verifi® test from Verinata 
(http://www.verinata.com) and the HarmonyTM prenatal test from Ariosa 
(http://www.ariosadx.com). The International Society of Prenatal Diagnosis (ISPD) 
formulated, on 24 October 2011 in a rapid response statement, its considerations and 
recommendations for the clinical use of the commercial MPS tests in women at high 
risk and at lower risk.58 A final position statement on screening for fetal aneuploidy of 
ISPD is in the process of being updated and will soon be released. Nowadays, the 
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option of NIPT of aneuploidy has reached pregnant women through the Internet, social 
media and gynecologists. Interest in large-scale validation studies grows. Molecular 
NIPT of trisomy 21 will play an important role in prenatal diagnosis and possibly in 
prenatal screening in the coming years (Figure 4.1).  
 
 
Figure 4.1 Schematic representation of the implementation of invasive and noninvasive prenatal 
testing for trisomy 21 in Europe.  
Invasive prenatal diagnosis of trisomy 21: Karyotyping detects all microscopically visible 
chromosome aberrations and is performed on fetal cells obtained by amniocentesis or chorionic 
villus sampling. Rapid aneuploidy detection (RAD) techniques currently used include: (1) 
interphase fluorescence in situ hybridization (FISH), (2) quantitative fluorescent PCR (QF-PCR) 
or (3) multiplex ligation-dependent probe amplification (MLPA). These tests are also performed 
on fetal cells obtained by amniocentesis or chorionic villus sampling and generate reliable 
results within 3 days that is much faster than karyotyping and are used to diagnose only 
trisomies 21, 18 and 13, although probes often also include the sex chromosomes.  
Noninvasive prenatal risk calculation tests for trisomy 21: The triple screening test (a second 
trimester screening test) is performed between the 15th and 20th week of pregnancy and 
measures high and low levels of alpha-fetoprotein (AFP) and abnormal levels of human chorionic 
gonadotrophin and estriol in maternal blood. The results are combined with the mother’s age, 
weight, ethnicity and gestation of pregnancy to assess probabilities of aneuploidy. The 
combined test (a first trimester screening test) is performed between the 11th and 13th weeks 
of pregnancy and combines the results from the nuchal translucency measurement and the 
levels of human chorionic gonadotrophin and placental-associated plasma protein A in maternal 
blood, with maternal age risk factors to assess probabilities of aneuploidy 
(www.americanpregnancy.org). 
 
In this article, we provide an up-to-date overview of all studies that have evaluated 
the diagnostic accuracy of one or more molecular techniques for NIPT of trisomy 21 in 
a clinical setting and that have reported test sensitivity and specificity. Firstly, we 
compared the characteristics of the different studies, including the molecular genetic 
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technique used for NIPT, the size, the inclusion criteria, the reference standard test 
and the timing of testing in pregnancy. Secondly, we derived or calculated diagnostic 
parameters and evaluated potential bias and applicability of the evidence using the 
revised tool for Quality Assessment of Diagnostic Accuracy (QUADAS-2).59 
4.3 Methods  
4.3.1 Search strategy and selection criteria  
We undertook a systematic review of the literature and selected relevant studies 
published between 1 January 1997 and 15 December 2012 in the online database 
PubMed. The search strategy used was (‘RNA’[Mesh]) or (‘DNA’[Mesh]) or (cff RNA) or 
(cffDNA) and (trisomy 21) or (‘Down Syndrome’[Mesh]) and (noninvasive prenatal 
diagnosis). The last search was performed on 15 December 2012. No limits were used. 
In addition, reference lists were checked for further published studies, and studies 
suggested by colleagues and reviewers were also assessed for eligibility. Studies were 
included, if they evaluated the diagnostic accuracy of one or more molecular 
techniques for NIPT of trisomy 21 and mentioned test sensitivity and specificity. We 
excluded studies that examined NIPT of other disorders, reviews, bioethical or other 
comments, studies that did not use cffDNA/RNA for the detection of trisomy 21 and 
proof of concept studies.  
4.3.2 Comparison of the included studies and calculation of predictive 
values  
We compared the characteristics of the different studies, including the molecular 
genetic technique used for NIPT, the size, the inclusion criteria, the reference standard 
test and the timing of testing in pregnancy. If a study mentioned more than one 
sensitivity and specificity, e.g. because the authors tested different ways of 
multiplexing, we included the best result in the comparison. If we believed that 
sensitivity and/or specificity should have been calculated differently than done by the 
authors, we recalculated and explained our motives in the comments of the table 
generated. In addition, we calculated the positive and negative predictive values (PPVs 
and NPVs, respectively) of the tests for different prevalence conditions because they 
are dependent on the prevalence. Firstly, we calculated them for a prevalence of 
trisomy 21 of 1:200 (which is equal to the a priori risk of a 38-year-old pregnant woman 
and which is the cutoff value for a high-risk pregnancy in the Netherlands), secondly, 
for a prevalence of 1:380 (the a priori risk of a 35-year-old pregnant woman and an 
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estimated trisomy 21 risk based on the European population) and thirdly, for a 
prevalence of 1:1 500 (the a priori risk of a 20-year-old pregnant woman).  
4.3.3 Quality assessment using the QUADAS-2 tool  
The quality of the diagnostic studies was evaluated by three independent reviewers 
(E.M., L.A.A.P.v.W. and L.J.M.S.) using the QUADAS-2 tool.59 In this redesigned tool, 
studies are scored as ‘high risk of bias’, ‘low risk of bias’ or ‘unclear risk of bias’ and 
‘high concerns regarding applicability’, ‘low concerns regarding applicability’ or 
‘unclear concerns regarding applicability’ for four key domains: patient selection 
(domain 1), index test (domain 2), reference standard test (domain 3) and flow and 
timing (domain 4). The ‘unclear’ category is used when insufficient data are reported 
to permit judgment. We set up a list of characteristics of the most ideal study on NIPT 
of trisomy 21 (Table 4.1). To tailor the QUADAS-2 tool to studies about NIPT of trisomy 
21, we adjusted the original signaling questions of the tool according to this list and 
formulated extra signaling questions to check applicability (Supplemental Table 4.5).  
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Table 4.1 The “ideal study” on NIPT of trisomy 21.  
Low risk of bias 
 - A consecutive or random sample of pregnant women is enrolled. 
 - A case-control design is avoided. 
 - Inappropriate exclusions based on the reference standard test results are avoided (e.g. another 
aneuploidy).a 
 - NIPT results are interpreted without knowledge of the reference standard test results. 
 - Reference standard test results are interpreted without knowledge of the NIPT results. 
 - Cutoff values or the threshold are explained before data-analysis. 
 - The used reference standard test is karyotyping after amniocentesis or chorionic villus sampling, 
or postnatal karyotyping, and all patients receive this reference standard test. 
 - All patients are included in the analysis. 
High applicability 
 - Pregnant women are considered as having high risk of trisomy 21 offspring, if the goal of the study 
is to compare the accuracy of NIPT with karyotyping after amniocentesis or chorionic villus 
sampling during pregnancy.b 
 - NIPT is performed before invasive testing.c 
 - One threshold is used, or in case the results can fall in between two thresholds (and is 
inconclusive), this is the case in maximum 5% of tested women. 
 - Fetal trisomy 21 is detected early in the pregnancy by the used reference standard test. 
 - The manuscripts includes samples until 20 weeks of gestation.d 
 - The window of gestational age is narrow enough (< 4 weeks).e 
Legend to Table 4.1: a. The test has to be able to exclude all non-trisomy 21 samples, including samples with 
other genetic abnormalities. b. A woman can be at high risk of trisomy 21 offspring when there is a positive 
family or obstetric history, when they are aged above 35 years, or when other diagnostic and screening 
procedures without cffDNA/RNA, such as ultrasound abnormalities, indicate a high risk of aneuploidy. c. The 
performance of an invasive procedure before the NIPT can increase the concentration of cell-free fetal 
DNA/RNA in maternal plasma samples, which can lead to an easier detection of the target condition by the 
index test.60 d. Concerns rise when NIPT has been performed late in the second trimester or even in the 
third trimester. To permit a consequence to the result of NIPT in countries, where by law a limit of 
gestational age for termination is set, the result of NIPT should be known before 22 weeks of gestation.61 
Taking into account the run time of NIPT itself, the studies should only include samples until 20 weeks of 
gestation (domain 4A). e. There are concerns about the derivation of a preferable time point in pregnancy 
for NIPT when a too broad window of gestational age is examined (> 4 weeks). 
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4.4 Results  
4.4.1 Inclusion and exclusion strategy  
Figure 4.2 shows the process of study selection. We identified 79 studies, of which 45 
described 1 or more molecular NIPT technique(s) of trisomy 21 detection during 
pregnancy. From these, 29 studies were further excluded, mainly because they were 
proof of concept studies. Only 16 of these 45 studies evaluated the diagnostic accuracy 
of 1 or more molecular NIPT technique(s) and mentioned test sensitivity and specificity 
and could, therefore, be included in the review. 
Figure 4.2 Process of study selection for the analysis of quality and outcome. 
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4.4.2 Characteristics of the included studies  
The 16 included studies, dating from 2007 to 2012, applied 6 different molecular 
genetic techniques for NIPT of trisomy 21 in a high-risk population (Table 4.2). Five 
studies investigated the diagnostic accuracy of NIPT of trisomy 21 by MPS without pre-
selection of chromosomes, and three studies examined one of the MPS methods with 
pre-selection of chromosomes, the DANSR method.38-42,45-47 Two of the 16 studies 
examined fetal chromosome 21 dosage by analysis of different epigenetic regions 
between maternal and fetal cfDNA by 2 different molecular techniques: the 
unmethylation index of the phosphodiesterases gene 9A (PDE9A) and methylated DNA 
immunoprecipitation and qPCR.54,55 Three of the included studies calculated the ratio 
of cffRNA SNP alleles of PLAC4, a gene that is not expressed in maternal blood cells, 
but only in placental tissue.22,24,25 Two studies calculated the ratio of chromosome 21 
cffDNA SNP alleles.26,27 Finally, one study examined the amplification of the HBB gene 
by qPCR in fetal trisomy 21 cases.20 The majority of the studies (9 out of 16) evaluated 
diagnostic accuracy in remarkably small cohorts (≤ 25 trisomy 21 cases). Four studies 
included less than ten trisomy 21 cases, and the lowest number of controls included 
was 20.24,26,27,47 Seven recently published larger studies (7 out of 16) evaluated the 
diagnostic accuracy of NIPT of trisomy 21 by MPS with or without pre-selection of 
chromosomes in larger cohorts (Table 4.2, studies 2-5, 7, 8 and 11).38-42,45,46 In the 
majority of the studies, high-risk pregnancies were included, although the inclusion 
criteria were often not clearly described, and different definitions of ‘high risk of 
trisomy 21’ were applied. Blood sampling took place throughout pregnancy, including 
sampling in the third trimester. The diagnostic accuracy of NIPT was compared with 
karyotyping, although in some studies in combination with another reference standard 
test. 
4.4.3 Diagnostic performance  
NIPT of trisomy 21 shows variable levels of sensitivity (58.82-100%) with, in general, 
higher levels of specificity (83.33-100%) (Table 4.3). Pooling of results could not be 
performed due to the use of different molecular techniques and different cutoff 
points. The larger studies on NIPT by MPS or DANSR (Table 4.3, studies 2-5, 7, 8 and 
11) showed higher sensitivities (98.58-100%) and specificities (97.95-100%), combined 
with narrower 95%-confidence intervals (CIs).38-42,45,46 Three smaller studies (1, 9 and 
12) report a sensitivity and specificity of 100%, with, however, broad 95% CIs.27,47,54 
Study 1 included 1949 subjects to examine sensitivity and specificity in a low-risk 
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population. In this group, only a small number of subjects will have a child with trisomy 
21, leading to a poor estimation of the sensitivity in particular.47 In the larger studies, 
due to the low likelihood of trisomy 21 on the one hand, and good sensitivity of NIPT 
on the other hand, NPVs were excellent (100%). However, PPVs showed large 
variation, ranging from 19.3% to 100% for the group with a high risk of trisomy 21 
offspring (1:200), from 11.2% to 100% for a risk of 1:380 and from 3.1% to 100% for a 
risk of 1:1500.38-42,45,46  
4.4.4 Analysis of quality by the QUADAS-2 assessment  
The QUADAS-2 assessment (Table 4.4) demonstrates that none of the 16 included 
studies had a low risk of bias or low concerns regarding applicability in all 4 domains 
evaluated by the reviewers. In general, most studies had a high risk of bias in domain 
1 of patient selection and had high concerns regarding applicability, in domains 4A and 
4B, the domains concerning the timing of NIPT in pregnancy. This was also the case for 
the seven larger studies (Table 4.4, studies 2-5, 7, 8, and 11) examining NIPT of trisomy 
21 by MPS with or without pre-selection of chromosomes.38-42,45,46 Five out of seven 
studies (4, 5, 7, 8 and 11) had a risk of bias in patient selection.38-41,45 and five out of 
seven (2, 3, 5, 7 and 8) had high concerns regarding applicability in domains 4A and/or 
4B because a too broad window of gestational age was included or blood sampling 
took place too late in pregnancy.39-42,46Moreover, studies 3-5 and 8 had also high risk 
of bias in domain 4, flow and timing because not all samples were included in the 
analysis.39,41,45,46 
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4.5 Discussion 
4.5.1 Implementation of NIPT of trisomy 21 in high-risk pregnancies  
The diagnostic accuracy of NIPT was compared with karyotyping in high-risk pregnant 
women, in 14 out of 79 studies assessed for eligibility in this systematic review (Table 
4.2, studies 3-16). Our study demonstrates that only a small number of studies were 
conducted on the topic and that the ideal study on NIPT has not been performed yet 
in high-risk pregnancies. In general, strikingly, small cohorts of pregnant women were 
examined. Eight cohort studies were too small to give precise estimates (number of 
trisomy 21 cases: ≤ 25). Therefore, conclusions were drawn from six large cohort 
studies that are currently all the studies evaluating the diagnostic accuracy of NIPT of 
trisomy 21 by MPS with or without pre-selection of chromosomes (Table 4.2, studies 
3-5, 7, 8 and 11).  
The outcome analysis illustrates variable levels of sensitivity (58.82-100%) with, in 
general, higher levels of specificity (83.33-100%) throughout the 14 articles. The large 
cohort studies on NIPT by MPS with and without pre-selection of chromosomes have 
a higher sensitivity, ranging from 98.58% to 100%, as well a high specificity, ranging 
from 97.95% to 100%. These NIPT techniques exhibit an excellent NPV in natural 
conditions with disease odds up to 1:200. However, PPVs were often very low, even in 
high-risk pregnancies. A PPV of 19.7% as can be calculated from the study of Chiu et 
al. in 2011 (Table 4.2, study 11) indicates that, even in a high-risk population (odds 
1:200), a positive test result is false in > 80% of the cases.38  
None of these six large cohort studies had an optimal quality. The QUADAS-2 results 
depict high concerns of sampling time in pregnancy in most of these studies, which 
was often too late in pregnancy or in a too broad window of gestational age. Only the 
DANSR technique was evaluated in a small window of gestational age in the first 
trimester (Table 4.2, study 4).45 At the moment, this technique can be performed more 
rapidly than MPS without pre-selection of chromosomes. Although the perfect study 
has not been performed yet, three studies, studies 4, 5 and 7, were of better 
quality.40,41,45 In the future, NIPT by MPS with and without pre-selection of 
chromosomes should be further explored, focusing on the inclusion of a consecutive 
sample early in the first trimester of pregnancy and the incorporation of all samples in 
the analysis. Large prospective studies will give more certainty about the predictive 
values in the high-risk group.  
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4.5.2 NIPT of trisomy 21 as a screening test in low-risk pregnancies 
The sensitivity and specificity of NIPT were examined in a population of low-risk 
pregnant women and in a mixed population in 2 out of 16 studies included in the 
QUADAS-2 assessment (Table 4.2, studies 1 and 2).42,47 Furthermore, we calculated the 
PPVs and NPVs in an average-risk population (1:380) and a low-risk population 
(1:1500) for these 2 studies and for the remaining 14 studies. In this systematic review, 
we demonstrate that the diagnostic parameters of NIPT are better than those of the 
current first trimester prenatal screening risk assessment for fetal trisomy 21.  
Therefore, NIPT is likely to replace the prenatal serum screening test that is currently 
combined with nuchal translucency measurement in the first trimester of pregnancy. 
The replacement of the current two-step triage testing procedure by NIPT of trisomy 
21 would maximize the benefits of NIPT at an early stage of pregnancy: the drawbacks 
of false-positive and false-negative results generated by the current risk assessment 
and the miscarriage risk attached to current invasive diagnostic methods would, 
thereby, be reduced.7 In that case, less invasive procedures would be needed, only to 
verify a positive NIPT result and to confirm non-inheritable or inheritable forms of 
Down syndrome, using the gold standard that is still karyotyping. Most likely, more 
women will opt for NIPT in pregnancy because of its proven diagnostic accuracy.  
However, there is still more evidence needed before NIPT of trisomy 21 can be 
introduced in routine prenatal care, e.g. as routine screening NIPT in the first trimester 
of pregnancy. Preferably, large prospective diagnostic accuracy studies, including low-
risk pregnant women recruited in a clinical setting early in pregnancy, will have to be 
performed before this will become a reality in the public, social insurance health-care 
systems in Europe. One study included in this systematic review examined diagnostic 
accuracy in low-risk pregnant women (Table 4.2, study 1).47 However, a 5-10 times 
larger sample size than the 1949 samples analyzed in this study is needed for a reliable 
estimation of the sensitivity in a priori low-risk first trimester pregnancies. Additional 
accuracy studies are currently designed and ongoing. Moreover, we believe that NIPT 
should be provided in a cost-effective, timely and equitable manner.  
Finally, further ethical exploration and evaluation of the current opinion of pregnant 
women and the formulation of proper informed consent information are needed.7 We 
estimate that it will take a few years until NIPT of trisomy 21 can be integrated as a 
part of routine prenatal care for every pregnant woman in the public, social insurance 
health-care system (Figure 4.1) We speculate that NIPT by MPS will replace the current 
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serum screening test after legal licenses are arranged and informed consent 
information is drawn.  
4.6 Conclusion 
The 16 NIPT studies included in the QUADAS-2 assessment illustrate that the results 
are promising. Nevertheless, considering the limited size and quality of the studies, 
additional large prospective studies will allow more precise estimates about 
sensitivity, specificity and predictive values in high-risk and low-risk pregnancies. We 
demonstrate that the diagnostic parameters of NIPT of trisomy 21 are better than 
those of the current first trimester risk assessment. Therefore, NIPT is likely to be 
implemented in this risk assessment, as a replacement for the current serum screening 
test. Due to the reduction in false-positive and false-negative results, fewer trisomy 
cases would be missed at the first screening step and fewer invasive procedures would 
be needed, only to verify a positive NIPT result and to confirm non-inheritable or 
inheritable forms of Down syndrome, using the gold standard karyotyping. Before 
NIPT of trisomy 21 can be introduced as a replacement for the current serum screening 
test in a public, social insurance health-care system, still more evidence is needed from 
large prospective diagnostic accuracy studies, including low-risk pregnant women 
early in pregnancy. Moreover, we believe that NIPT should be provided in a cost-
effective, timely and equitable manner. Finally, further ethical exploration and 
evaluation of the current opinion of pregnant women and the formulation of proper 
informed consent information are needed. 
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Legend to Supplemental Table 4.5:  
a. A woman can be at high risk of trisomy 21 offspring when there is a positive family or 
obstetric history, when she is aged above 35 years or when other diagnostic and screening 
procedures without cffDNA/RNA, such as ultrasound abnormalities, indicate a high risk of 
aneuploidy. We believe that the final result of this research should be the development of a 
test that is suitable for all pregnant women. However, most research focuses at the moment 
on the high-risk pregnant women. The current state of the art is to first develop a test for 
high-risk pregnant women. 
b. The performance of an invasive procedure before NIPT, can increase the concentration of 
cell-free fetal DNA/RNA in maternal plasma samples, which can lead to an easier detection 
of the target condition by the index test. 
c. The gold standard of invasive prenatal testing for aneuploidy is still karyotyping. 
Karyotyping after amniocentesis has a sensitivity of 99.6% and a specificity of 99.93% for 
aneuploidy detection. Also after chorionic villus detection, the sensitivity and specificity of 
karyotyping for aneuploidy detection is high (99.6% and 99.9% respectively).62  
d. Non-issue since the target condition does not vary over time. 
e. Follow-up and loss to follow-up are no issues for the target conditions. 
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5.1 Abstract 
Background: Implementation of non-invasive prenatal testing (NIPT) in Down 
syndrome screening programs requires health policy decisions about its combination 
with other tests and its timing in pregnancy.  
Aim: Our aim was to aid health policy decision makers by conducting a quantitative 
analysis of different NIPT implementation strategies.  
Methods: Decision trees were created to illustrate all plausible alternatives in a 
theoretical cohort of 100 000 pregnant women in five screening programs: classical 
screening by the first-trimester combined test (FCT), pre-selection of high-risk women 
prior to NIPT by the FCT, NIPT as the first screening test at 10 weeks and at 13 weeks, 
and the simultaneous conductance of NIPT and the FCT.  
Results: Pre-selection by FCT prior to NIPT reduces the number of amniocenteses to a 
minimum because of a reduction of false-positive NIPT results. If NIPT is the first 
screening test, it detects almost all fetal Down syndrome cases. NIPT at 10 weeks 
reassures women early in pregnancy, while NIPT at 13 weeks prevents unnecessary 
tests due to spontaneous miscarriages and allows for immediate confirmation by 
amniocentesis.  
Conclusion: Every implementation strategy has its advantages and disadvantages. The 
most favorable implementation strategy may be NIPT as the first screening test at 13 
weeks, offering the most accurate screening test for Down syndrome, when the risk 
for spontaneous miscarriage has declined remarkably and timely confirmation by 
amniocentesis can be performed.  
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5.2 Introduction 
For the past few years, professionals involved in prenatal diagnostic testing have seen 
the rapid development of non-invasive prenatal testing (NIPT) of Down syndrome by 
massively parallel sequencing of cell-free DNA in maternal plasma.1-4 In several large 
clinical validation studies, it was established that NIPT can detect fetal Down syndrome 
accurately from 10 weeks of gestation onwards in high-risk and low-risk pregnancies 
with a sensitivity and specificity of > 99% and a negative predictive value of almost 
100%.1,2,5-8 However, the positive predictive value of NIPT for Down syndrome varies 
between 62 and 93% in a high-risk population (risk of 1 in 200), drops to 50-80% in a 
more general population and may even fall below 50% in young, low-risk women.1,2,5-
8 As a result, the International Society for Prenatal Diagnosis recently stated that NIPT 
is a screening test that is not fully diagnostic and can be offered as the primary 
screening test or as a secondary screening test subsequent to conventional screening. 
After suspicion of fetal Down syndrome following a positive NIPT result, invasive 
diagnostic testing is recommended to confirm the diagnosis.9 
NIPT has been available through commercial laboratories since 2011, mostly for high-
risk pregnant women, at 10 weeks of gestation or later in pregnancy.6-8,10-13 Ideally, 
NIPT should be incorporated into a well-designed screening program based on 
informed decision-making and equity of access.13 The aim of a prenatal screening 
program for Down syndrome is to provide pregnant women with an autonomous 
reproductive choice about continuing or terminating the pregnancy on the basis of the 
prenatal diagnosis of fetal Down syndrome. At present, several countries are 
organizing the implementation of NIPT in their Down syndrome screening program.14-
16 There are a number of ways to implement NIPT into a Down syndrome screening 
program. Health policy decisions are now required about the possible restriction of 
NIPT to preselected high-risk women, its timing in pregnancy and its combination with 
other tests. For health policy choices, a thorough understanding is needed of the 
consequences, the potential harms and benefits, of different implementation 
strategies of NIPT in Down syndrome screening programs. The clinical utility, cost-
effectiveness and ethical consequences of plausible NIPT implementation strategies 
have been evaluated in previous studies.17-23 In addition, the attitudes of pregnant 
women and obstetricians and gynecologists towards NIPT have been investigated 
through questionnaires and interviews.15,24-27 In this study, we aim to aid health policy 
decision makers by conducting a comprehensive analysis of the advantages and 
disadvantages of different implementation strategies through a decision-analytic 
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model.28 After a quantitative estimation of pre-defined clinical outcome measures and 
a reflection upon the results in the light of practical and psychological considerations, 
we formulate an advice about what may be the most favorable NIPT implementation 
strategy. 
5.3 Methods  
5.3.1 The Down syndrome screening programs  
Four hypothetical Down syndrome screening programs in which NIPT was 
implemented (programs P1-P4) and the classical screening program (program C) were 
compared in a decision-analytic model (Figure 5.1).  
 
 
Figure 5.1 The timing of the offered screening tests (FCT and/or NIPT) in the four hypothetical 
Down syndrome screening programs in which NIPT is implemented (P1-P4) and the classical 
screening program (C). Following suspicion of fetal Down syndrome, pregnant women are 
offered an amniocentesis (AC) to confirm the diagnosis in all programs. 
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In the classical screening program, pregnant women first underwent the first-trimester 
combined test (FCT) between 11 + 0 and 13 + 6 weeks of gestation, the classical non-
invasive risk assessment in most Western countries. Following a risk of fetal Down 
syndrome of 1 in 200 or higher, the risk threshold used in the Netherlands, the women 
were offered an amniocentesis to confirm the diagnosis of fetal Down syndrome.  
In the hypothetical screening programs, NIPT was offered at 10 weeks or at 13 weeks 
of gestation. NIPT should not be offered too late in pregnancy because it is not 
preferable that implementation of NIPT leads to a delay in the timing of the invasive 
test compared with the classical screening program. The accuracy of NIPT was 
confirmed in clinical validation studies as early as 10 weeks of gestation.1, 2, 5-8  
In program P1, all pregnant women first underwent the FCT before 13 weeks of 
gestation, followed by NIPT at 13 weeks of gestation if women had a risk of fetal Down 
syndrome of 1 in 200 or higher. If fetal Down syndrome was still suspected following 
NIPT, women were offered an amniocentesis. In program P2, NIPT was offered to all 
pregnant women as an early screening test at 10 weeks of gestation (10-week NIPT), 
and in program P3, NIPT was available for all pregnant women at 13 weeks of gestation 
(13-week NIPT). Following suspicion of Down syndrome by NIPT, an amniocentesis was 
offered. In the last program P4, NIPT and the FCT were offered to all pregnant women. 
NIPT was performed at 10 weeks of gestation, and FCT was conducted between 11 and 
13 weeks of gestation. Assuming that the result of the NIPT would be dominant for 
decision-making in case of discordant results of the FCT and the NIPT, because of the 
better accuracy of NIPT, an amniocentesis was offered to all women with a positive 
NIPT result. Arguments to keep the FCT despite the better accuracy of NIPT are listed 
in the Discussion section of this paper.  
In our screening programs, we preferred amniocentesis over chorionic villus sampling 
(CVS) to confirm the NIPT result. Although CVS can be performed earlier in pregnancy, 
the potential of confined placental mosaicism should be considered. Analysis of 
amniotic fluid cells is considered to be a more reliable test for the true fetal karyotype.9 
Following amniocentesis, women will receive a definitive confirmation of the presence 
of fetal Down syndrome as fast as 3 days later through rapid aneuploidy detection.29  
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5.3.2 Decision trees 
For each Down syndrome screening program, a decision tree was created in Microsoft 
Excel using the open source Excel Add-in Simple Decision Tree.30 We assumed that of 
the total pregnant population, a theoretical cohort of 100 000 pregnant women of all 
age categories would opt for prenatal screening. The decision trees illustrate all 
plausible alternatives and outcomes for these women within a hypothetical screening 
program between 10 and 18 weeks of gestation. A decision tree starts with a ‘decision 
node’, indicating the hypothetical top-down health policy choice for the screening 
program. It consists further of ‘chance nodes’ from which two or more branches start 
to illustrate possible alternative scenarios. The probability variables were obtained 
through a systematic analysis of the literature and are listed in Table 5.1. The 
estimated uptake of the offered prenatal tests, the probability of a true or false result 
of these tests, and the estimated fetal losses due to amniocentesis complications were 
incorporated in the decision trees. Furthermore, we incorporated the chances of 
spontaneous miscarriage in the time windows in which NIPT was hypothetically 
offered, i.e. between 10 and 13 weeks of gestation and between 13 and 15 weeks of 
gestation. 
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  Table 5.1 Variables and probabilities used in the decision-analytic model 
Probability variable  Proba-
bility, % 
Plausible 
range, %  
Source of probabilities and 
plausible ranges 
Prevalence of fetal Down syndrome in women 
of all age categories at 10 weeks of gestation  
0.2 0.17-0.23 Weighted mean of European and 
American population39,40; 95% CI 
used for plausible range. 
Spontaneous loss rates for fetuses with Down 
syndrome  
  
Calculated using published 
estimates for spontaneous loss 
rates for fetuses with trisomy 21 
between various gestations and 
delivery at 40 weeks by Snijders 
et al. (1999).41 
  Between 10 weeks and 13 weeks of gestation 12.0  
  Between 13 weeks and 15 weeks of gestation 5.7  
  Between 15 weeks of gestation and delivery     
  at term 
22.9  
Spontaneous loss rates for fetuses without 
chromosomal abnormalities 
  
Weighted mean of the three 
largest studies from the 
systematic review by Avalos et al. 
(2012).31 
  Between 10 weeks and 13 weeks of gestation 3.9  
  Between 13 weeks and 15 weeks of gestation 1.2  
Sensitivity of the FCT for fetal Down syndrome 
in women of all age categories for a risk 
threshold of 1 in 200 
89.0 83.9-92.7 Kagan et al. (2008)42; 95% CI used 
for plausible range. 
Specificity of the FCT for fetal Down syndrome 
in women of all age categories for a risk 
threshold of 1 in 200 
95.4 95.3-95.5 Kagan et al. (2008)42; 95% CI used 
for plausible range. 
Proportion of women opting for NIPT following 
Down syndrome suspicion by the FCT 
100 39.4-100 Our model assumes that all 
women are in favor of NIPT; 
lower border of plausible range 
based on publication by Chetty et 
al. (2013).43 
Sensitivity of NIPT for fetal Down syndrome for 
high-risk and low-risk pregnancies 
99.6 
 
Weighted mean of the larger 
clinical validation studies in high-
risk pregnancies.1 
Specificity of NIPT for fetal Down syndrome for 
high-risk and low-risk pregnancies 
99.9 
 
Weighted mean of the larger 
clinical validation studies in high-
risk pregnancies.1 
Proportion of women opting for amniocentesis 
following Down syndrome suspicion by the 
screening test (FCT or NIPT) 
90.0 50.0-90.0 Own estimation based on the 
intention of the program (100% 
confirmation by invasive PND).  
Risk of fetal loss following amniocentesis 
complications 
0.60 0.11-0.60 Mujezinovic and Alfirevic 
(2007)44; lower border of 
plausible range based on meta-
analysis by Akolekar et al. 
(2015).45 
Sensitivity of the rapid aneuploidy detection 
for fetal Down syndrome 
100 
 
Own estimation 
Legend to Table 5.1: 95% CI, 95% confidence interval; FCT, first trimester combined test; NIPT, 
non-invasive prenatal testing; PND, prenatal diagnosis 
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5.3.3 Quantitative analysis of clinical outcome measures and order of 
preference 
The clinical outcome measures that were quantitatively analyzed are listed in Table 
5.2. Based on the results of this analysis, the screening programs were ordered from 
most favorable to least favorable. 
 
Table 5.2 Pre-defined clinical outcome measures that were quantitatively evaluated 
- Fetal Down syndrome cases detected by screening and confirmed by amniocentesis 
- Fetal Down syndrome cases detected by screening without confirmation by amniocentesis  
- Fetal Down syndrome cases not detected by first-trimester screening 
- Number of women reassured about the absence of fetal Down syndrome by first-trimester 
screening 
- Total number of amniocenteses performed 
- Number of women that undergo amniocentesis and do not carry a fetus with Down syndrome  
- Fetal losses because of amniocentesis complications 
- Cases of spontaneous miscarriage while waiting for the first-trimester screening result 
- Cases of spontaneous miscarriage while waiting for the amniocentesis 
 
5.3.4  One-way sensitivity analyses 
As the used probabilities may be associated with some degree of uncertainty, 
reasonable probability changes must be specified.28 For probabilities that were 
uncertain, we defined a plausible range (Table 5.1). Where possible, 95% confidence 
intervals were used; otherwise, we made up a range in mutual consultation. To test 
the model’s robustness to variations in the probabilities employed, one-way sensitivity 
analyses were performed. In these analyses, we assessed for each probability variable 
whether or not variation across the plausible range led to a change in the order of 
preference. 
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5.4 Results 
Four hypothetical Down syndrome screening programs in which NIPT was 
implemented (programs P1-P4) and the classical screening program (program C) were 
compared in a decision-analytic model. In Figures 5.2-5.5, the decision trees of the 
programs are visualized. In Table 5.3, the screening programs are ordered from most 
favorable to least favorable for each of the pre-defined clinical outcome measures of 
the quantitative analysis. For all clinical outcome measures, variation across the 
plausible ranges revealed no change of preferred program.  
5.4.1  Comparison of implementation of NIPT with the classical screening 
program  
Irrespective of the implementation strategy, incorporating NIPT in Down syndrome 
screening programs resulted in important advantages for pregnant women compared 
with the classical Down syndrome screening programs. As can be seen from our 
decision-analytic model, implementation of NIPT reduced the number of missed Down 
syndrome cases by 94% in most programs, except for P1. Furthermore, our model 
showed a 98-100% reduction of false-positive first-trimester screening results by NIPT 
compared with classical screening by the FCT. As a consequence, a 94-97% reduction 
of the amniocenteses and of fetal losses due to amniocentesis complications was 
calculated (Figures 5.2-5.5; Table 5.3). 
Below, we compare the different NIPT implementation strategies while considering 
detection of Down syndrome, the number of women reassured correctly about the 
absence of Down syndrome, the number of false-positive results and conducted 
amniocenteses, the number of unnecessary tests, and the time until confirmatory 
testing (Figures 5.3-5.5; Table 5.3). 
5.4.2  Detection of fetal Down Syndrome 
Considering Down syndrome detection, the preferred screening programs were the 
programs in which NIPT was offered as the first screening test at 10 weeks (P2 and P4) 
or at 13 weeks of gestation (P3). In these programs, the largest proportion of the 200 
fetal Down syndrome cases was detected by NIPT: 175 cases in P2 and P4, and 165 
cases in P3. Missed cases were explained by a false-negative NIPT result in 1 case 
(1/200; 0.5%) and by a spontaneous loss of the pregnancy before a screening result 
could be obtained in the remaining cases (24/200; 12% in P3 and P4; 34/200; 17% in 
P3). When NIPT was offered to high-risk women, pre-selected by the FCT (P1), only 
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147 cases of fetal Down syndrome were detected by NIPT due to 19 false-negative 
results of the FCT (19/200; 9.5%), 1 false-negative result of NIPT (1/200; 0.5%) and 
spontaneous miscarriages occurring between the conductance of FCT and the result 
of the NIPT (33/200; 16.5%). Five of the missed cases due to a false-negative result of 
one of the screening tests in P1 were predicted to result in fetal loss after NIPT 
conductance, while the remaining 15 cases were predicted to result in continuing 
pregnancies.  
5.4.3 Reassurance about the absence of fetal Down syndrome  
Considering reassurance about the absence of fetal Down syndrome, the programs in 
which NIPT was offered at 10 weeks of gestation were preferred (P2 and P4): 95 812 
women were reassured by a negative 10-week NIPT result (96%). When NIPT was 
offered to high-risk women, pre-selected by the FCT (P1), 91 496 women were 
correctly reassured by the FCT about the absence of fetal Down syndrome (92%). 
Later, in 4354 additional cases in which the FCT had provided a false high risk of fetal 
Down syndrome, women were reassured by a true-negative result of the 13-week NIPT 
(4%). If NIPT was offered as the first screening test at 13 weeks of gestation (P3), the 
13-week NIPT was true-negative in 94 662 cases (95%). These women waited 2-3 
weeks longer for this result than the women of P2 and P4.  
5.4.4 Number of false-positive results and performed amniocenteses  
Considering the number of false-positive results and performed amniocenteses, the 
preferred program was P1 in which NIPT was offered to high-risk women, preselected 
by the FCT. In the case of pre-selection by the FCT prior to NIPT, a 95% reduction in 
the number of false-positive NIPT results was predicted, in comparison with P2-P4. In 
P1, the number of false-positive screening results was reduced from 4412 following 
FCT to only 4 following NIPT (4%). In total, 136 amniocenteses were conducted to 
identify 132 out of 200 fetal Down syndrome cases. Only one loss of a fetus with Down 
syndrome because of amniocentesis complications was predicted. In programs P2-P4, 
the NIPT was false-positive in 95-96 cases (0.1%). Comparing P2, P3 and P4, there was 
no difference in the number of performed amniocenteses (234), number of Down 
syndrome cases confirmed by amniocenteses (148/200) and number of spontaneous 
miscarriages due to amniocentesis complications (1 fetus with Down syndrome and 1 
fetus without Down syndrome). In all programs, we predicted that some fetal Down 
syndrome cases detected by first-trimester screening would not be confirmed by an 
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amniocentesis (15 in P1 and 17 in P2-P4). A detection of fetal Down syndrome by 
screening could be not confirmed because the pregnant woman chose not to undergo 
amniocentesis, a spontaneous miscarriage occurred before amniocentesis was 
possible or a fetal loss occurred following amniocentesis complications. 
5.4.5 Unnecessary tests and time until the confirmatory amniocentesis  
Considering unnecessary tests and the time until the confirmatory testing, the 
program in which NIPT was offered at 13 weeks of gestation was preferred (P3). A 
decline by more than 50% of the number of spontaneous miscarriages that occurred 
between the NIPT conductance and the result of the NIPT, assuming a 2-week 
turnaround time (from 3916 to 1161), in comparison to programs P2 and P4, was 
calculated. This meant a decline of more than 50% of unnecessary NIPTs in P3. 
Additionally, following a positive 13-week NIPT (P1, P3 and P4), a timely confirmatory 
amniocentesis was possible, and a miscarriage occurring before amniocentesis was 
unlikely. 
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5.5 Discussion 
In this study, we used a decision-analytic model to compare four hypothetical Down 
syndrome screening programs, in which NIPT was offered as a single first-trimester 
screening test or in combination with the FCT. We compared these programs with the 
classical Down syndrome screening program. As can be seen from our decision-
analytic model, and according to the literature, every program has its advantages and 
disadvantages.17-23  
5.5.1 A suggestion for the most favorable program – P3: NIPT as the first 
screening test for Down syndrome at 13 weeks of gestation  
We reflected upon the results of the quantitative analysis in the light of psychological 
and practical considerations, e.g. the chance that women are correctly reassured by a 
negative screening result, the chance of a correct positive screening result, the time 
until the result of the screening test, the time from the result of the screening test until 
the confirmation of a positive result by amniocentesis, the number of decision-making 
moments for women, etc. 
We concluded that the most favorable Down syndrome screening program may be P3, 
in which NIPT is offered to all women at 13 weeks of gestation as the first screening 
test. Our conclusion is based on the following arguments: (1) The most sensitive 
programs, in which a minimal number of fetal Down syndrome cases is missed by the 
first-trimester screening, are the programs in which NIPT is offered to all women. The 
decline in detection of fetal Down syndrome at 13 weeks of gestation compared with 
10 weeks of gestation is only explained by the occurring miscarriages. (2) Additionally, 
women only have to make a decision about whether or not they want to undergo an 
invasive test based on the result of one screening test, which is the least confusing 
scenario for the women. (3) At 13 weeks of gestation, NIPT is offered when the risk for 
spontaneous miscarriage has declined remarkably. Possibly, the number of 
spontaneous miscarriages was overestimated in the reference that we used, because 
early dating ultrasound was not routine practice in that time.31 However, we wanted 
to calculate the miscarriage risk in the specific time windows in which NIPT was 
offered, and we could not obtain this information from more recent studies.32,33 No 
change in the order of preference was seen if the miscarriage risks in fetuses without 
Down syndrome were much lower, i.e. half of the current estimated risk. The most 
preferable program was still P3. (4) Furthermore, following a positive 13-week NIPT, 
timely confirmatory amniocentesis is possible. After amniocentesis, a definitive 
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diagnosis of fetal Down syndrome can be made by rapid aneuploidy detection. As a 
result, a total turnaround time from blood drawing for NIPT to a definitive diagnosis 
would be on average 3 weeks for all women, and a spontaneous miscarriage between 
a positive NIPT and the result of the amniocentesis is very unlikely to occur. (5) A last 
benefit of NIPT at 13 weeks of gestation is that women are offered some more time 
for adequate counseling and for reflection before they decide to undergo NIPT. At 10 
weeks of gestation, women may speak to their midwife or obstetrician for the first 
time. 
5.5.2 What would be the arguments to keep the FCT? 
An advantage of preservation of the FCT may be that in the case of a NIPT failure, 
which has been reported in 1.3-5%, women can base their decision of follow-up testing 
on the result of the FCT.10-13 It has been suggested that the prevalence of aneuploidy 
is higher in the NIPT failure group than in the overall population, so this group of 
women would benefit from an additional test.7  
In the case of pre-selection by the FCT prior to NIPT, almost no false-positive results of 
NIPT are predicted; as a consequence, almost no unnecessary amniocenteses would 
be performed (4/100 000 in our cohort). This is a 1000-fold decline in comparison to 
the classical screening program. It is interesting to note that pre-selection by the FCT 
prior to NIPT would imply a similar Down syndrome detection rate (157/200 in our 
cohort), as in the classical screening program, and even a small increase in false-
negative results of the screening (2/200 instead of 1/200 in our cohort). Therefore, we 
still believe that P3 (NIPT as a single test at 13 weeks) is the preferable program, 
leading to the detection of almost all cases of fetal Down syndrome by the screening 
while 85 out of 100 000 screened women undergo an unnecessary amniocentesis. A 
possible way to overcome the decline of Down syndrome detection in the case of pre-
selection by the FCT prior to NIPT is to lower the risk threshold from ≥ 1:200 to ≥ 
1:1000 or ≥ 1:2500 to be eligible for NIPT and to offer women with a risk above a very 
high risk threshold (≥ 1:100 or ≥ 1:150) the choice between a direct invasive test and 
NIPT.16,20 This approach is called contingent screening and is investigated in two 
separate clinical studies in the state healthcare-funded system in the UK. It is also 
considered an appropriate screening option by the International Society for Prenatal 
Diagnosis.9 Unfortunately, contingent screening could not be included in our model 
because no information is available about the percentage of high-risk women that 
would choose amniocentesis or NIPT. Of course, the number of unnecessary 
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amniocenteses increases if the risk threshold of the FCT is lower.  
Finally, the Down syndrome screening program could still include the FCT to provide 
pregnant women information about their risk for other conditions, such as 
chromosomal abnormalities other than trisomies 21, 18 and 13, or structural 
anomalies and developmental disorders.34,35 However, some of the current NIPT 
assays already provide risk assessments for sex chromosomal aneuploidies, polyploidy 
and some microdeletions and duplications.3,36,37 If the FCT would be offered next to 
NIPT to target other conditions, this must be in line with the requirement of 
proportionality.17 In other words, the advantages should clearly outweigh the possible 
disadvantages. If this is proportional, and classical incidental findings are turned into a 
screening target, an accordingly adapted informed consent is required. Furthermore, 
there is no reason to believe that the early structural ultrasound at 12 weeks to screen 
for severe structural abnormalities, such as anencephaly, would disappear. An 
increased nuchal translucency seen during the early structural survey will as all other 
ultrasound abnormalities lead to follow-up investigations, including follow-up 
ultrasound or karyotyping. 
5.5.3 What would be the arguments to offer NIPT at 10 weeks of 
gestation? 
An advantage of NIPT at 10 weeks of gestation is that women are reassured earlier if 
the NIPT result is normal. If the result is abnormal, they either have some more time 
to plan and prepare for raising a child with Down syndrome or to make a decision 
about terminating the pregnancy.17,18 Furthermore, in the case of a NIPT failure, there 
is still time to repeat the NIPT or to perform an FCT next to the repeated NIPT to 
increase the chance to provide the couple with a prenatal screening result. 
5.5.4 What did we not include in our model?  
We are aware that health policy choices about followed strategies are among others 
based on the financial capacity and organizational capabilities of the healthcare 
system. In our decision-analytic model, we did not take into account the costs of the 
tests and assumed that all hypothetical strategies could be organized by the healthcare 
system. Furthermore, some scenarios were left out of the analysis for practical 
reasons. To have comparable results of the quantitative analysis, it was necessary to 
assume the same undefined uptake in all screening programs, leading to 100 000 
women undergoing prenatal screening (FCT and NIPT) for Down syndrome. Still, the 
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uptake could be very different if other tests are available. Additionally, women who 
opt to go straight for invasive testing following a high risk of the FCT rather than 
undergo NIPT were not included in the model. They could make this decision either 
because they do not want to wait 2 weeks for the NIPT result or because of the 
increased accuracy of amniocentesis. Occasionally, if both screening tests are 
performed, it can happen that the risk provided by NIPT is low, while the FCT provides 
a very high risk. In that case, women can choose to undergo an invasive procedure 
despite the low risk of the NIPT, also because this very high risk may indicate another 
chromosome abnormality that is not detected by NIPT.35 Failure of NIPT was also not 
included in the model. Women undergo significant delay and potential stress from a 
failed test. If, after repeating the NIPT, still no result can be reported, women may opt 
for another prenatal test if they meet the conditions, or may choose to withdraw from 
prenatal screening for Down syndrome. 
5.5.5 Top-down decision or individualized choice? 
In view of the primary aim of prenatal screening, i.e. the provision of autonomous 
reproductive choice, it can be argued that women should, as far as is reasonably 
possible, be given the opportunity to decide for themselves what test strategy best fits 
their personal values and preferences. This strategy is termed individualized choice.38 
Women could be offered the choice between 10-week NIPT and 13-week NIPT or 
above what risk threshold of the FCT they wish to undergo NIPT. Obviously, such 
individualized choice requires adequate professional support during pre-test 
counseling. The results of this study could be used to explain to women how their 
choice influences their risk to undergo an unnecessary amniocentesis and 
consequently their risk for fetal loss because of amniocentesis complications. 
Empirical research into feasibility, barriers and facilitators of individualized choice is 
crucially important. 
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5.6 Conclusion 
We conducted a quantitative analysis of the clinical outcome measures of four 
hypothetical programs and the classical Down syndrome screening program in order 
to aid health policy decision makers. Irrespective of the implementation strategies, 
offering NIPT results in important advantages for pregnant women compared with the 
classical Down syndrome screening program. However, every NIPT implementation 
strategy has its advantages and disadvantages. After a reflection upon the results of 
our analysis in the light of psychological and practical implications, we concluded that 
offering NIPT to all women at 13 weeks of gestation may be the most favorable 
program if detection of Down syndrome is the primary goal. In this program, women 
undergo one highly accurate screening test for Down syndrome when their risk for 
spontaneous miscarriage has declined remarkably. If fetal Down syndrome is 
suspected, a confirmatory amniocentesis can be scheduled shortly afterwards, leading 
to a total turnaround time from blood drawing to the result of the rapid aneuploidy 
detection of on average 3 weeks. 
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6.1 Abstract  
Objective: It is expected that in the coming years it will be possible to screen for a 
broad range of fetal conditions by noninvasive prenatal screening (NIPT). For women 
that only have access to NIPT through a national public health setting, this expansion 
is not available yet. The aim of this study was to explore the opinion of pregnant 
women about expanding the NIPT to sex chromosome trisomies (SCTs) in a national 
screening program. From a broader perspective, the expansion of disorders included 
in the NIPT panel was discussed. 
Methods: We conducted qualitative semi-structured interviews with eight pregnant 
women about a hypothetical broader NIPT, with emphasis on sex chromosome 
trisomies. 
Results: The interviewees expressed a variety of opinions concerning NIPT for SCTs. 
Four of them agreed with adding SCTs to the NIPT panel. The overall opinion is that 
women want to choose for themselves which disorders in the NIPT panel they wish to 
screen for, and which conditions they want to confirm by invasive testing. 
Conclusion: While opinions about screening for SCTs were very diverse among the 
interviewees, all requested adequate information about every condition included in 
the NIPT panel, and the possibility to choose for themselves which screening strategy 
best fits their personal values and preferences.  
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6.2 Introduction 
For the past few years, pregnant women have been offered noninvasive prenatal 
testing (NIPT) for fetal autosomal aneuploidy (trisomies 13, 18 and 21) from 10 weeks 
of gestation onwards.1 The safe NIPT assays, based on next-generation sequencing of 
fetal cell-free DNA in maternal blood, proved to be much more reliable screening tests 
than the traditional biochemical screening tests, with significantly higher detection 
rates and lower false positive rates.2-4 Recently, some commercial laboratories added 
detection of sex chromosome aneuploidy (SCA) to their NIPT assay, since it requires 
only minor technical alterations to the original NIPT assays, and no biochemical 
screening tests have been available for these disorders.5-9 These assays are mostly 
available to pregnant women through individual practitioners or practices, such as in 
the USA. SCAs result from numerical abnormalities of the X and Y chromosomes with 
diverse clinical manifestations and dissimilar prevalences.10 Sometimes the fetal 
anomaly ultrasound scan shows fetal anomalies that may point towards a SCA, but 
more often fetal SCAs are prenatally diagnosed as an incidental finding of karyotyping 
aiming to rule out autosomal aneuploidy.11 A different NIPT accuracy was reported for 
each of them.5-9 
The two most common SCAs are the sex chromosome trisomies (SCTs) involving the X 
chromosome: Klinefelter syndrome (47,XXY), occurring in approximately 1 in 600 male 
births, and Triple X syndrome or Trisomy X (47,XXX), occurring in 1 in 1000 females 
births.12,13 Children born with SCTs have typically a normal lifespan and few, if any 
dysmorphic features.14 The conditions are estimated to remain undiagnosed in 64% of 
males with Klinefelter syndrome, and in up to 90% of women with Triple X 
syndrome.13,15 Incidental prenatal diagnoses of SCTs are reported to lead to milder 
phenotypes than found in individuals diagnosed on clinical grounds, but the prognosis 
of any child prenatally diagnosed with an SCT cannot be predicted.11,16,17 Klinefelter is 
associated with a variable level of testosterone deficiency, leading to small testes and 
infertility, which can be treated by timely testosterone replacement therapy.15-18 
Furthermore, boys with 47,XXY are at increased risk for mild developmental delay, 
speech-language disorders, learning disabilities, attention deficit hyperactivity 
disorder (ADHD), and other psychological conditions.15-18 Girls with Triple X are at 
increased risk of motor and speech delays, cognitive deficits, learning disabilities, 
attention deficits and mood disorders (anxiety and depression).13  
The interpretation of NIPT results and the counseling of pregnant couples can be 
challenging. While NIPT is excellent at excluding fetal SCTs, its positive predictive value 
Chapter 6 
148 
is only around 50% (33.3-42.9% for Klinefelter syndrome, and 57.1-70.0% for Triple X 
syndrome).7,8,19 This means that a positive result of the NIPT is discordant with the true 
fetal karyotype in approximately half of the cases. A second challenge is that Triple X 
of the mother can be detected while screening the cell-free DNA in maternal blood for 
a fetal SCT.20,21 For these reasons, an invasive diagnostic procedure is recommended 
to confirm the diagnosis after suspicion of a fetal SCT following a positive NIPT result.19 
Here, a third challenge arises. The generally mild and very variable phenotype may not 
justify an invasive procedure for some parents. 
In some countries, where women only have access to NIPT through a national public 
health setting, NIPT for SCA is not available yet. The aim of this study was to explore 
the opinion of pregnant women about expanding the NIPT to SCTs in a national 
screening program. We investigated the motives and considerations of pregnant 
women concerning screening for these conditions, as well as their wishes regarding 
information provision and support. From a broader perspective, the expansion of 
disorders included in the NIPT panel was discussed.  
 
6.3 Methods 
6.3.1 Participants 
The study was approved by the Medical Ethics Committee of the Academic Hospital 
Maastricht and Maastricht University. Pregnant women (> 18 years) who underwent 
prenatal screening for fetal trisomies 13, 18 and 21 by the first trimester combined 
screening test or NIPT received oral and written information about the study. The 
women were invited to participate in an interview with the investigator (E.M.). 
Women were asked to return a filled out consent form in a freepost envelope or 
contact the investigator when interested in participating in the study.  
6.3.2 Semi-structured interviews 
Individual interviews were conducted in the hospital. Before the start of the interview, 
participants filled out two brief questionnaires: one on demographic and socio-
economic characteristics and one on reproductive and genetic history. Subsequently, 
some written and oral information was provided about SCTs and the possibilities and 
limitations of NIPT for SCTs (see Supplemental data). After ascertaining that the 
information about SCTs and NIPT for SCTs was clear for the participants, their ideas 
Opinions of pregnant women about NIPT for SCTs 
  149 
regarding NIPT for SCTs and the expansion of the spectrum of detectable disorders by 
NIPT were explored using open questions in a semi-structured interview schedule (see 
Supplemental data). All interviews were audiotaped and collected data was coded to 
guarantee the privacy of the respondents. 
6.3.3 Analysis 
True verbatim transcription of all audiotaped interviews was conducted and 
transcriptions were manually coded by two researchers (E.M. and K.R.). Open coding 
was followed by axial coding to retrieve the most important themes. In the axial coding 
the interviews were re-read to confirm that the themes arising from the open coding 
accurately represented the interview responses. Any discrepancies were discussed 
until consensus was reached.  
 
6.4 Results 
6.4.1 Sample characteristics 
Of the twenty-five pregnant women that were invited to participate between July and 
October 2015, eight responded and agreed to take part (32%, Table 6.1). Lack of 
knowledge about SCTs and preferring not to think about any genetic disorder in their 
fetus after being reassured by the screening for autosomal aneuploidy, were the main 
arguments for not participating. Seven participants had undergone screening for 
trisomies 13, 18 and 21 by the first trimester combined test or NIPT. One pregnant 
woman was a young woman (23 years) and had not undergone prenatal screening but 
expressed interest in prenatal screening at older age. For every participant, screening 
for SCTs was hypothetical. Theoretical saturation was reached in interview 7 (i.e. no 
additional information was obtained in interview 8) and recruitment was ended.  
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Table 6.1 Characteristics of the pregnant women (F)  
Demographic and socio-
economic characteristics 
n (F) Reproductive and genetic history n (F) 
Mean age (years) (range)  32 (23-42)  Number of pregnancy  
   1st 1 (F4) 
Nationality   2nd 4 (F1, F3, F5, F7) 
 Dutch 8  4th 2 (F2, F6) 
   7th 1 (F8) 
Education   Trimester of pregnancy  
 High 5 (F1-F5)  Second 3 (F2, F7, F8) 
 Medium 3 (F6-F8)   Third 5 (F1, F3-F6) 
 Low 0 Screening in this pregnancy  
   NIPT 1 (F1) 
Religion   First trimester combined test 7 (F1-F7) 
 Roman Catholic 2 (F1, F7)  No screening yet 1 (F8) 
 None 6 (F2-F6, F8) Obstetric history  
   IVF, this pregnancy 2 (F1, F6) 
   Fetal trisomy 21, previous 
pregnancy 
1 (F1) 
   TOP, previous pregnancy 2 (F1, F7) 
   Spontaneous miscarriage(s) 2 (F2, F8) 
  Familial history  
   Son with autism 1 (F7) 
   Niece with Turner syndrome 1 (F2) 
   Aunt with mental retardation 1 (F8) 
Legend to Table 6.1: IVF, in vitro fertilization; TOP, termination of pregnancy 
6.4.2 Themes 
Six broad themes emerged from the analysis (Table 6.2). The first five themes were 
proposed by the investigator and discussed by open questions from the interview 
schedule. A sixth theme (individualized choice) was derived from the answers of the 
participants. Themes 1 and 2 were divided into subthemes. Most subthemes were part 
of the original interview schedule, only the first subtheme from theme 2 (safety and 
timing of NIPT) was derived from the answers of the interviewers.  
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Table 6.2 Main themes and subthemes 
Legend to table 6.2: SCTs, Sex chromosome trisomies 
6.4.3 Theme 1: Prenatal screening for SCTs 
Four of the respondents indicated that SCTs should be added to the spectrum of 
detectable genetic conditions by NIPT (F1, F3, F6, F7). The other four stated that they 
saw no additional value for themselves to screen for SCTs during pregnancy (F2, F4, 
F5, F8). To clarify their opinion, the pregnant women were asked to elaborate on these 
topics: the severity of SCTs, possible advantages and disadvantages of screening for 
SCTs, and how they felt about knowing the fetal sex early in pregnancy. 
Severity of SCTs 
The vast majority of the pregnant women (7/8) perceived SCTs as less severe than the 
autosomal trisomies. Arguments were the normal lifespan and a lower burden and 
impact on the quality of life of the parents. Two illustrative citations are: “IQ a little 
less, some troubles at school, this is not comparable with trisomy 13, which is simply 
not compatible with life” (F1), “In case of Down syndrome, I would terminate the 
pregnancy. But for these disorders, I would absolutely not terminate the pregnancy” 
(F7). Only one pregnant woman valued the SCTs as equally severe as the other 
trisomies if her own child would be affected (F6).  
Advantages and disadvantages of prenatal screening for the pregnant couple 
All eight women would appreciate to receive additional information about their fetus, 
Main themes Subthemes 
1. Prenatal screening for SCTs Severity of SCTs  
 
Advantages and disadvantages of prenatal 
screening for the future parents 
 
Advantages and disadvantages of prenatal 
screening for the fetus 
 Fetal sex is known 
2. Specific aspects of cell-free DNA testing Safety and timing of NIPT 
 The limited positive predictive value  
 Detection of maternal Tripe X syndrome 
3. Postnatal screening for SCTs  
4. Pre-test and post-test informed decision-making  
5. Prenatal screening in general   
6. Individualized choice  
Chapter 6 
152 
and would be relieved if the fetus was not affected. As F1 said: “It is of course always 
an advantage if you receive the confirmation that your child is healthy.” Five women 
stated that the test provides the possibility to prepare for the support of a child that 
might face problems: “I think for you as a parent, it is nice to be able to have that clarity 
already. You know okay, this is coming, and you can take it into account, and prepare 
yourself” (F5). Only two participants (F3 and F6) mentioned the option of termination 
of pregnancy (TOP) as a benefit of screening. Interestingly, three other interviewees 
firmly stated that they would disagree with offering pregnant women the possibility 
for TOP because of a fetal SCT. 
All women summed up a number of disadvantages of screening for SCTs. Being 
informed about a disorder in pregnancy with unclear consequences for the life of their 
future child was a disadvantage that was reported by the majority of the women (5/8). 
Following a positive NIPT result, women would no longer have a worry-free pregnancy, 
or would not be without worries during the childhood of their future child (7/8). They 
would receive a prenatal test result about a disorder with unclear consequences for 
the future child’s life (5/8), and for which they would take no further actions, nor 
during pregnancy, nor during childhood (4/8). F2 said: “I think this entails a lot of 
worries, making the pregnancy and the time when the child is born less pleasant. Since 
I think these are relatively mild disorders, I wonder if you should do this”. One woman 
mentioned that she may feel guilty in case of a continued pregnancy if problems would 
occur during the child’s life.  
Advantages and disadvantages of prenatal screening for the future child 
Two participants brought up that knowing the diagnosis at the start of life could 
increase the acceptance and understanding of the own behavior and difficulties, and 
in case of Klinefelter syndrome the child could be treated for its infertility in time. F2 
said: “Maybe if you know this in advance, you let it be part of who you are, without it 
being a kind of shock at that moment [when diagnosed at later age]”. In contrast to 
this statement, two interviewees indicated that knowing about the SCT at the start of 
life could be detrimental for the future child, because it could lead to stigmatization, a 
damaged parent-child relationship, and possible distress due to the infertility: “I think 
you receive a certain label as a child. No, I do not believe that I would want to know 
this as a parent. Maybe if we would not know the child would develop in a normal way, 
while if it is known by the parents and the environment, the child is treated differently 
in advance” (F4).  
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The fetal sex is known 
All participants wanted to be informed about the fetal sex .Three women stated that 
a consequence of taking the test is knowing the sex, and that pregnant women should 
be aware of this prior to testing. None of them would screen for SCTs only to know the 
fetal sex.  
6.4.4 Theme 2: Specific aspects of cell-free DNA testing 
Safety and timing of NIPT 
Almost all women (7/8) praised that NIPT is a test without risk for mother and child 
that can be conducted early in pregnancy.  
The limited positive predictive value 
The limited positive predictive value of NIPT for SCT was well understood by the vast 
majority of the interviewees (7/8). Most women mentioned potential unnecessary 
anxiety while waiting for the definitive answer: “I think it causes unnecessary stress for 
the pregnant woman. I didn’t go through it myself, but I know people with a positive 
nuchal translucency measurement. This was a stressful phase for them. Later, it turned 
out that everything was fine. So, yes, I think a predictive value of 50% of a positive test 
is low and a disadvantage” (F4). Half of the participants preferred confirmation after 
birth, instead of a follow-up invasive test during pregnancy, because of its additional 
miscarriage risk. 
Detection of maternal Triple X syndrome 
The possibility to detect maternal Triple X syndrome was well understood by the 
majority of the participants as well (7/8). None of them would refrain from NIPT 
because of the possibility to receive the diagnosis of Triple X syndrome themselves 
during pregnancy.  
6.4.5 Theme 3: Postnatal screening for SCTs 
Postnatal screening for SCTs as a part of the new-born blood spot screening program 
was proposed by the interviewer as a hypothetical alternative, while discussing the 
disadvantages of prenatal screening for SCTs. Three interviewees stated that new-born 
screening for SCTs could be a good alternative to prenatal screening if TOP was not 
allowed or not preferred by the future parents. Only two interviewees preferred new-
born screening above prenatal screening because stress during pregnancy is avoided 
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in this scenario, while timely support of the child, and for testosterone administration 
in the case of Klinefelter syndrome is still possible. For example, F5 said: “I think I would 
be happier to know the diagnosis after the pregnancy. Because during pregnancy it 
brings just too much turmoil and uncertainty. While it would be no reason for me to 
terminate a pregnancy”. Three participants mentioned violation of the autonomy right 
of the future parents, because of the loss of the option of TOP. The couple brought up 
that also the autonomy right of the child is violated, since it does not have the right 
not to know. 
6.4.6 Theme 4: Pre-test and post-test informed decision-making  
The topics our participants wished to be informed about during pre-test counseling, 
are summarized in Table 6.3. All women requested a face-to-face pre-test 
consultation, preferably with their own obstetrician or midwife. It was suggested that 
pre-test information should be repeated more than once.  
 
Table 6.3 Pre-test informed decision making  
Prior to NIPT, pregnant women request to be informed about n out of 8 F 
The health and expected quality of life of children with SCTs 8 
The positive and negative predictive value 6 
The possibility to find maternal Triple X syndrome 6 
All further steps in the screening process 5 
The risks for the mother and child of the screening test itself 3 
Is termination of the pregnancy an option? 3 
The possibility to confirm a positive NIPT result with an invasive procedure 3 
The additional miscarriage risk of a confirmatory invasive procedure 3 
Potential stress and anxiety during pregnancy following a positive NIPT result 2 
The prevalence of SCTs 1 
The fetal sex will be known early in pregnancy 1 
What is the legal abortion timeframe? 1 
 
After a positive NIPT result, all women wanted to be informed again about the 
consequences for their future child and the further steps in the screening process. 
Support was requested during the decision of undergoing a follow-up invasive test 
(3/8), during the decision about TOP (3/8), during the rest of the pregnancy (5/8), and 
after birth (1/8). For post-test information, half of the interviewees preferred their 
own obstetrician as the central contact person.  
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6.4.7 Theme 5: Prenatal screening in general 
When asked to deliberate on which disorders should be screened for by NIPT, most 
interviewees answered that these should be early-onset disorders, that shorten life or 
that substantially limit the quality of life. Four pregnant women requested from the 
government a list of diseases serious enough to warrant prenatal screening. The 
couple and two other women requested such a list of conditions to warrant selective 
abortion. Remarkably, the majority of interviewees mentioned concerns about 
eugenics and pursuing a perfect child. Two participants worried about the message 
that certain groups are not welcome in society. 
6.4.8 Theme 6: Individualized choice  
All women believed that participation and all further steps in the screening process 
should be voluntary and based on adequate information. Four interviewees expressed 
the belief that pregnant women undergoing NIPT should be given the opportunity to 
indicate which specific outcomes they do not want to be informed about. As one 
interviewee put it: “Maybe people should be given the choice in advance. They can fill 
out a list: I do want to screen for these disorders, and I don’t want to screen for these 
disorders” (F2). 
  
6.5 Discussion 
To explore the opinion of pregnant women about including SCTs in the NIPT panel in a 
public health setting, semi-structured interviews were conducted with eight pregnant 
women. Similar to a previous study, our participants were unfamiliar with SCTs.22 
However, after explanation of the SCTs and possibilities and limitations of NIPT for 
SCTs, all participants were able to formulate possible advantages and disadvantages, 
and discuss the themes brought up by the investigator. Although we had a limited 
sample size, saturation was reached. We have interviewed a representative group of 
women that opt for prenatal screening, and were able to obtain very different 
opinions. Lack of knowledge about SCTs and preferring not to think about any genetic 
disorder in their fetus after being reassured by the screening for autosomal 
aneuploidy, were the main arguments for not participating. Most likely, the 
hypothetical character of the study, where women had to imagine how they would 
feel about a screening offer that in reality is not available for them, has contributed to 
the limited sample size. It is likely that the low response rate (32%) had some effects 
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on the conclusions drawn from this paper. Our article did not include the opinion of 
pregnant women that do not want to undergo the currently offered prenatal 
screening, because we assumed that these women also would not opt for prenatal 
screening for SCTs. Although all of the interviewees were in favor of screening for 
trisomies 13, 18 and 21, only four of them would also undergo screening for SCTs. This 
is not in agreement with two recent studies that found that the majority of pregnant 
women supports NIPT for fetal SCA.22,23 One possible explanation for this difference is 
that we have limited our interviews to the SCTs, which are milder chromosome 
aneuploidies than for example Turner syndrome (45,X). Furthermore, either 
questionnaires or focus groups were used in the other studies. We believe that 
individual interviews, as used in our study are the best medium to investigate this 
subject, in order to identify detailed perceptions, opinions, beliefs, and attitudes.  
The SCTs were perceived as less severe than the autosomal trisomies by the majority 
of the interviewees, because of the normal lifespan of children with SCTs and the 
limited negative effect on the quality of life of the future parents. Benefits of screening 
for SCTs brought up by the participants were receiving additional information about 
their fetus, being reassured by a negative test result, and the option to prepare for the 
support of their future child. Our study identified several potential disadvantages: 
receiving a prenatal test result about a disorder with unclear consequences for the 
future child’s life and for which they would take no further actions, a less worry-free 
pregnancy and childhood, and possible guilt about continuation of pregnancy. 
Negative effect on emotions during pregnancy and childbirth have been reported by 
pregnant women after an incidental finding of fetal sex chromosome aneuploidy.24 
Two participants mentioned the option of TOP as a benefit of screening, while others 
firmly stated that they disagreed with offering pregnant women the possibility to 
terminate the pregnancy because of a fetal SCT. Cultural and societal factors play a 
role in the parental decision about TOP because of a fetal SCA.25 Internationally, a 
decreasing trend of abortions for SCTs is observed.14 In continuing pregnancies, the 
early knowledge of the diagnosis may positively affect the child’s cognitive and 
physiological development.11 However, knowing about the SCT at the start of life could 
be detrimental for the future child, because it could lead to stigmatization, a damaged 
parent-child relationship, and possible distress due to the infertility. 
All interviewees were positive about NIPT in general. The limited positive predictive 
value was perceived as a negative aspect of NIPT for SCTs. In concordance with 
previous studies not all participants agreed to undergo confirmatory invasive testing 
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for these conditions during pregnancy, because of its additional miscarriage risk.23 
None of the interviewees thought that it was a problem that the fetal sex was known 
early in pregnancy. The detection of maternal Triple X during pregnancy was perceived 
as not important or even as an advantage of the test. It would allow personal life 
experiences and potential struggles to be seen in a different perspective. For simplicity 
reasons, maternal mosaicism, e.g. for monosomy X, was not discussed with the 
participants. 
All participants requested to be well-informed about every condition in the NIPT panel 
prior to testing and brought up that participation and all further steps in the screening 
process should be voluntary and based on adequate information. Similar to previous 
studies, the participants emphasized the importance of acquiring pre-test and post-
test information and support from their obstetric provider.22,26 Without being explicitly 
asked, all interviewees in this study brought up aspects of individualized choice, in 
which women decide for themselves what prenatal test strategy best fits their 
personal values and preferences, in contrast to a fixed prenatal screening program for 
everyone.27,28 They expressed the belief that, based on adequate information, women 
are able to choose which conditions they want to screen for, if they want to undergo 
confirmatory invasive testing, and if they choose for TOP. While voluntary choices 
about follow up testing and TOP are guaranteed, opt-in and opt-out options are only 
limited possible at the moment.  
 
6.6 Conclusion 
A plurality of opinions about screening for SCTs asks for an individualized prenatal 
screening trajectory. All participants requested adequate information before 
undergoing NIPT and the possibility to choose for themselves which screening strategy 
best fit their personal values and preferences  
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1. Additional written and oral information  
Original: Dutch. Translated into English for publication. 
1. What is NIPT? 
In the blood of a pregnant woman, her own DNA is present, as well as DNA from the 
child she is carrying. DNA contains the code that determines our genetic 
characteristics. Drawing blood from the pregnant woman to test the unborn child’s 
DNA, is called noninvasive prenatal testing, abbreviated to NIPT. [picture illustrating 
maternal and fetal cell-free DNA] 
2. Chromosomes 
The DNA in our body is folded into chromosomes. There are two copies of each 
chromosome. Only the sex chromosomes differ for men and women (X and Y). A 
woman has two X chromosomes, and a man has one X chromosome and one Y-
chromosome. [picture illustrating the karyotypes 46,XX and 46,XY] 
3. Currently in the Netherlands  
Today in the Netherlands, the DNA of the unborn child is tested by NIPT for Down 
syndrome (3 times chromosome 21), Edwards syndrome (3 times chromosome 18), 
Patau syndrome (3 times chromosome 13). The NIPT is only offered to women that 
have a high risk of one of these chromosome disorders following the combined test (a 
risk of 1 in 200 or higher). The combined test consists of two parts: a blood test and an 
ultrasound to measure the nuchal translucency of the child. 
4. NIPT of sex chromosome aneuploidy 
Foreign commercial laboratories also offer NIPT. Currently, these companies may also 
test for other genetic disorders using NIPT, because this is technically easy to do so. 
This is not done in the Netherlands yet. However, we are wondering what pregnant 
couples in the Netherlands think of this option. In this study, we want to investigate 
what your opinion is about expanding the existing NIPT to also screen for sex 
chromosome disorders. Additional information is provided below on sex chromosome 
disorders, which you may take into account when forming your opinion. 
4.1. What is a sex chromosome disorder?  
In a sex chromosome disorder, a change in the number of sex chromosomes occurs. 
We limit ourselves in this study to the two most common disorders: an extra X 
chromosome in a woman (Triple X syndrome) and an extra X chromosome in a man 
(Klinefelter syndrome). [picture illustrating the karyotypes 47,XXX and 47,XXY] 
4.2. Consequences for the unborn child 
The effect of an extra X chromosome is usually mild. People have a normal life span 
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and little or no external characteristics. Children with Klinefelter syndrome and Triple 
X syndrome rarely have an intellectual disability, although the IQ may be 10-15 points 
lower than in siblings. There is more risk of a mild impairment in speech and language 
development (this occurs in 50-80% of cases). In addition, learning problems in school 
are seen (in > 70% cases). Therapy and support for these problems are the same as in 
children without sex chromosome disorders. Psychological or psychiatric problems 
may occur (in 25% of cases), such as attention deficit hyperactivity disorder (ADHD) or 
depression. The main problem of boys with Klinefelter syndrome is their infertility. No 
or very few sperm cells are produced. In addition, these boys have small testes after 
puberty and extra administration of testosterone (male hormone) may be required. 
Girls with triple X syndrome are normally fertile. 
4.3. What does NIPT for sex chromosome disorders offer? 
1) Reassurance. If the NIPT shows no extra X chromosome, then the pregnant woman 
can be reassured: her baby will not have a change in the number of sex chromosomes. 
2) An increased risk of Klinefelter syndrome or Triple X syndrome. If the NIPT shows 
an extra X chromosome, in half the cases, the baby still does not have Klinefelter 
syndrome or Triple X syndrome. One reason is that the extra X chromosome comes 
from the pregnant woman herself. In the blood of a pregnant woman, her own DNA 
and the DNA of her unborn child are present. The NIPT will examine all DNA 
simultaneously. It is possible that the pregnant woman does not know she has Triple 
X syndrome, because it often causes no symptoms. If the NIPT shows an extra X 
chromosome, a follow-up test by chorionic villus sampling or amniocentesis is 
required, along with a maternal blood test. The follow-up test takes an extra week 
(with a rapid test). The risk of miscarriage is 0.3-0.5%. 
3) Knowing the diagnosis during pregnancy and at the beginning of life. On the one 
hand, knowing that the child has an extra X chromosome can be stressful for the 
pregnant couple during pregnancy and birth. During the time after birth parents can 
sometimes have doubts about the development of the child. It may also be difficult for 
parents if an when they decide to tell their child about the condition. On the other 
hand, parents may appreciate the clarity that comes with an earlier diagnosis during 
pregnancy. Finally, parents are faced with the decision whether to continue or 
terminate the pregnancy. This can be difficult, because it is uncertain whether or not 
the child will have problems and to what extent. 
4) The sex. If the test is carried out the sex of the child will be known by the laboratory. 
This does not have to be communicated to the parents in case of a normal result (no 
extra X chromosome). 
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2. Interview guide 
Part 1. Exploring question 
1. What is your opinion about the evolution that more disorders are included in the 
NIPT screening test? 
Open question 
Part 2. The interviewer asks about the possible motives and considerations 
concerning NIPT for sex chromosome trisomy 
2. What is your opinion about the severity of the sex chromosomal trisomies? Are they, 
according to you, equally severe or more or less severe than the trisomies that are 
currently screened for? 
Open question + question with three possible answers 
3. Are there, according to you, advantages of screening for sex chromosome trisomy 
during your pregnancy? 
Open question (When participant has elaborated on advantages for other women, ask 
what the advantages for herself are). 
4. Are there, according to you, disadvantages of screening for sex chromosome trisomy 
during your pregnancy? 
Open question (When participant has elaborated on disadvantages for other women, 
ask what the disadvantages for herself are). 
5. What is your opinion about the accuracy of NIPT? 
Open question (When needed, explain again the meaning of positive and negative 
predictive value, and mention the limited positive predictive value of NIPT for sex 
chromosome trisomy).  
6. What do you think about the fact that the result of the NIPT might be an altered 
number of sex chromosomes in yourself? 
Open question, only for pregnant woman (When needed, explain again how this is 
possible. Specifically ask if the pregnancy is an appropriate  time to find out.) 
7. What is your opinion about the fact that NIPT is a prenatal test and that, following 
confirmation of a positive result, a choice about continuation or termination of the 
pregnancy can be made? 
Open question. Topics that can be suggested by the interviewer are: knowledge of the 
disorder at the time of birth, guidance during pregnancy, new-born screening as 
alternative.  
8. What do you think about knowing the sex of the fetus following NIPT? 
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Open question 
9. Should NIPT for SCTs be added to the current NIPT assay? Why? 
Yes/No question + open question 
This was the final question of the part of the interview about your opinion about NIPT 
for SCTs. To control that I understood you correctly, I will give a short summary of your 
answers. Was the summary correct and complete? Do you want to add anything?  
Part 3. The interviewer asks about the wishes of the couples concerning patient 
education and counseling (20-30 min) 
10. If the test would be offered, what information should be explained during pre-test 
counseling? 
Open question. Topics that can be suggested by the interviewer are: the phenotype, 
the variability of the phenotype, the positive and negative predictive values, the 
possibility to find maternal sex chromosome trisomy, the possibility of a choice 
between continuation or termination of the pregnancy, the potential stress and anxiety 
during pregnancy and after birth.  
11. How would you like to obtain pre-test information? 
Open question. Topics that can be suggested by the interviewer are: website, booklet, 
movie, consultation with a clinical geneticist/midwife/gynecologist. 
12. If the NIPT would be positive, what information should be explained during post-
test counseling? 
Open question.  
13. How would you like to obtain post-test information? 
Open question.  
This was the final question of the part of the interview about patient information and 
guidance. To control that I understood you correctly, I will give a short summary of 
your answers. Was the summary correct and complete? Do you want to add anything?  
Part 4. The interviewer asks again about the wishes of the couples concerning 
expansion of the disorders included in the NIPT panel 
14. If you would be able to choose, which disorders should be screened for during 
pregnancy? 
Open question.  
Part 5. End of the interview 
15. Do you want to add anything concerning this topic that was not yet discussed 
during the interview?  Open question.  
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In 1997, Lo et al. discovered the presence of fetal cell-free DNA (cfDNA) in the blood 
circulation of pregnant women.1 Since then, cfDNA has increasingly been used in 
prenatal care, and in prenatal screening and diagnosis of genetic disorders. Safe, 
noninvasive cfDNA tests, require simply a maternal venous blood sampling. In prenatal 
care, fetal blood group genotyping in the cfDNA of alloimunised pregnant women has 
replaced the invasive procedures in the prevention of hemolytic disease in the fetus 
and newborn.2,3 Furthermore, when a genetic determination of the fetal sex is 
required during pregnancy, a blood sample of the pregnant woman is now routinely 
drawn.4,5 Another goal has been to replace the invasive procedures by cfDNA testing 
for the detection of genetic disorders. This has led to the use of cfDNA in prenatal 
screening and diagnosis.6 In prenatal diagnosis, the cfDNA test offers women at 
increased risk for a genetic condition in the fetus, a definite answer to the question 
whether the genetic condition is present in the fetus. These noninvasive prenatal 
diagnostic tests are abbreviated as NIPD. In prenatal screening, the cfDNA test 
identifies pregnant women at high risk for a genetic condition in the fetus. These 
screening tests are referred to as noninvasive prenatal testing (NIPT). In this thesis, 
noninvasive prenatal screening and diagnosis of genetic disorders through analysis of 
fetal cfDNA in maternal blood was investigated. Furthermore, part of my research 
aimed at contributing to a further responsible implementation of NIPT.  
In Part I the use of cfDNA for prenatal genetic diagnostic testing was explored. This 
part comprised the design of in-house noninvasive diagnostic tests for fetal sex 
determination as well as single-gene mutation detection. In this final chapter, the 
results of part I are discussed along the following themes: (1) improving noninvasive 
fetal sex determination, (2) noninvasive evaluation of cell-free RNA (cfRNA) levels in 
maternal plasma, (3) development and implementation of NIPD of single-gene 
disorders. 
Part II investigated the responsible application of cfDNA in prenatal screening. The 
diagnostic accuracy and clinical implementation of trisomy 21 screening was 
examined. Additionally, the opinion of pregnant women regarding the inclusion of 
fetal sex trisomies in the NIPT panel, was explored within the broader context of the 
expansion of the scope of screening. In this general discussion chapter, the results of 
part II are discussed in these topics: (1) NIPT of trisomies 13, 18 and 21 from 2011 until 
now, (2) broadening the scope of noninvasive prenatal screening, (3) false positive and 
false negative NIPT results, and (4) autonomous reproductive choice.  
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7.1 Part I: Design of noninvasive prenatal diagnostic tests – 
results in perspective 
7.1.1 Improving noninvasive fetal sex determination 
Sex determination was one of the first clinical applications of fetal cfDNA testing and 
is routinely used in European countries.4 In the Netherlands, it has been offered as a 
prenatal diagnostic test for clinical purpose since the beginning of 2003.5 This test is 
only available for a small group of pregnant women with a clinical indication for 
prenatal determination of the fetal sex. These are women carrying a fetus that 
presents with ambiguous genitalia during ultrasound examination, and women 
carrying a fetus that is at risk of an X-linked disorder, or a fetus at risk of the autosomal 
recessive disorder congenital adrenal hyperplasia, where masculinization of the 
external genitalia of girls occurs.7-9 Up until now the blood from pregnant women with 
a clinical indication for prenatal diagnosis of the fetal sex in the clinical genetics 
department of the Maastricht UMC+, and our collaborating clinical genetics 
department of the Radboud UMC, is sent to Sanquin in Amsterdam.5 Sanquin is the 
national reference laboratory for noninvasive prenatal sex determination. However, 
in case of a female fetus the testing at Sanquin can take more than a week, and 
sometimes fails sometimes to provide a clear result.  
To address these problems, a novel noninvasive fetal sex determination assay was 
developed and tested in 75 pregnant women who were between 9-34 weeks of 
gestation (Chapter 2). In this novel single-tube assay amplification of Y chromosome-
derived cfDNA, derived from Y-linked amelogenin (AMELY), is combined with reverse 
transcription PCR (RT-PCR) of trophoblast-derived cfRNA. A remarkable stability of 
cfRNA in blood was seen, possibly due to protection against enzymatic degradation by 
vesicle-like structures.10 In our assay, the cfRNA functions as a specific marker for 
fetoplacentally derived nucleic acids in the plasma sample. This fetoplacental marker 
is part of the NIPD assay, and sex-independent. The fetal sex was correctly determined 
in all 75 pregnant women without failure or false results (this thesis). The assay can 
compete with the current noninvasive fetal sex determination assays in that it is a 
cheap single-tube assay that can determine the fetal sex within one or two days. For 
the same reasons, it is a useful addition to the next-generation sequencing (NGS) 
workflow and it can also be conducted in laboratories that do not have access to NGS 
facilities.  
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One could question if the presence of the fetoplacental RNA marker actually means 
that there is also an adequate amount of fetal cfDNA in the plasma. Our proof-of-
principle study results all indicate that the presence of the fetoplacental cfRNA marker 
is strongly correlated with the presence of an adequate amount of fetal cfDNA for 
noninvasive sex determination. Moreover, our study shows that cfDNA and cfRNA are 
equally stable and both require storage at -80 °C and a minimal number of freeze/thaw 
cycles to ensure optimal conservation. A limitation of our test is that Y chromosome 
determination is based on AMELY only, because too many primer interactions in the 
multiplex RT-PCR were seen when additional Y chromosome gene markers were added 
(data not shown). Deletion of AMELY could result in allelic dropout, and consequently, 
a false negative result. However, the frequency of AMELY deletions is low (0.018% in 
Europe, 0.02% in Australia, 1.85-2.36% in India).11,12 Furthermore, sex determination 
based on AMELY detection is widely accepted for genetic sex determination, e.g., in 
the forensic field, prenatal diagnosis, and preimplantation genetic diagnosis. In 
conclusion, I expect that this theoretical limitation does not hinder the 
implementation of the test. Clearly, this proof-of-principle study needs further 
replication before entering the diagnostic arena. Our novel assay will now be 
compared to the Sanquin test, in all pregnant women with a clinical indication for 
prenatal determination of fetal sex in Maastricht. If the assay continues to show 100% 
accuracy and provides a faster answer, the assay can be offered in the clinical genetics 
department of the Maastricht UMC+, as well as other laboratories. Furthermore, I 
recommend testing more samples from pregnant women between 7 and 10 weeks of 
pregnancy, before offering the test that early in pregnancy. 
7.1.2 Noninvasive evaluation of cfRNA levels in maternal plasma 
Multiplex RT-PCR assays, targeting specific fetal transcripts, or transcriptome analysis 
by NGS (RNA sequencing) could provide more information than simply the presence 
of fetal nucleic acids.13 CfRNA levels in maternal plasma are variable and reflect 
differential expression during fetal development.14 It is known that the majority of 
circulating fetal transcripts in third-trimester maternal blood are related to the sensory 
and central nervous system development, sense of smell and the ability to mount an 
inflammatory response.15 The cfRNA in amniotic fluid in pregnancies with twin-to-twin 
transfusion syndrome, fetal hydrops and fetuses with trisomies 18 and 21 has been 
analysed.16-18 In these disorders, diseases-specific upregulation of genes was 
identified. Furthermore, an association between upregulation of corticotrophin-
releasing hormone cfRNA and preeclampsia, a pregnancy related disorder 
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characterized by hypertension and proteinuria, has been demonstrated.19 These 
findings have not been translated into prenatal care at the moment. Possibly, fetal 
transcriptome analysis in maternal blood could be used in the future to noninvasively 
monitor the fetus and provide insight in placental and fetal development.15,20 
Detection of abnormal patterns of gene expression could identify fetuses at risk of 
developmental delay, intra-uterine growth restriction and congenital heart defect, in 
particular when abnormalities are observed on ultrasound scan.21 Other placental 
transcripts in maternal blood could serve as biomarkers for preeclampsia.  
7.1.3 Development and implementation of NIPD of single-gene disorders  
A. Noninvasive prenatal diagnosis of single-gene disorders: challenges 
A few years after the discovery of fetal cfDNA in the plasma of pregnant women, the 
first studies aimed at diagnosing single-gene disorders in cfDNA were published. 
Single-gene disorders can have recessive, dominant or X-linked Mendelian inheritance 
patterns. In approximately 4600 of these disorders, the causative gene is currently 
known.22 NGS has been used for the development of reliable noninvasive assays of all 
types of single-gene disorders since 2012. Disorders that have been detected in the 
cfDNA using NGS include achondroplasia and thanatophoric dysplasia, Huntington 
disease, beta-thalassemia, congenital adrenal hyperplasia, Wilson disease, congenital 
deafness, and Duchenne and Becker muscular dystrophies (Chapter 1, Table 1.1).23-34 
Two of the greatest technical challenges in the development of noninvasive tests for 
single-gene disorders are the predominance of maternal cfDNA in the plasma sample, 
and the difficulty to reliably distinguish fetal cfDNA fragments from maternal cfDNA 
fragments.35,36 Consequently, noninvasive prenatal determination of single-gene 
disorders depends on the relative proportions of normal and mutated cfDNA. In Figure 
7.1 different inheritance patterns and their consequences for the noninvasive 
determination of single-gene disorders are described. Due to the “maternal 
background” problem it is more straightforward to detect either paternally inherited 
mutations or de novo mutations than to detect maternally inherited mutations. In the 
case of maternal inheritance, the maternal mutation is already present in most cfDNA 
sequences in the maternal plasma, and the NIPD assay has to determine whether or 
not the mutation is also present in the fetal cfDNA. However, even in the case of 
paternal inheritance or a de novo mutation, sensitive detection of the low level of 
mutant alleles is required. Another challenge is the low concentration of total and fetal 
cfDNA.37,38 Additionally, prenatal diagnosis for single-gene disorders is mostly 
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requested early in pregnancy, when the fetal fraction is at its lowest. Last, due to the 
short cfDNA fragments, direct mutation detection is not eligible for all disorders, such 
as repeat expansion disorders and large deletions.39,40  
In addition to the technical challenges, it is problematic to collect a large cohort of 
pregnant women requesting prenatal diagnosis for an individual single-gene disorder, 
due to the low prevalence of these disorders. This makes it difficult to validate a novel 
assay.  
Notwithstanding the technical difficulties, the NGS-based noninvasive assays for 
single-gene disorders can provide a definite answer to the question whether the 
disorder is present in the fetus, without the need for an invasive follow-up test to 
confirm the result (NIPD). NIPD provides early in pregnancy a safe alternative to the 
invasive procedures. There are several reasons why NIPD is possible for single-gene 
disorders: (1) Due to targeted deep sequencing of regions of interest, these tests are 
less influenced by the fetal fraction than chromosome tests. (2) Methods are being 
developed to reduce incorrect variant calling by NGS because of PCR mistakes and 
sequencing mistakes.41 (3) Usually, the mutation(s) in the family is (are) known, and 
the fetus has often a very high risk to inherit the disorder, e.g. 25% or 50%. The high 
chance of the examined pregnant women to actually carry a fetus with the disorder, 
will lead to a higher positive predictive value, i.e. the chance that a positive test result 
is a true test result is high. (4) In case of single-gene disorders, no placental mosaicism 
(possibly leading to false positive NIPD results) has been described. (5) No unexpected 
maternal chromosome abnormalities may confound results.42  
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Figure 7.1 Detection of causal mutations in autosomal dominant (A) and autosomal recessive 
disorders (B) in cell-free DNA (cfDNA). Noninvasive prenatal detection of the fetal inheritance 
depends on the relative proportions of normal and mutated cfDNA. In this example the fetal 
fraction is 10%. 
 
There is a significant demand for NIPD of single-gene disorders, and the continuing 
advances in technology and data analysis facilitate the expansion of the NIPD test 
repertoire.43 Dutch and international researchers nowadays attempt to design NIPD 
assays for a broader range of single-gene disorders. Both direct and indirect haplotype-
Chapter 7 
174 
based methods have been developed (Chapter 1, Table 1.1). The goal is to provide as 
many pregnant women as possible that carry a fetus at risk of a specific single-gene 
disorder the possibility to undergo NIPD instead of an invasive procedure.  
A current challenge is developing NIPD assays for the detection of nucleotide repeat 
expansions. Nearly thirty hereditary disorders in humans are known to result from an 
increase in the number of copies of simple repeats in genomic DNA.44,45 This specific 
class of disorders is a common indication for prenatal diagnosis. In Chapter 3 we 
presented a novel assay for NIPD of myotonic dystrophy type 1 (DM1), caused by 
expansion of a CTG trinucleotide repeat in the dystrophia myotonica protein kinase 
gene (DMPK).46,47 In a proof-of-principle study, we tested the cfDNA obtained from a 
plasma sample from a pregnant woman carrying a fetus that inherited DM1 from its 
affected father. In this assay single molecule molecular inversions probes (smMIPs) 
were designed and optimized for targeted NGS of DMPK repeat surrounding single 
nucleotide polymorphisms (SNPs).41 First, a trio (pregnant woman, affected father and 
previous affected child) was sequenced, to detect twelve informative SNP loci for the 
disease status of the father and the fetus. Subsequently, the plasma cfDNA was 
sequenced to determine the fetal inheritance, calculated from the percentage of the 
informative SNPs in the cfDNA reads. Ten SNPs unequivocally reported the presence 
of the mutated paternal allele in the cfDNA. Five of them proved the presence of the 
paternal risk allele in the plasma, while the remaining five showed that the paternal 
wild type allele was not present in the plasma. The fetal fraction was determined based 
on unique paternal variations. The results of this proof-of-principle study are 
promising.  
We are the first to use smMIPs for NIPD. Molecular inversion probes represent an 
attractive platform for targeted capture because of their very low per-sample cost, 
workflow simplicity, target-set modularity and low sample input requirement.41 Direct 
measurements of the mutations can also benefit from additional haplotyping to 
provide a reliable combined direct and indirect NIPD assay. For this purpose, it could 
be ideal to design smMIPs to target the coding regions of disease genes, as well as 
common SNPs flanking these regions. As a result, this NIPD assay can be used for all 
autosomal dominant disorders, and paternal as well as maternal mutations may be 
detected. Obviously, more evaluation and optimization is required of the smMIPs NIPD 
approach for different disorders in the coming period. 
In the case of haplotype-based NIPD assays for prenatal diagnosis of a repeat 
expansion disorder, only the mutated allele, carrying the repeat, can be detected. The 
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exact repeat length in the fetus cannot be determined in cfDNA because of the 
degraded fragment size of the cfDNA. However, repeat expansion disorders are often 
characterized by anticipation: in successive generations within a family, affected 
family members are at risk for further expansion of the repeat, which can result in 
decreasing age of onset and increasing severity.48 Therefore, it is of clinical relevance 
to know the length of the repeat during pregnancy. Following a haplotype-based NIPD 
assay that reveals inheritance of the mutated allele in the fetus, pregnant women can 
opt for an invasive procedure to know the repeat length during pregnancy, or for 
testing after birth. Some groups have attempted direct detection of the repeat 
expansion mutation, mostly in Huntington’s disease.33,49,50 Direct detection of repeat 
expansion mutations has been possible for small repeats that have a size of one to 
three times the average size of cfDNA fragments.33 This suggests that in case of repeat 
expansion disorders larger cfDNA fragments may be present in the maternal plasma. 
It has been suggested that plasma cfDNA fragments are derived from the enzymatic 
processing of DNA from apoptotic placenta cells.39 The length of the fetal and total 
cfDNA fragments resemble the nuclease cleaving in between the nucleosomes, where 
the double stranded DNA is wrapped around a histone core, as a part of the apoptotic 
process.39,51 DNA repeats seem to be predisposed to expansion because they have 
unusual structural features, which disrupt the cellular replication, repair and 
recombination machineries.44,45 It is unknown whether the structural DNA changes in 
repeat expansion regions prevent normal nuclease cleaving during apoptosis, leading 
to longer cfDNA fragments. Theoretically this may explain why direct repeat expansion 
mutation detection in some patients reveal cfDNA fragments that are longer than 
predicted during apoptosis. Further investigation of this phenomenon will provide 
insight about the possibility to predict increase of repeat size in the cfDNA. This 
happens in parallel with further improvements in NGS technology. The ideal 
sequencing platform in this context would work on a single cfDNA molecule without 
any need for DNA fragmentation and pre-amplification.52 Single molecule long read 
sequencing technology comes most close to this ideal platform and the first proof of 
concept study for repeat expansions has already been published.52-54  
In the coming years a further parallel development of NGS technologies and targeted 
and more broad tests for all types of single-gene disorders early in pregnancy is to be 
expected. 
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B. Implementation of NIPD assays for single-gene disorders and future perspectives 
A translation into clinical practice of a NGS-based NIPD assay for some single-gene 
disorders has already occurred in the United Kingdom (Chapter 1, 1.5.3).43,55 For 
selected diseases couples can undergo NIPD from 9 weeks of gestation onwards.56 
When a skeletal dysplasia is identified by ultrasound scan, e.g. achondroplasia or 
thanatophoric dysplasia, NIPD can be used to confirm the diagnosis. It is currently not 
possible for this laboratory to offer NIPD for maternal inheritance or for repeat 
expansion disorders. In the near future, it can be expected that for more single-gene 
disorders a noninvasive prenatal diagnostic test will be offered to pregnant women, 
also in the Netherlands.  
In the coming years NIPD assays will be developed for all disorders for which at the 
moment conventional prenatal diagnosis, pre-implantation genetic diagnosis (PGD) 
and preconception or prenatal carrier screening is offered. PGD could be offered in 
combination with NIPD to reassure couples during pregnancy that an embryo without 
the disorder was selected for transfer to the woman’s uterus. Probably, some couples 
will prefer early NIPD, if possible in the future, instead of PGD, because the latter 
demands in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment 
and the chance of conception with IVF/ICSI/PGD is limited even among normally fertile 
couples.57 Carrier screening of the parents before or during pregnancy could also be 
offered in combination with NIPD.58 Ethical considerations of this combination of 
carrier screening and NIPD are discussed further in detail in this general discussion 
chapter while discussing cfDNA-based screening. 
NGS-based NIPD assays with disease-focused panels of candidate genes in case of 
prenatal ultrasound anomalies will most likely be offered in the near future.22 
Examples are panels containing genes for Noonan syndrome in case of an increased 
fetal nuchal translucency, or skeletal dysplasia panels to differentiate between the 
different skeletal dysplasias in case of skeletal abnormalities seen on the fetal anomaly 
scan.22 
Before a widespread implementation of diagnostic cfDNA-based tests for women at 
high-risk for single-gene disorders, it is important to consider its costs and ethical 
implications.42,58 The costs of NIPD are dependent upon the complexity of the testing 
technique required.42 For that reason, it has been predicted that for autosomal 
dominant conditions the NIPD costs would be lower than those of the invasive 
procedure, while for autosomal recessive and X-linked conditions the NIPD costs 
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would be higher than those of the invasive procedures. However, universal indirect 
methods, using SNP-based haplotyping, such as our smMIPs NIPD assay, have similar 
costs for all types of single-gene disorders. With further developments in NGS, the 
costs to detect all conditions will be declining rapidly in the coming period. 
Furthermore, it is perfectly possible to test several different conditions and include 
multiple causative mutations in a single assay, which also lowers the costs. There is no 
reason to restrict NIPD assays to a specific inheritance pattern. However, we can 
expect an increase in uptake in comparison to the invasive tests when NIPD assays will 
be offered to high-risk pregnant women.42 In particular, future parents with a fetus at 
risk for a single-gene disorder that have no intention to terminate the pregnancy may 
now request cfDNA-based testing while in the past they would not opt for invasive 
testing, due to the miscarriage risk. This will give the parents the opportunity to 
prepare for the birth of an affected child. However, for late onset genetic disorders, 
parents should be discouraged to do so, as continuing a pregnancy of an affected child 
will violate the autonomy of the future child to choose for a predictive test or not. The 
simplicity and safety of the tests could lead to more autonomous decision-making for 
pregnant women, but it could also lead to increased pressure on women to take up 
prenatal diagnostic testing.58 Health professionals in the United Kingdom, where NIPD 
is already implemented for some disorders, fear this increased pressure to test during 
pregnancy and even to terminate a pregnancy.59 However, they also felt that this could 
be overcome with thorough pre- and post-test counseling. 
Most likely, detection of single-gene disorders will not remain an option only for 
pregnant women with an indication, at risk of passing on an inherited disorder. It will 
be technically possible within the foreseeable future to offer to all pregnant women a 
comprehensive noninvasive NGS-based screening test for a broad range of autosomal 
recessive, autosomal dominant and X-linked single-gene disorders. Possible 
applications and ethical concerns of prenatal screening tests for single-gene disorders 
are discussed further in this general discussion chapter while discussing the possible 
broader range of heritable and congenital conditions for which prenatal screening 
could be offered. 
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7.2 Part II: Noninvasive prenatal screening for fetal 
chromosome disorders – Results in perspective  
7.2.1 NIPT of trisomies 13, 18 and 21 from 2011 until now 
The search for a noninvasive prenatal test that could reliably detect fetal trisomies 13, 
18 and 21 started very soon after the discovery of fetal cfDNA in maternal plasma, and 
has been compared in the literature to the search for the Holy Grail.60 This drive 
originates in the fact that these chromosome imbalances have always been important 
indications for invasive prenatal diagnosis. In 2008 it was suggested to use NGS to 
calculate the over- or underrepresentation of any chromosome in the cfDNA.61,62 Since 
then it has been possible to reliably detect fetal chromosome imbalances in maternal 
plasma. In 2011, at the time I started the research upon which this doctoral 
dissertation is based, the first diagnostic accuracy studies were published using NGS 
to detect fetal trisomies 13, 18 and 21 in maternal plasma (Chapter 1, Table 1.2).63-72 
This was accompanied by the first commercial release of NIPT in Hong Kong in August 
2011, and in the United States (US) in October 2011.73  
In Chapter 4 we performed a systematic review of all studies evaluating the diagnostic 
accuracy of molecular techniques for noninvasive detection of trisomy 21 between 
1997 and the beginning of 2012. In this systematic review, seven studies examined the 
sensitivity and specificity of NGS-based cfDNA testing of fetal trisomy 21.64-66,68,69,72,74 
We evaluated the diagnostic parameters and the quality of the studies (potential bias 
and applicability) using the revised tool for Quality Assessment of Diagnostic Accuracy 
(QUADAS-2).75 The important diagnostic parameters that are evaluated in diagnostic 
accuracy studies are listed in Table 7.1. 
Table 7.1 Diagnostic parameters in noninvasive fetal trisomy detection 
Sensitivity How likely is the cfDNA-based test to detect the presence of 
trisomy when the pregnant woman carries a fetus with a trisomy?  
Specificity How likely is the cfDNA-based test to detect the absence of trisomy 
when the pregnant woman carries no fetus with a trisomy? 
Positive predictive 
value (PPV)  
How likely is a pregnant woman with a positive cfDNA-based test 
result to actually carry a fetus with the trisomy? 
Negative predictive 
value (NPV) 
How likely is a pregnant woman with a negative cfDNA-based test 
result to actually not carry a fetus with a trisomy? 
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In these NGS-based studies the sensitivity and specificity were compared with the gold 
standard karyotyping, in mainly high-risk pregnant women. We concluded that 
sensitivity and specificity in these seven studies was high: sensitivities were between 
98.58% [95% confidence interval (CI) 95.9-99.5%] and 100% (95% CI 96-100%) and 
specificities were between 97.95% (95% CI 94.1-99.3%) and 100% (95% CI 99.1-100%).  
Nevertheless, in our review, and in other literature, it was clear that these tests would 
not be diagnostic tests, replacing the invasive procedures.76 In the beginning years, 
cfDNA testing companies did not always report information about the positive and 
negative predictive values of their test. Therefore, we calculated the positive 
predictive value and negative predictive value for different prevalence conditions for 
the seven NGS-based studies in our systematic review. We stated that NIPT of fetal 
trisomy 21 exhibits an excellent negative predictive value (100%) in conditions with 
disease odds from 1:1500 to 1:200 (the a priori risk of a 20-year-old pregnant woman 
and the a priori risk of a 38-year-old pregnant woman, respectively). However, we 
reported for the first time that the positive predictive value showed large variation. 
Immediately upon publication of Chapter 4, the variable positive predictive value was 
reported by others.76 The reasons behind the variable positive predictive value are 
explained more in detail further in this general discussion chapter. In general, if the 
consequences of a false positive result of a test have detrimental effects on patients, 
a test with a high positive predictive value is essential. If the disorder may not be 
missed, a test with a high negative predictive value is chosen, if the consequences of 
a false positive result, e.g. treatment, in case of no disease are not harmful for the 
patient. Since a false positive NIPT result can lead to abortion of a healthy fetus, an 
invasive procedure followed by rapid aneuploidy detection or karyotyping is 
recommended by the International Society for Prenatal Diagnosis to confirm suspicion 
of fetal trisomy following a positive cfDNA-based test result.6,77 At that time the term 
“noninvasive prenatal testing” (NIPT) was formulated, referring to cfDNA-based tests 
that are used as a screening test and require a confirmation by a follow-up test. 
In the last years, large prospective studies allowed more precise estimates about 
sensitivity, specificity and predictive values in high-risk and low-risk pregnancies 
(Chapter 1, Table 1.2).78-96 The efforts of commercial companies to validate NIPT 
assays have been huge.97 Thousands of plasma samples have been tested in many 
large cohort studies evaluating NIPT for trisomy 21, as well as for trisomies 13 and 18. 
In these studies, only minor technical alterations and bioinformatics improvements 
were made to the original studies. The focus was mainly on including large cohorts of 
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low-risk pregnant women early in pregnancy, as NIPT would be a screening test. It was 
shown that cfDNA-based tests using NGS can detect fetal trisomy in high-risk and in 
low-risk pregnant women from 10 weeks of gestation onwards with a sensitivity and 
specificity of more than 99% and a negative predictive value of almost 100%. However, 
a variation in the positive predictive value was still observed. The positive predictive 
value drops especially when the a priori chance of carrying a fetus with a trisomy 
declines.85 The positive predictive value varies between approximately 60% and 95% 
in a high-risk population (risk of 1 in 200), drops to 50% to 80% in a more general 
population, and may even fall below 50% in young, low-risk pregnant women. 
A rapid global implementation of the screening test was seen. In 2015 commercial 
NIPT was already offered in over 60 countries throughout six continents, although a 
recent market report shows that the US account for 64.5% of global NIPT revenue, 
followed by Europe.73 The goal since 2011 has been to replace current screening tests, 
such as the first trimester combined test (FCT), with NIPT, or to offer NIPT as a second 
tier screening test. Although NGS cfDNA-based tests may have failed to provide the 
final answer on whether a trisomy is present in the fetus, they proved to be much 
better screening tests that the traditional biochemical screening tests so far.85,92 For 
example, the FCT is estimated to have a sensitivity of 89.0% and a specificity of 95.4% 
for fetal trisomy 21 detection, if considering women of all age categories and a risk 
threshold of 1 in 200.98 This is considerably lower than the sensitivity and specificity of 
the NIPT, that both exceed 99%. 
Nowadays, the option of NIPT for fetal aneuploidy screening has reached most 
pregnant women in the Western world through the internet, traditional media, family 
and friends, as well as through information provided by gynecologists. Several 
countries are working on the implementation of NIPT in their prenatal trisomy 
screening program.99-101 In the last years, the clinical utility, cost-effectiveness and 
ethical consequences of plausible NIPT implementation strategies have been 
evaluated.101-107 In addition, the attitudes of pregnant women and obstetricians and 
gynecologists towards NIPT have been studied through questionnaires and 
interviews.108-112 In Chapter 5 we compared different implementation strategies of 
NIPT for trisomy 21. For this, a quantitative analysis of different NIPT implementation 
strategies was conducted. We suggested that the most favorable screening program 
may be a program in which NIPT is offered to all women at 13 weeks of gestation as 
the first screening test (13-week NIPT). In this case, a minimal number of fetal 
chromosome disorders is missed since NIPT is offered to all women. Additionally, 
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women only have to make a decision about whether or not they want to undergo an 
invasive test based on the result of one screening test, which is the least confusing 
scenario for the women. At 13 weeks of gestation, NIPT is offered when the risk for 
spontaneous miscarriage has declined remarkably. Furthermore, following a positive 
13-week NIPT, timely confirmatory amniocentesis is possible. A last benefit of NIPT at 
13 weeks of gestation is that women are offered some more time for adequate 
counseling and for reflection before they decide to undergo NIPT. Earlier in pregnancy, 
women may speak to their midwife or obstetrician for the first time. In practice, NIPT 
for fetal trisomy 21 is always conducted together with NIPT for fetal trisomies 13 and 
18. Furthermore, most assays also detect submicroscopic chromosome aberrations 
and fetal sex chromosome disorders. The conclusions of Chapter 5, drawn for the 
implementation of trisomy 21, are also applicable for broad NIPT assays targeting 
trisomies 13 and 18, and submicroscopic chromosome aberrations and fetal sex 
chromosome disorders. 
An acceptable alternative to our proposed NIPT implementation strategy in Chapter 5 
is reflex prenatal screening. In this scenario two blood samples are collected together 
at a prenatal visit at 11-13 weeks of gestation.113 The first one for a FCT and the second 
one for NIPT in case of a high risk predicted by the FCT, e.g. > 1:800. Women are 
offered only one combined screening result and it avoids causing distress to women 
by recalling them for a second test and sample collection. The greatest advantage of 
this strategy is that in the case of a NIPT failure, which has been reported in 1.3-5%, 
women can base their decision of follow-up testing on the result of the FCT.83,114-116 
NIPT failure is an important factor to consider while organizing implementation, since 
it has been suggested that the prevalence of fetal aneuploidy is higher in the NIPT 
failure group than in the overall population.92,117 If no FCT is conducted, it should be 
clarified to women with a failed NIPT that it is highly recommended to repeat the NIPT 
or to undergo invasive prenatal diagnosis. 
7.2.2 Broadening the scope of noninvasive prenatal screening 
A. Defining the scope of prenatal screening 
It will be technically possible to offer to all healthy pregnant women a broad 
noninvasive screening test that is able to screen for all frequent recessive and 
dominant single-gene disorders, as well as for imbalances of whole chromosomes and 
parts of chromosomes. What disorders should be included in a broad screening test? 
The European and the American Society of Human Genetics (ESHG and ASHG) 
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recommend to offer prenatal screening only for serious congenital and childhood 
disorders, following sound validation studies and a comprehensive evaluation of all 
relevant aspects.118 They suggest limiting the scope to a range of well-defined 
disorders, and avoiding traits with little or variable medical morbidity or reporting 
variants of unknown significance. 
In the next years, we can expect studies exploring the technical possibilities to expand 
the scope of NIPT, accompanied by validation studies, ethical reflections, cost-
effectiveness analyses, and more qualitative studies investigating the opinion of 
experts and potential users. 
B. Genome-wide analysis for fetal chromosome disorders 
Genome-wide NGS-based NIPT allows sequencing all cfDNA fragments in the maternal 
plasma to evaluate whether there is an excess or deficiency of fragments, which would 
be indicative for an imbalance of any of the autosomal or sex chromosomes. The 
imbalances can either be a chromosomal aneuploidy, a segmental imbalance, or a 
submicroscopic chromosome imbalance. Since 2013, some NIPT assays can detect 
submicroscopic chromosomal abnormalities and sex chromosome imbalances.119-128 
Clinically significant microdeletion and microduplication syndromes can now be 
detected, such as DiGeorge syndrome (22q11.2 deletion). The sex chromosome 
disorders that can be detected include monosomy X and sex chromosome trisomies 
(SCTs; 47,XXX; 47,XXY and 47,XYY). Extension of cfDNA screening to detect rare 
autosomal trisomies and inherited deletion and duplication copy-number variations is 
currently being investigated.129 
It can be argued that NIPT for genome-wide chromosome imbalances currently does 
not meet the generally accepted criteria for a worthwhile screening test: a well-
defined disorder, established performance characteristics and acceptable patient 
management steps following a positive result.130 According to the recommendations 
of the ESHG and ASHG, genome-wide cfDNA-based screening tests for chromosome 
disorders should only target the chromosome abnormalities with known phenotypes.  
Critics may argue that NIPT for sex chromosome aneuploidy is also beyond the scope 
suggested by the ESHG and ASHG, because of the mild and variable phenotype. In 
Chapter 6 we assessed Dutch pregnant women’s opinions about NIPT for SCTs within 
the broader context of the expansion of disorders included in the NIPT panel. Although 
all of the interviewees were in favor of screening for trisomies 13, 18 and 21, only half 
of them would also like to undergo screening for SCTs. Our study identified several 
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potential disadvantages of NIPT for SCTs, beyond the technical issues leading to false 
negative and false positive results: receiving a prenatal test result about a disorder 
with unclear consequences for the future child’s life and for which they would take no 
further actions, a less worry-free pregnancy and childhood, possible guilt about 
continuation of pregnancy, and possible insecurity about parenting. Some of the 
participants firmly stated that they disagreed with offering the possibility to terminate 
the pregnancy because of a fetal SCT. Furthermore, knowing about the SCT at the start 
of life could be detrimental for the future child, because it could lead to stigmatization, 
a damaged parent-child relationship, and possible distress due to the probable 
occurrence of infertility. 
C. Genome-wide analysis for single-gene disorders 
Postnatally, it is possible to sequence an entire genome in a few days.22 Are we heading 
towards noninvasive prenatal whole genome sequencing (WGS) and whole exome 
sequencing (WES) in the cfDNA? Will this be the future diagnostic or even screening 
test? There is limited experience with WGS and WES in fetal cells obtained by an 
invasive amniocentesis or chorionic villus sampling in ongoing pregnancies, and in fetal 
cells in terminated pregnancies.22,131,132 The entire genome can also be sequenced in 
the cfDNA. In 2010, genome-wide deep sequencing (up to 65-fold haploid genome 
coverage) of a plasma sample revealed that both the entire fetal and maternal genome 
is represented in cfDNA, at a constant relative proportion.39 In 2012, another group 
used genome-wide deep sequencing of a maternal plasma sample to a deeper extent 
(78-fold haploid genome coverage), in combination with haplotype-resolved genome 
sequencing of the mother and shotgun genome sequencing of the father, to detect 
both inherited variations and de novo mutations in the fetal cfDNA.133  
Both the costs and the amount of labor needed to analyze the fetal genome 
noninvasively, currently preclude its clinical applications.22 Interpretation of variants 
in postnatal WGS and WES form a huge challenge, because of incomplete penetrance, 
modifier genes and variable clinical presentation. Even more challenges and ethical 
considerations arise when offering WES and WGS for noninvasive prenatal diagnosis 
and screening: it is prenatally too time consuming to filter sequencing variants to 
identify pathogenic ones, incidental findings can be found in the parents while trio 
sequencing, variants of unknown significance cannot be translated into a phenotype 
in prenatal post-test counseling, and it is practically impossible to provide detailed 
information on all possible results and genetic conditions that a diagnostic WGS or 
WES can harvest.22 For these reasons I think that it would not be wise to offer WGS 
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and WES of fetal cfDNA for diagnostic or screening purposes. 
In my opinion, single-gene disorders that could be included in a broad cfDNA-based 
prenatal screening test are disorders with complete penetrance, a clear genotype-
phenotype correlation, early onset of disease (congenital and childhood), and either 
severe clinical implications or treatment options. Disorders with incomplete 
penetrance and a broad variety of clinical consequences should only be included after 
more research is done to draw the phenotypical map. Prenatal screening for recessive 
disorders with a high carrier frequency in the society (e.g. cystic fibrosis) could be 
offered as the combination of parental carrier screening before conception or during 
pregnancy, with prenatal noninvasive fetal testing in case of positive carrier status. In 
that case specific ethical concerns come up.58 Women who are newly diagnosed as 
carriers may be particularly vulnerable to a routine offer of this noninvasive test, 
thereby possibly undermining informed consent. There is also the possibility of a 
conflict of the moral rights of a woman and her partner. For example, if the father 
refuses carrier screening, and the pregnant woman undergoes carrier screening and a 
cfDNA-based screening test for the fetus, the father may know his own carrier status. 
7.2.3 False positive and false negative NIPT results 
In pre-test counseling it should be explained that both false positive and false negative 
NIPT predictions, discordant to the actual fetal karyotype, have been reported.6,134-144 
False positive results will be detected by the confirmatory diagnostic test following an 
invasive procedure. In case of a negative NIPT result, the condition will be missed. The 
positive and negative predictive value of trisomies 13, 18 and 21 are currently best 
known.134-136 Also for submicroscopic chromosome aberrations and fetal sex 
chromosome disorders this is now being evaluated.121-124,137-139 Especially for trisomy 
13 and the submicroscopic chromosome aberrations a high number of false positive 
results have been reported.124,140 An important factor correlating with test success and 
reliability of interpretation, is the “fetal fraction”, i.e. the fetal cfDNA subfraction from 
the total maternal and fetal cfDNA in the plasma.141 The fetal fraction can be < 4% in 
the first trimester, which can lead to missed cases of fetal trisomy (false negative 
predictions).141-143 In addition, the statistical algorithms used to distinguish a trisomic 
pregnancy from a non-trisomic pregnancy could be improved. A biological reason of 
false reassurance by NIPT is a trisomic rescue in the fetoplacental trophoblast cells, 
the source of fetal cfDNA, while the trisomy persists in the fetus.6  
More frequent are the false positive predictions (0.1-0.2%), leading to the lower 
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positive predictive value.6 A biological explanation of the false positive predictions is a 
trisomy only occurring in the fetoplacental trophoblast cells and not in the fetus itself 
(confined placental mosaicism), due to either rescue mechanisms in fetal development 
or post-zygotic errors during placental mitosis.6,140,144 Only placental mosaicism limited 
to the chorionic stroma/mesenchymal cells will not influence a NIPT result, as these 
cells do not release cfDNA in the maternal plasma.140 Another biological cause for a 
false-positive NIPT is a vanishing twin with a chromosome abnormality. Furthermore, 
maternal copy-number variations, maternal mosaicism in blood cells, and cfDNA 
sequences with chromosomal aberrations that are released from a maternal 
malignancy can lead to false-positive results.140,145 
Moreover, the positive and negative predictive values are not general characteristics 
of the test. The values are only true if the NIPT is conducted in the exact same way as 
published in the same well-defined population. The predictive values are strongly 
dependent on the prevalence of a disorder in the population. As a result, the low 
positive predictive value is mostly a consequence of the low a priori chance of the 
examined pregnant women to actually carry a fetus with a trisomy. The lower that 
chance, the harder it is for the cfDNA-based test to give the correct result, and the 
higher the chance for a false positive result. This is illustrated in the following example. 
The prevalence of fetal Down syndrome in women of all reproductive ages in the 
European and US population at 10 weeks of gestation is 0.2% (weighted mean of 
European and US population, calculated in Chapter 5).146,147 If we now assume a 
population of 100 000 pregnant women, undergoing a NIPT assay with a sensitivity of 
99.3% and a specificity of 99.8%, then the diagnostic parameters can be calculated as 
in Table 7.2. 
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Table 7.2 Hypothetical example of the accuracy of a NIPT assay for fetal  Down syndrome 
in a population with a prevalence of 0.2%. 
Hypothetical situation            
  Down syndrome  
  
Yes No Total 
NIPT 
Positive 199 200 399 
Negative 1 99 600 99 601 
 
Total 200 99 800 100 000 
Calculation of the diagnostic parameters: 
Sensitivity: (199/200)*100% = 99.3% 
Specificity: (99 600/99 800)*100% = 99.8% 
Positive predictive value: (199/399)*100% = 50% 
Negative predictive value: (99 600/99 601)*100% = 99.9% 
 
As seen in the above example, a NIPT assay can have both a high sensitivity and 
specificity while in only half of the positive results the fetus actually has Down 
syndrome, if the predictive values are calculated only based on the prevalence. It is 
nevertheless a good screening test for the condition. However, it is known that test-
specific characteristics, such as the height of the z-score indicating that the fetus has 
a trisomy, or the fetal fraction, also have an influence on the positive and negative 
predictive value of the test.6 A positive NIPT result in a fetal fraction of 20% and a z-
score of 8 is most likely to be a true result, even if the pregnant woman only has a 
chance of 1 in 1000 to carry a child with Down syndrome, based on her age. Because 
of all of these different aspects influencing the predictive values, I would recommend 
all laboratories to provide next to a positive or negative result of the NIPT, also the 
positive and negative predictive value specific for the tested pregnant woman and the 
precise test characteristics This can for example be done with this calculator 
developed at the university of Groningen (Figure 7.2). In post-test counseling, after 
receiving a positive NIPT result, pregnant women can have a more accurate idea of 
how great the chance is that they actually carry a child with a trisomy. This is helpful 
for an informed decision about undergoing an invasive confirmatory diagnostic test 
for a positive NIPT result. The pregnant women and caretakers may use other online 
calculators providing the positive and negative predictive value of the different 
commercially offered NIPT assays for a specific a priori risk, age and gestational 
age.148,149 However, these calculators may underestimate the positive predictive value 
and overestimate the negative predictive value, because they are mainly based on the 
prevalence of the trisomy, and not on the test characteristics. 
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Figure 7.2 Calculator of the positive predictive value (https://molgenis60.target.rug.nl/). On the 
right an example of the positive predictive value of a positive NIPT test for a woman of 30 years 
old, undergoing NIPT at 11 weeks of gestation without undergoing first the FCT, with a maximum 
of 4 % fetal fraction and a z-score of 4.  
7.2.4 Autonomous reproductive choice 
International guidelines recommend offering prenatal screening in a non-directive way 
in order to provide an informed and autonomous reproductive choice to pregnant 
women.150 In this non-directive framework, health services adopt a position of 
neutrality, do not convey a discriminatory message about individuals with disabilities, 
and provide pregnant couples with free pre-test and post-test choices. 
In view of the primary aim of prenatal screening, i.e. the provision of autonomous 
reproductive choice, it can be argued that women should, as far as reasonably 
possible, be given the opportunity to decide for themselves whether or not to undergo 
prenatal screening and if so which prenatal screening strategy best fits their personal 
values and preferences. This strategy is termed individualized choice.151 In Chapter 5 
we described individualized choice for women that opt for NIPT for Down syndrome, 
more specifically concerning its timing in pregnancy and its combination with other 
tests. In Chapter 6, while discussing prenatal screening for sex chromosome trisomies, 
pregnant women expressed the belief that based on adequate information, women 
are able to choose which conditions if any they want to screen for, if they want to 
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undergo confirmatory invasive testing, and if they wish to continue or terminate the 
pregnancy. So, what is reasonably possible? I will discuss possible adaptions in pre-test 
counseling and the laboratory flow in order to obtain individualized choice. 
A. Informed consent 
Informed decision-making is based on sufficient knowledge and is consistent with the 
pregnant women’s values.152 Offering sufficient knowledge to pregnant women is the 
first challenge in pre-test counseling. In the light of the increased number of conditions 
for which women can undergo noninvasive prenatal screening, a generic counseling 
model could be offered.152 Generic consent emphasizes broader concepts and 
common-denominator issues in genetic screening, such as the type of information 
sought (e.g. fetal chromosome disorders that can result in birth defects, intellectual 
disability and shortened life expectancy of the baby), limitations of screening (e.g. false 
positive and false negative NIPT predictions have been described), the possible need 
for a follow-up test to establish a definitive diagnosis, the reproductive options that 
might have to be considered, the costs of screening, and social issues, including 
confidentiality and the possibility of social stigmatization. The key concept is that 
detailed information about any specific test or disorder would be given only if a 
condition was detected, although patients would still have the opportunity to receive 
more detailed information by requesting at any time. A generic consent model may 
lead to less information overload during pre-test counseling. However, this does not 
address the request from the pregnant women in Chapter 6 to be well-informed for 
every condition included in the test panel, in order to make a decision about which 
disorders they want to screen for. I believe that, although some aspects of NIPT could 
be explained in a more general fashion (e.g. the possibility of test failure or the 
confirmation of a positive screening result with an invasive procedure), a generic 
counseling model should be avoided while discussing the clinical consequences of the 
different conditions before the decision to undergo prenatal screening.  
In Table 7.3 suggested counseling points to guide pre-test conversations with women 
who are considering NIPT for trisomies 13, 18 and 21, and sex chromosome 
aneuploidies are summarized.153  
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Table 7.3 Pre-test counseling points for noninvasive prenatal testinga 
Legend to Table 7.3: aTable adapted from Sachs et al. (2015)153 . I added the suggestions about 
the positive and negative predictive values from this general discussion chapter to the table. 
  
1. Testing is optional All screening and diagnostic testing for fetal aneuploidy is 
optional. Women should be given an opportunity to consider 
the potential implications of test results. The decision to 
proceed should depend on how each individual perceives the 
benefits of obtaining information about aneuploidy when 
weighed against the potential emotional and physical risk of 
testing. 
2. Define screening Clarify that NIPT is a screening test. It cannot diagnose or 
eliminate the chance that a fetus has a particular chromosome 
condition; rather it separates women into higher or lower risk 
categories. 
3. Clinical features and variability of 
conditions 
Describe the clinical features of each condition included in the 
screen using sensitive, neutral language. 
4. Describe technology The specific testing methods vary by laboratory.  
5. Explain the reporting format Women should be told when and how their results will be 
provided. The chance for a non-reportable result should be 
discussed too. 
6. Sensitivity Describe the sensitivity for the different conditions. 
7. False positive rate and 
confirmation of abnormal results 
A karyotype or microarray of cultured chorionic villi or 
amniocytes is necessary for confirmation of an abnormal NIPT 
result.  
8. Positive and negative predictive 
values 
A NIPT assay can have both a high sensitivity and specificity 
without being a good predictor of whether the fetus actually 
has fetal aneuploidy. The predictive values are dependent of 
the prevalence of the disorder and test-specific characteristics. 
If a calculator is used to report the pregnant woman’s individual 
positive predictive value, this should be discussed as well. 
9. Limitations Emphasize that while NIPT screens for several of the more 
common aneuploidies, diagnostic testing through chorionic 
villus sampling or amniocentesis can test for all aneuploidies, 
can distinguish between full trisomy and trisomy caused by a 
chromosomal rearrangement, can detect mosaicism, 
microdeletions, microduplications, single-gene disorders and 
neural tube defects. 
10. Incidental findings Incidental findings include maternal chromosome differences, 
in particular sex chromosome aneuploidies, maternal 
malignancies and fetal or placental chromosome differences 
other than the aneuploidies specifically targeted by NIPT. 
11. Timing Discuss the earliest time at which NIPT can be performed, the 
laboratory-specific turnaround time, the local legal limit for 
pregnancy termination and the turnaround time for 
amniocentesis results. 
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A second challenge is to offer to women the opportunity to make autonomous 
decisions about undergoing screening and all further steps in the screening process 
consistent with their values. In the context of prenatal screening, autonomous choice 
does not mean that the pregnant woman is not influenced by others.154 On the 
contrary, relationships do play a role in decision-making regarding pregnancy testing. 
Women prefer to discuss the options, especially with their partners, but also with 
family and friends. Taking decisions compatible with their responsibilities and their ties 
with others can help women to feel more comfortable with their final choice. Health 
services should offer this time to discuss screening with others. I suggest a two-step 
counseling system with timely offering of pre-test counseling for NIPT to pregnant 
women in a first visit, and the decision about which disorders she would like to screen 
for in the second visit. In between the two visits written information, e.g. patient 
leaflets or websites, helps to make the decision. This decision-making process would 
be easier if women are already well informed about DNA, genetic disorders, and 
prenatal screening and diagnosis in the preconception phase. Well-informed pregnant 
women could already discuss the options with others, before talking to their 
obstetrician or midwife for the first time about screening. In that case, a second visit 
would probably not be necessary. Perhaps, decision-aids may help in the process.155  
Finally, opt-in and opt-out options for the genetic conditions in the NIPT panel are 
reasonable. Women should not be obligated to screen for a genetic condition in their 
fetus because they want to screen for another one. Today, in the Netherlands it is not 
allowed to only screen for the more severe trisomies 13 and 18. It is obligated to 
combine screening for these conditions with screening for trisomy 21. It is however 
allowed to only screen for trisomy 21.156 Future parents should be explained that even 
if they thick all the boxes of every available screening test, a negative result will never 
exclude all possible congenital abnormalities in their fetus. 
B. Laboratory flow 
If prenatal screening is offered to provide future parents an informed decision, than 
one should not be overprotective of the current laboratory flows. These should be 
organized to support the individualized choice and to be flexible for opt-in and opt-out 
options. The performance (sensitivity and specificity) of NIPT in a general obstetrical 
population is equivalent to its performance in high-risk pregnant women. No 
bioinformatics or technical adjustments are required in low-risk women in comparison 
to high-risk women. Consequently, for all women, either tested early in pregnancy, 
pre-screened by the FCT or following the fetal anomaly scan, the NIPT result can be 
General discussion 
  191 
reported within the same turnaround time. However, as suggested earlier in this 
general discussion chapter, the result of the NIPT could be reported in combination 
with the specific positive and negative predictive value for the pregnant woman. 
Within a certain time frame, the timing of the NIPT can be flexible. The time frame is 
determined by two factors. Too early in pregnancy, the fetal fraction can be too low 
for a reliable test.142,143 Most laboratories do not offer the result before 10 weeks of 
gestation. Too late in pregnancy, women would no longer have a reproductive choice.  
NIPT should be performed so that the result is known before the legal time of abortion 
(< 24 weeks in most countries).157 
Efforts should be made to develop generic NIPT assays. In these tests, a broad panel 
of disorders to screen for can be offered to the pregnant women. As discussed earlier, 
these are preferably early-onset disorders with clear clinical consequences. To 
promote opt-in and opt-out choices, a filter should be available allowing to only 
visualize the results that are requested for by the future parents. Consequently, the 
laboratory staff and the clinicians are not informed about a disorder in the fetus that 
the parents do not want to know, avoiding a possible moral dilemma. The current NIPT 
assay, in which the panel of genetic disorders comprises trisomies 13, 18, 21, sex 
chromosome aneuploidy and microdeletions and duplications, is an example of a test 
for which this filter is possible. It is relatively easy to only filter the autosomal trisomies 
and not any of the other aberrations the assay can detect.  
7.3 Concluding remarks 
The analysis of fetal cfDNA in the maternal blood circulation provides a safe alternative 
to the invasive procedures for the prenatal diagnosis of single-gene disorders. 
Furthermore, it offers the possibility for a highly reliable screening test for fetal 
aneuploidy. In the coming years, cfDNA and cfRNA might be used to noninvasively 
monitor the fetus, to provide insight in placental and fetal development, and to offer 
pregnant women a prenatal screening test for a broader range of conditions. The aim 
of this thesis was to develop novel noninvasive prenatal diagnostic tests as well as to 
investigate the responsible application of cfDNA-based testing in prenatal screening. 
The latter investigation is at least as important as the exploration of what can be 
detected in the cfDNA. Parallel with technical innovations, further research is required, 
e.g. into the preferences of pregnant women, and the optimal path to informed 
decision making. 
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Fetal cell-free DNA (cfDNA) is present in the blood circulation of pregnant women. 
Fetal cfDNA has increasingly been used in prenatal care, and in prenatal screening and 
diagnosis of genetic disorders. The analysis of fetal cfDNA in maternal plasma offers 
the possibility for a safe and highly reliable screening test for fetal aneuploidy. 
Furthermore, it provides a safe alternative to the invasive procedures for prenatal 
diagnosis of single-gene disorders. In this thesis, prenatal detection of genetic 
disorders through analysis of fetal cfDNA in maternal plasma was investigated, from 
bench to clinic. The aims of this thesis were to develop novel noninvasive prenatal 
diagnostic tests (Part I) and to investigate the responsible application of cfDNA-based 
testing in prenatal screening (Part II). 
Chapter 1 defines the terms prenatal screening and diagnosis and provides a historical 
overview of the applications of cfDNA from its discovery until today. The aims of this 
thesis are presented with an outline of the two parts, subdivided in individual 
chapters.  
Part I: Design of noninvasive prenatal diagnostic tests 
Sex determination was one of the first clinical applications of fetal cfDNA testing and 
is routinely used in European countries. Delay of the test result or even failure of the 
test can occur, particularly when the presence of fetal cfDNA in the plasma sample 
cannot be proven. In Chapter 2 the development is described of a novel fast single-
tube noninvasive fetal sex determination assay, in which a gender-independent 
fetoplacental marker is incorporated in the test, requiring no extra time or expenses 
by the laboratory. The assay combines amplification of Y-linked amelogenin (AMELY) 
cfDNA with one-step reverse transcription PCR of trophoblast-derived cell-free RNA 
(cfRNA). In a proof-of-principle study, 75 blinded plasma samples from pregnant 
women were tested to find out whether the fetal sex could be determined and 
whether cfRNA was a reliable fetoplacental marker in this process. The fetal sex was 
correctly determined in all 75 pregnant women without failure or false results. It was 
concluded that amplification of trophoblast-derived cfRNA is a reliable marker for the 
confirmation of the presence of fetoplacentally derived nucleic acids in noninvasive 
fetal sex determination. 
A current challenge is developing universal noninvasive prenatal diagnostic (NIPD) 
assays for the detection of single-gene disorders, and in particular disorders caused by 
nucleotide repeat expansions. In Chapter 3 a novel assay is presented for NIPD of 
myotonic dystrophy type 1 (DM1) in the cfDNA. DM1 is a single-gene disorder, caused 
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by expansion of a CTG trinucleotide repeat in the dystrophia myotonica protein kinase 
gene (DMPK). Single molecule molecular inversion probes (smMIPs) containing 
common repeat flanking single nucleotide polymorphisms (SNPs) in the targeted 
sequence were designed for targeted next-generation sequencing (NGS). We are the 
first to use smMIPs for haplotype-based NIPD. SmMIPs enable precise quantification 
of the variation in the cfDNA and are robust to relatively small amounts and poor 
quality of source DNA. As a proof of concept, the smMIP NIPD assay was applied to 
cfDNA isolated from the plasma of a woman carrying a fetus affected with DM1, as 
diagnosed by invasive prenatal testing. After sequencing the SNP markers from the 
pregnant woman, and from the father and a previous child (= reference) with DM1, 
informative SNPs for the mutated allele of the father and reference were selected. 
Subsequently, the cfDNA was sequenced to determine the fetal inheritance, calculated 
from the percentage of the informative SNPs in the cfDNA reads. In this study, it was 
demonstrated that the assay could detect the paternal mutated DMPK allele in the 
fetal cfDNA. 
Part II: Noninvasive prenatal screening for fetal chromosome disorders 
The search for a noninvasive prenatal test that could reliably detect fetal trisomies 13, 
18 and 21 started very soon after the discovery of fetal cfDNA in maternal plasma. The 
use of NGS, allowing to identify the chromosomal origin of each sequenced cfDNA 
molecule, and to calculate the over- or underrepresentation of any chromosome in 
maternal plasma led to a practical screening test that could be used routinely. In 2011 
the first diagnostic accuracy studies were published using NGS to detect fetal trisomies 
13, 18 and 21 in maternal plasma. In Chapter 4 an overview is provided of all studies 
evaluating the diagnostic accuracy of molecular techniques for noninvasive detection 
of trisomy 21 between 1997 and the beginning of 2012. The quality of the studies and 
the diagnostic parameters were evaluated using the QUADAS-2 tool. We noted that 
NGS-based detection of fetal trisomy 21 in the cfDNA exhibits a high sensitivity and 
specificity and an excellent negative predictive value. However, we also reported for 
the first time that the positive predictive value shows large variation between 
pregnant women, and can be as low as 50% in case of a low a priori probability for 
having a fetus with trisomy 21. Furthermore, we concluded that additional large 
prospective studies would allow more precise estimates about sensitivity, specificity 
and predictive values in high-risk and low-risk pregnancies. Finally, we predicted that 
noninvasive detection of trisomy 21 in the cfDNA was likely to be implemented as a 
replacement for the current serum screening test.  
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Immediately after publication of Chapter 4, the variable positive predictive value was 
also reported by others. Since a false positive result can lead to the abortion of a 
healthy fetus, independent validation by an invasive procedure followed by rapid 
aneuploidy detection or karyotyping is recommended by the International Society for 
Prenatal Diagnosis. In the chorionic villi or amniocytes, rapid aneuploidy detection, 
karyotyping or array can confirm the presence of an aneuploidy in the fetus. The term 
“noninvasive prenatal testing” (NIPT) was formulated, referring to cfDNA-based tests 
that are used as a screening test and require a confirmation by a follow-up test. In the 
years following our publication, large prospective studies have allowed more precise 
estimates about sensitivity, specificity and predictive values in high-risk and low-risk 
pregnancies. As we predicted, the goal since 2011 has been to replace current 
screening tests, such as the first trimester combined test (FCT), with NIPT, or to offer 
NIPT as a second tier screening test. A rapid global use of NIPT for fetal aneuploidy was 
seen, mostly offered in a commercial setting. Since 2013, some NIPT assays can detect 
submicroscopic chromosomal abnormalities and sex chromosome imbalances. 
Clinically significant microdeletion and microduplication syndromes can now be 
detected, such as DiGeorge syndrome (22q11.2 deletion). The sex chromosome 
disorders that can be detected include monosomy X and sex chromosome trisomies 
(47,XXX; 47,XXY and 47,XYY). 
Nowadays, several countries are working on the implementation of NIPT in their 
prenatal trisomy screening program. In Chapter 5 different hypothetical NIPT 
implementation strategies are compared for such a national screening program. For 
this, a quantitative analysis was conducted. Decision trees were created to illustrate 
all plausible implementation strategies in a theoretical cohort of 100 000 pregnant 
women. This resulted in five screening programs: classical screening by the FCT, pre-
selection of high-risk women prior to NIPT by the FCT, NIPT as the first screening test 
at 10 weeks and at 13 weeks, and the simultaneous conductance of NIPT and the FCT. 
Our results suggested that the most favorable screening program may be a program 
in which NIPT is offered to all women at 13 weeks of gestation as the first screening 
test (13-week NIPT). The conclusions of Chapter 5, drawn for the implementation of 
trisomy 21 screening, are also applicable for broad NIPT assays targeting trisomies 13 
and 18, and submicroscopic chromosome aberrations and fetal sex chromosome 
disorders. 
In some countries, NIPT for sex chromosome disorders is not available yet. 
Furthermore, critics may argue that NIPT for sex chromosome aneuploidy is beyond 
 Summary 
  205 
the scope of a worthwhile prenatal screening test, given that these abnormalities 
often result in a very mild phenotype. In Chapter 6, we assess pregnant women’s 
opinions about NIPT for sex chromosome trisomies (SCTs) within the broader context 
of the expansion of disorders included in the NIPT panel. Individual semi-structured 
interviews were conducted with eight pregnant women that only have access to NIPT 
in case of an increased risk for trisomy 13, 18 or 21 after the FCT or on the basis of 
their personal history, through a national public health setting. Before the start of the 
interview, information was provided about SCTs and the possibilities and limitations 
of NIPT for SCTs. After ascertaining that the information about SCTs and NIPT for SCTs 
was clear for the participants, their ideas regarding NIPT for SCTs and the expansion 
of the spectrum of detectable disorders by NIPT were explored. The interviewees 
expressed a variety of opinions concerning NIPT for SCTs. Four of them agreed with 
adding SCTs to the NIPT panel. The overall opinion of these women was that they 
wanted to choose for themselves which disorders in the NIPT panel they wished to 
screen for, and which conditions they wanted to confirm by invasive testing. 
In Chapter 7 the results of the individual studies are put into perspective. The results 
of Part I are discussed along the following themes: 1) improving noninvasive fetal sex 
determination, 2) noninvasive evaluation of cell-free RNA levels in maternal plasma, 
3) development and implementation of NIPD of single-gene disorders. The results of 
Part II are discussed in these topics: 1) NIPT of trisomies 13, 18 and 21 from 2011 until 
now, 2) broadening the scope of noninvasive prenatal screening, 3) false positive and 
false negative NIPT results, and 4) autonomous reproductive choice. It is concluded 
that the investigation of responsible application of cfDNA-based testing in prenatal 
screening is at least as important as the exploration of what can be detected in the 
cfDNA. Parallel with technical innovations, further empirical research is required, in 
particular with regard to the organization and implementation of NIPT and NIPD in the 
different national health systems, the preferences of pregnant couples, and the 
optimal path to informed decision making. 
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In het bloed van zwangere vrouwen is celvrij DNA aanwezig dat afkomstig is van de 
foetus. De analyse van foetaal celvrij DNA wordt in toenemende mate gebruikt voor 
prenatale screening en diagnostiek van genetische aandoeningen. Het analyseren van 
foetaal celvrij DNA in een maternaal plasmamonster biedt de mogelijkheid voor een 
betrouwbare foetale aneuploïdie screeningstest. Bovendien is het een veilig 
alternatief zonder risico voor de foetus voor invasieve procedures (vlokkentest en 
vruchtwaterpunctie) bij prenatale diagnostiek van monogene aandoeningen. Wij 
bestudeerden de prenatale detectie van genetische aandoeningen via het analyseren 
van foetaal celvrij DNA in het maternaal plasma, van het laboratorium tot in de 
klinische praktijk. De doelstellingen van deze thesis waren het ontwikkelen van nieuwe 
niet-invasieve prenatale diagnostische testen (Deel I) en het bestuderen van de 
verantwoorde toepassing van de analyse van celvrij foetaal DNA voor prenatale 
screening (Deel II). 
In Hoofdstuk 1 worden de termen prenatale screening en diagnostiek uitgelegd en 
wordt een historisch overzicht gegeven van de toepassingen van de analyse van 
foetaal celvrij DNA, sinds de ontdekking ervan tot op heden. De doelstellingen van 
deze thesis worden beschreven, met een overzicht van de twee delen en de 
individuele hoofdstukken. 
Deel I: De ontwikkeling van niet-invasieve prenatale diagnostische testen 
Foetale geslachtsbepaling was één van de eerste klinische toepassingen van de analyse 
van foetaal celvrij DNA. Het wordt routinematig uitgevoerd in Europese landen als er 
kans is op een geslachtsgebonden aandoening of als er een ambigue genitaal wordt 
gezien tijdens prenatale echografie. Wanneer de aanwezigheid van foetaal celvrij DNA 
in het plasmamonster niet bewezen kan worden, kunnen de testresultaten van de 
reguliere test niet of vertraagd afgegeven worden. In Hoofdstuk 2 wordt de 
ontwikkeling van een nieuwe niet-invasieve test voor foetale geslachtsbepaling, 
volledig uitgevoerd in één pipetteerbuisje, beschreven. Een geslachtsonafhankelijke 
foetoplacentaire marker is ingebouwd in de test, wat geen extra tijd of uitgaven van 
het laboratorium vraagt om de aanwezigheid van foetoplacentaire nucleïnezuren aan 
te tonen in het maternaal plasma. Onze nieuwe test combineert amplificatie van celvrij 
DNA van het gen AMELY, afkomstig van het Y-chromosoom, met one-step reverse 
transcription PCR van celvrij RNA, afkomstig van de trofoblast van de placenta. In een 
proof of principle studie werden 75 plasmamonsters van zwangere vrouwen getest om 
te onderzoeken of het geslacht juist bepaald kon worden, en of het celvrij RNA een 
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betrouwbare marker was voor de aanwezigheid van foetaal materiaal tijdens dit 
proces. Het foetaal geslacht werd correct bepaald bij alle 75 zwangere vrouwen zonder 
testfalen. De conclusie was dat amplificatie van celvrij RNA, afkomstig van de 
trofoblast van de placenta, een betrouwbare marker was voor het bevestigen van de 
aanwezigheid van foetoplacentaire nucleïnezuren tijdens niet-invasieve foetale 
geslachtsbepaling. 
Een uitdaging in de huidige tijd is het ontwikkelen van universele niet-invasieve 
prenatale diagnostische (NIPD) testen voor de detectie van monogene aandoeningen, 
en in het bijzonder aandoeningen veroorzaakt door een nucleotide repeat expansie. 
In Hoofdstuk 3 wordt een nieuwe test besproken voor NIPD van myotone dystrofie 
type 1 (DM1). DM1 is een monogene aandoening die veroorzaakt wordt door een 
expansie van een CTG trinucleotide repeat in het dystrophia myotonica protein kinase 
gen (DMPK). Er werden single molecule molecular inversion probes (smMIPs) 
ontworpen met een frequente repeat flankerende single nucleotide polymorfisme 
(SNP) in hun doelsequentie. Hiermee konden we NIPD uitvoeren middels op next-
generation sequencing (NGS) gebaseerde haplotypering. We zijn de eerste 
onderzoeksgroep die smMIPs gebruiken voor NIPD. SmMIPs laten precieze 
kwantificatie van een variant in het celvrij DNA toe, en zijn robuust, ook voor relatief 
kleine hoeveelheden en slechte kwaliteit van het DNA. Als proof of concept werd de 
smMIPs NIPD test toegepast op cfDNA dat geïsoleerd werd uit het plasma van een 
vrouw die zwanger was van een foetus met DM1. Na het sequencen van de SNP 
markers van de zwangere vrouw, en van de vader en een eerder kind (= index patiënt) 
met DM1, werden informatieve SNPs voor het gemuteerde allel van de vader en de 
index geselecteerd. Vervolgens werd het cfDNA gesequencet voor het bepalen van de 
foetale overerving, wat berekend wordt uit de percentages van de informatieve SNPs 
in de cfDNA reads. In deze studie werd aangetoond dat de smMIPs NIPD test de 
paternaal overgeërfde DMPK mutatie kon aantonen in het moederlijk bloedplasma. 
  
Samenvatting 
210 
Deel II: Niet-invasieve prenatale screening voor foetale chromosoom 
aandoeningen 
De zoektocht naar een niet-invasieve prenatale test die betrouwbaar de foetale 
trisomieën 13, 18 en 21 kan detecteren, werd snel na het ontdekken van celvrij DNA 
gestart. NGS laat het toe om de chromosomale origine van elke gesequencete DNA 
molecule te identificeren, en zo een teveel of te weinig van elk chromosoom in het 
maternale plasma te bepalen. In 2011 werden de eerste diagnostische studies 
gepubliceerd waarin NGS werd gebruikt voor de detectie van de foetale trisomieën 13, 
18 en 21 in het maternale plasma. In Hoofdstuk 4 wordt een overzicht gegeven van 
alle van 1997 tot 2012 gepubliceerde studies die de diagnostische waarde van een 
moleculaire techniek voor de niet-invasieve detectie van trisomie 21 evalueerden. De 
kwaliteit en de diagnostische parameters van de studies werden beoordeeld, via de 
QUADAS-2 beoordeling. We vonden dat de detectie van foetale trisomie 21 in het 
celvrij DNA op basis van NGS zowel een hoge sensitiviteit als een hoge specificiteit, en 
een uitstekende negatieve voorspellende waarde had. We rapporteerden echter ook 
voor het eerst dat de positieve voorspellende waarde veel variatie tussen zwangere 
vrouwen vertoonde, en dat deze zelfs kleiner dan 50% kan zijn bij een laag a priori 
risico op een foetus met trisomie 21. We concludeerden dat grotere prospectieve 
studies nodig waren om meer precieze inschattingen te maken van de sensitiviteit, 
specificiteit, en voorspellende waardes in hoog-risico en laag-risico zwangerschappen. 
Ten slotte voorspelden we dat niet-invasieve detectie van trisomie 21 in het celvrij 
DNA waarschijnlijk geïmplementeerd zou worden als vervanging voor de huidige 
serum screening test. 
Onmiddellijk na het publiceren van het artikel uit Hoofdstuk 4, werd de variabele 
positief voorspellende waarde van niet-invasieve detectie van trisomie 21 ook 
gerapporteerd door anderen. Aangezien een vals positief resultaat kan leiden tot het 
aborteren van een gezonde foetus, is een onafhankelijke validatie nodig in foetaal 
materiaal, verkregen via een invasieve procedure. In de vlokken of het vruchtwater 
kan snelle aneuploïdie detectie, karyotypering, of array diagnostiek aantonen of er 
werkelijk sprake is van een aneuploïdie. Dit advies is vastgelegd in een richtlijn van de 
International Society for Prenatal Diagnosis. De term “niet-invasief prenataal testen” 
(NIPT) werd vervolgens gepreciseerd, verwijzend naar testen op basis van celvrij DNA 
die gebruikt worden als screeningstest en een bevestiging met een follow-up test 
vragen. Het is sinds 2011 de bedoeling om de huidige screeningstesten, zoals de eerste 
trimester combinatie test (CT) te vervangen door NIPT, of om NIPT aan te bieden als 
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tweede screeningstest bij een verhoogd risico na de CT. Sinds 2013 kunnen sommige 
NIPT assays ook submicroscopische chromosomale afwijkingen en numerieke 
geslachtschromosoomafwijkingen detecteren. Klinisch significante microdeletie- en 
microduplicatiesyndromen kunnen nu getest worden, zoals DiGeorge syndroom 
(22q11.2 deletie). Tot de numerieke geslachtschromosoomafwijkingen die kunnen 
gevonden behoren monosomie X en de trisomieën van de geslachtschromosoom 
(47,XXX;47,XXY;47,XYY).  
Op dit moment werken verschillende landen aan de implementatie van NIPT in hun 
prenataal trisomie screeningsprogramma. In Hoofdstuk 5 worden verschillende 
hypothetische NIPT implementatie-strategieën voor een nationaal 
screeningsprogramma vergeleken. Hiervoor werd een kwantitatieve analyse 
uitgevoerd. Er werden beslisbomen ontworpen om mogelijke implementatie-
strategieën te illustreren in een theoretisch cohort van 100 000 zwangere vrouwen. 
Dit resulteerde in vijf hypothetische screeningsprogramma’s: klassieke screening met 
behulp van de CT, selectie van hoog-risico vrouwen vóór NIPT met behulp van de CT, 
NIPT als de eerste screeningstest tijdens de 10e zwangerschapsweek of tijdens de 13e 
zwangerschapsweek, en het simultaan uitvoeren van NIPT en CT. Onze resultaten 
tonen aan dat het meest gunstige screeningsprogramma mogelijk een programma is 
waarin NIPT als eerste screeningstest wordt aangeboden aan alle vrouwen tijdens de 
13e zwangerschapsweek. De conclusies van Hoofdstuk 5, die werden gebaseerd op 
screening voor trisomie 21, zijn ook van toepassing voor uitgebreidere NIPT voor 
bijvoorbeeld trisomie 13 en 18, submicroscopische chromosoomafwijkingen en 
numerieke geslachtschromosoomafwijkingen. 
NIPT voor numerieke geslachtschromosoomafwijkingen is nog niet algemeen 
beschikbaar. Het is de vraag of NIPT voor geslachtschromosoomaneuploïdie binnen de 
reikwijdte van een prenatale screeningtest zou moeten vallen, aangezien de 
aandoeningen die het gevolg zijn van een aneuploïdie van de geslachtschromosomen 
vaak leiden tot een mild fenotype. In Hoofdstuk 6 onderzoeken we de mening van 
zwangere vrouwen over NIPT voor geslachtschromosoomtrisomieën, binnen de 
bredere context van de uitbreiding van het aantal aandoeningen dat in het NIPT panel 
geïncludeerd kunnen worden. Er werden individuele semi-gestructureerde interviews 
gehouden met acht zwangere vrouwen die op dit moment enkel toegang tot NIPT 
hebben bij een verhoogd risico op trisomie 13, 18 of 21, na de CT of op basis van hun 
voorgeschiedenis. Vóór aanvang van de interviews werd informatie gegeven over 
geslachtschromosoomtrisomieën en de mogelijkheden en beperkingen van NIPT voor 
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deze aandoeningen. Nadat werd vastgesteld dat deze informatie duidelijk was voor de 
deelnemers, werden hun ideeën over NIPT voor deze aandoeningen en de uitbreiding 
van het spectrum van detecteerbare aandoeningen via NIPT geëxploreerd. De 
geïnterviewden hadden diverse meningen over NIPT voor 
geslachtschromosoomtrisomieën. Vier van hen vonden het toevoegen van 
geslachtschromosoomtrisomieën aan het NIPT panel een goed idee. De algemene 
opinie van deze vrouwen was dat zij zelf wilden kiezen voor welke aandoeningen in 
het NIPT panel zij wensten te laten screenen, en welke aandoeningen zij wilden laten 
bevestigen met een invasieve test.  
In Hoofdstuk 7 worden de resultaten van de beschreven studies in perspectief 
geplaatst. De resultaten van Deel I worden bediscussieerd in de volgende thema’s: 1) 
verbetering van niet-invasieve foetale geslachtsbepaling, 2) niet-invasieve analyse van 
celvrij RNA in maternaal plasma, 3) ontwikkeling en implementatie van NIPD van 
monogene aandoeningen. De resultaten van Deel II worden besproken in de volgende 
onderwerpen: 1) NIPT van trisomie 13, 18 en 21 vanaf 2011 tot nu, 2) het uitbreiden 
van de reikwijdte van niet-invasief prenataal screenen, 3) vals positieve en vals 
negatieve NIPT resultaten, en 4) autonome reproductieve keuze. We concluderen dat 
naast het ontwikkelen van nieuwe niet-invasieve prenatale diagnostische testen, het 
eveneens belangrijk is om het proces van verantwoorde prenatale screening met 
behulp van celvrij foetaal DNA te bestuderen. Parallel aan de technische innovaties, is 
er verder onderzoek noodzakelijk, in het bijzonder naar de organisatie en 
implementatie van NIPT en NIPD in verschillende nationale gezondheidszorgsystemen, 
de voorkeuren van zwangere koppels, en de optimale weg tot het maken van 
geïnformeerde keuzes. 
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This addendum describes the valorization of the relevant findings from the research 
upon which this doctoral dissertation is based. This means that I translate these 
findings into available products for the society. The word “products” should be 
interpreted in a broad sense in this context, ranging from novel noninvasive prenatal 
diagnostic laboratory tests (Part I), to knowledge aiding the national debate and 
decision-making concerning noninvasive prenatal screening (Part II). 
Valorization of Part I: Design of noninvasive prenatal diagnostic tests 
Part I comprised the design of in-house noninvasive diagnostic tests for fetal sex 
determination as well as for single-gene mutation detection (Chapters 2 and 3). 
A noninvasive fetal sex determination assay was developed and tested in 75 pregnant 
women from 9-34 weeks of gestation (Chapter 2). Noninvasive fetal sex determination 
in cell-free fetal DNA (cfDNA) in maternal blood is only available for a small group of 
pregnant women with a clinical indication. These are women carrying a fetus that 
presents with ambiguous genitalia during ultrasound examination, women carrying a 
fetus that is at risk of an X-linked disorder, or a fetus at risk of the autosomal recessive 
disorder congenital adrenal hyperplasia, where masculinization of the external 
genitalia of girls occurs.1-3 The fetal sex was correctly determined in all 75 pregnant 
women without failure or false results. For clinical application, the assay is competitive 
opposed to current assays: it is a non-expensive, fast, single-tube assay that can 
determine the fetal sex within one or two working days, with an equal turnaround 
time for boys and girls. Up until now the blood from pregnant women with a clinical 
indication for prenatal diagnosis of fetal sex was sent to Sanquin, the national 
reference laboratory for noninvasive prenatal sex determination.4 In case of a female 
fetus the test in Sanquin can take more than a week, and sometimes fails to provide a 
certain result.  
After publication of Chapter 2, our noninvasive fetal sex determination assay was 
further validated in 13 pregnant women from 10-12 weeks of gestation (Addendum 
Table 1).5 Comparison of the results of our new assay with the results of invasive 
prenatal testing revealed that the fetal sex was correctly determined in all samples. 
Before the assay can be offered to pregnant women in the Clinical Genetics 
department of the Maastricht UMC+, further validation is required, especially early in 
pregnancy (8-10 weeks of gestation). Currently, approval by the Medical Ethics 
Committee of the Academic Hospital Maastricht and Maastricht University is 
requested for this validation in 100 pregnant women. Plasma will be obtained in two 
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populations: (1) When a sample is sent to Sanquin for fetal sex determination, a 
second blood sample will be drawn for our new test. The results of the two sex 
determination assays will be compared. Annually, 5-10 samples are sent to Sanquin 
for X-linked disorders, and another 5-10 samples for ambiguous genitalia. (2) When 
blood is drawn for the first trimester fetal aneuploidy screening (combined test), an 
additional blood sample will be drawn. In these women, follow-up of the pregnancy 
should be guaranteed, e.g. by 20 weeks ultrasound or postnatal information, so that 
the fetal sex can be compared with the result of our assay. 
Following implementation our new noninvasive fetal sex determination assay in the 
Clinical Genetics department of the Maastricht UMC+, pregnant women are provided 
a more robust and fast test, and the department can send an invoice to the health care 
insurers. In the future, after gaining some more experience and confidence conducting 
the test, our laboratory may even opt to establish itself as an additional national 
reference laboratory for noninvasive fetal sex determination. 
 
Addendum Table 1 Further validation of the one-tube noninvasive prenatal sex determination assay 
Sample  Noninvasive prenatal sex determination Invasive testing 
# 
Gestational age 
(weeks + days) 
CSH cfRNA CGB cfRNA 
AMELY 
cfDNA 
 
1 12+0 + + + boy 
2 12+1 + + + boy 
3 11+4 + + + boy 
4 12+4 + + + boy 
5 12+2 + + - girl 
6 11+2 + + + boy 
7 11+2 + + - girl 
8 11+2 + + - girl 
9 10+6 + + + boy 
10 12+3 + + + boy 
11 11+2 + + - girl 
12 12+3 + + - girl 
13 11+4 + + - girl 
Sensitivity 100%     
Specificity 100%     
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The design of a newly developed in house NIPD assay for single-gene disorders was 
described in Chapter 3. Single molecule molecular inversion probes (smMIPs) were 
designed, together with the Human Genetics department of the Radboud UMC in 
Nijmegen, for targeted next-generation sequencing (NGS) for NIPD by haplotyping.6 
We are the first to use smMIPs for NIPD of single-gene disorders. The designed MIPs 
were optimized for analysis of fetal cfDNA, which is fractionated and present in a low 
concentration. Adding single molecule tagging to the MIPs allows us to mark sequence 
reads derived from a common progenitor molecule (that is, the same genomic 
equivalent in source DNA). This results in counting of unique captured molecules, and 
tag-based consensus calling to minimize errors from PCR or sequencing. SmMIPs 
enable precise quantification of the variation in the cfDNA and are robust to relatively 
small amounts and poor quality of source DNA.  
In Chapter 3 the first proof of concept was described. As a proof of concept, the smMIP 
NIPD assay was applied to cfDNA isolated from the plasma of a woman carrying a fetus 
affected with myotonic dystrophy type 1 (DM1), as diagnosed by invasive prenatal 
testing. DM1 is a single-gene disorder, caused by expansion of a CTG trinucleotide 
repeat.7,8 After sequencing the SNP markers from the pregnant woman, and from the 
father and a previous child (= reference) with DM1, informative SNPs for the mutated 
allele of the father and reference were selected. Subsequently, the cfDNA was 
sequenced to determine the fetal inheritance, calculated from the percentage of the 
informative SNPs in the cfDNA reads. In the proof of concept, it was demonstrated 
that the assay could detect the mutated DMPK allele, inherited from the father, in the 
fetal cfDNA. 
Validation of the smMIPs NIPD assay is ongoing. Plasma samples are being collected in 
Maastricht and Nijmegen when a pregnant woman undergoes an invasive procedure 
for prenatal genetic diagnosis for one of the following indications: (1) a fetus at high 
risk of having inherited a dominant or recessive disorder of his/her affected parent(s), 
or (2) a fetus at risk of having a de novo disorder on the basis of ultrasound findings. 
Annually, 40-60 couples are referred for prenatal diagnosis of a single-gene disorder, 
both in Maastricht and Nijmegen. In anticipation of this study, smMIP assays have 
already been designed for three other single-gene disorders:   
- autosomal dominant: spastic paraplegia 4 (SPG4, gene: SPAST) 
- autosomal recessive: cystic fibrosis (CF, gene: CFTR) 
- autosomal dominant, caused by a trinucleotide repeat expansion: Huntington’s 
disease (HD, gene: HTT) 
 Addendum: valorization 
  217 
For SPG4 and CF, smMIPs were developed to cover all exons and to target intronic and 
gene surrounding common SNPs (combined direct and indirect mutation detection by 
SNP-based haplotyping). For HD, as for DM1, smMIPs were designed to target common 
repeat flanking SNPs (only SNP-based haplotyping).  
Because of the unique smMIPs design, especially adapted to fetal cfDNA testing, the 
first steps for the development of an international competitive NIPD assay were taken. 
We are heading towards an in-house NIPD for paternally and maternally inherited 
disorders, even X-linked disorders and repeat expansion disorders. By combining the 
unique knowledge of the Radboud UMC regarding next-generation sequencing, as well 
as of the Maastricht UMC+ regarding direct and indirect detection of all types of 
genetic disorders in pre-implantation genetic diagnosis, translation of the newly 
developed assay into prenatal diagnostic tests for pregnant women is realistic. 
Valorization of Part II: Noninvasive prenatal screening for fetal chromosome 
disorders 
In Part II the diagnostic accuracy and clinical implementation of trisomy 21 screening 
by NIPT were examined (Chapters 4 and 5). Additionally, the opinion of pregnant 
women regarding the inclusion of fetal sex trisomies in the NIPT panel was explored, 
within the broader context of the expansion of the scope of screening (Chapter 6). 
In 2007, in the Netherlands a national prenatal screening program was introduced 
aiming to provide all pregnant women the option of prenatal screening for trisomies 
13, 18 and 21 with the first trimester combined test (FCT).9 The FCT combines a serum 
screening test with a nuchal translucency measurement in the first trimester of 
pregnancy. Traditionally, women with a risk of fetal trisomies 13, 18 or 21 of 1 in 200 
or higher after the FCT were offered an  invasive procedure to further investigate these 
fetal chromosome disorders. 
In 2011, at the time I started the research upon which this doctoral dissertation is 
based, the first diagnostic accuracy studies were published of noninvasive prenatal 
testing (NIPT) for fetal trisomies 13, 18 and 21 in maternal plasma.10 In Chapter 4 a 
systematic review was conducted and an overview was provided of all studies 
evaluating the diagnostic accuracy of NIPT for trisomy 21 between 1997 and the 
beginning of 2012.10 We concluded that the positive predictive value of NIPT (How 
likely is a pregnant woman with a positive cfDNA-based test result to actually carry a 
fetus with the trisomy?) declines if the a priori risk for a fetus with a trisomy declines. 
Addendum: valorization 
218 
NIPT requires a confirmation by a follow-up diagnostic test, for a definite diagnosis of 
fetal aneuploidy in the fetus. We predicted that NIPT was likely to replace the prenatal 
serum screening test that is currently combined with nuchal translucency 
measurement in the FCT. Due to the reduction in false-positive and false-negative 
results in comparison to the FCT, fewer trisomy cases would be missed at the first 
screening step and fewer invasive procedures would be needed, only to verify a 
positive NIPT result and to confirm non-inheritable or inheritable forms of Down 
syndrome, using the gold standard karyotyping. The results of our study were among 
others cited by the Nederlandse Vereniging voor Obsetrie en Gynaecologie (NVOG) in 
their opinion about NIPT in May 201311, and in the Wet op het bevolkingsonderzoek 
niet-invasieve prenatale test bij verhoogd risico op trisomie in December 2013, from 
the Health Council of the Netherlands Health Council, an advisory board of the Dutch 
Ministry of Health.12  
The first commercial releases of NIPT were seen in Hong Kong in August 2011, and in 
the United States (US) in October 2011.13 Different companies offered commercial 
NIPT to high-risk pregnant women, such as the MaterniT21TM PLUS test from 
Sequenom (http://www.sequenom.com), the Praena-Test® from their European 
partner LifeCodexx (http://www.lifecodexx.com), the verifi® test from Verinata 
(http://www.verinata.com) and the HarmonyTM prenatal test from Ariosa 
(http://www.ariosadx.com). During a 3 year-period after the first commercial release, 
the news about the option for NIPT had reached Dutch pregnant women through the 
internet, traditional media as well as family and friends. However, for them, it was not 
possible to undergo NIPT in The Netherlands. Following the publication of Chapter 4, 
we were approached for an interview for the newspaper NRC, in which we explained 
to pregnant women the principle of the NIPT, and when we expected the test to be 
available in the Netherlands.14 
Since April 2014, a national implementation study has been organized in the 
Netherlands (the TRIDENT study).15 In this study, the genetic laboratories of the 
country collaborate to investigate the accuracy of NIPT and compare it to the 
published accuracy. Prenatal screening for trisomies 13, 18 and 21 by NIPT is offered 
as a part of the TRIDENT-1 study to women with an increased risk based on the FCT (≥ 
1:200), or based on their personal history. Also in Maastricht UMC+, pregnant women 
can undergo NIPT as a part of the TRIDENT-1 study. Recently, the Health Council, an 
advisory board of the Dutch Ministry of Health, advised to offer all pregnant women 
the choice for NIPT as the first screening test.16 In September 2016, the Minister of 
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Health gave permission to start with the TRIDENT-2 study in April 2017. In the 
TRIDENT-2 study women can choose between three different scenarios: NIPT as the 
first screening test, the FCT as the first and only screening test, and pre-selection by 
the FCT prior to NIPT.15 At the moment, the Minister does not follow the suggestion of 
the Health Council that the NT measurement could be offered to pregnant women 
that only undergo NIPT. The university hospitals are allowed to offer these scenarios 
under the following conditions: adequate counseling about the advantages and 
disadvantages of these three scenarios, as well as counseling about incidental findings 
and the possibility to opt-out for incidental findings, scientific study of the impact of 
analysis filters (that preclude incidental findings) on the quality of NIPT, protecting the 
women’s right not to know and avoiding routinization offer of NIPT. 
In Chapter 5 different hypothetical NIPT implementation strategies were compared 
for a national screening program. Decision trees were created to illustrate all plausible 
alternatives in a theoretical cohort of 100 000 pregnant women in five screening 
programs: classical screening by the first-trimester combined test (FCT), pre-selection 
of high-risk women prior to NIPT by the FCT, NIPT as the first screening test at 10 weeks 
and at 13 weeks, and the simultaneous conductance of NIPT and the FCT. We reflected 
upon the results of the quantitative analysis in the light of psychological and practical 
considerations, e.g. the chance that women are correctly reassured by a negative 
screening result, the chance of a correct positive screening result, the time until the 
result of the screening test, the time from the result of the screening test until the 
confirmation of a positive result by amniocentesis, the number of decision-making 
moments for women, etc. The results of Chapter 5 were presented in the European 
Human Genetics Conference (31 May- 3 June 2014, Milan, Italy). The results may be 
used for to inform pregnant couples about the advantages and disadvantages of the 
three programs of TRIDENT-2. 
In Chapter 6, we assessed pregnant women’s opinions about NIPT for sex chromosome 
trisomies (SCTs) within the broader context of the expansion of disorders included in 
the NIPT panel. Individual semi-structured interviews were conducted with eight 
pregnant women. The results of our study revealed several topics to consider when 
offering NIPT for SCTs or expanding the NIPT panel. Our study identified several 
potential disadvantages of NIPT for SCTs: receiving a prenatal test result about a 
disorder with unclear consequences for the future child’s life and for which they would 
take no further actions, a less worry-free pregnancy and childhood, and possible guilt 
about continuation of pregnancy. Two participants mentioned the option of 
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termination of pregnancy as a benefit of screening, while others firmly stated that they 
disagreed with offering pregnant women the possibility to terminate the pregnancy 
because of a fetal SCT. Furthermore, the limited positive predictive value was 
perceived as a negative aspect of NIPT for SCTs. In concordance with previous studies, 
not all participants agreed to undergo confirmatory invasive testing for these 
conditions during pregnancy, because of its additional miscarriage risk. All participants 
requested to be well-informed about every condition in the NIPT panel prior to testing 
and brought up that participation and all further steps in the screening process should 
be voluntary and based on adequate information. The overall opinion was that couples 
wanted to choose for themselves which disorders in the NIPT panel they wished to 
screen for, and which conditions they wanted to confirm by invasive testing. Hopefully, 
also this Chapter will have societal impact, contributing to the discussion about how 
NIPT should be offered to pregnant couples, and which conditions should be in the 
NIPT panel. 
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gevonden, in het centrum van Maastricht, en het is groot!”; “Ik heb een zwangere voor 
de MAMOET studie!”; “Een PhD is volhouden, volhouden, volhouden.”; “Vanavond 
naar Il Fiore?”;  “Er is een monogene, zal ik hem doen? Ik heb wel tijd, hoor.”, “Je kan 
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